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THE HISTORY OF THE PULMONARY CIRCULATION 
The first systematic explanation of the cardiopulmonary circulation was provided in the 
second century AD, by the Roman scientist and philosopher Galen.(1) In his extensive theory, 
which would dominate and influence the Western medical science for at least 15 centuries, 
he claimed that blood was formed in the liver with components originating from the gut. The 
blood would flow into the right ventricle, from where it would divide into two blood flows. 
Some blood would ‘nourish’ the lungs via the pulmonary artery, and some blood would flow 
directly into the left ventricle (LV) via invisible pores in the interventricular septum. The blood 
that went into the LV would gain the ‘vital spirit’ via ‘pneuma’ or ‘soul’ which was retrieved 
from the inhaled air. Through the arterial system peripheral tissues could be provided with 
the vital spirit. After that, the blood would disappear and its waste products would travel back 
via the pulmonary vein to the lungs, where they could be exhaled in the expired air (Figure 
1.1).(1,2) 
 
Despite the discovery of the Persian physician, theologist and jurist Ibn al-Nafis in the 13th 
century that no direct pathway between the right- and left ventricle existed and blood 
therefore had to pass the lungs before returning to the LV, it would take the Western medical 
society until the 17th century to cautiously leave Galens theory. In 1628, William Harvey 
published his ‘Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus’.(3) He 
argued: ‘If Nature does nothing in vain, she would not have added the right ventricle (RV) for 
the sole purpose of nourishing the lungs, but to propel blood through the lungs in the cavity 
of the LV!’(3) In the same century, Marcello Malphigi discovered the pulmonary capillaries and 
alveoli.(4) Ever since, enormous progress has been made in understanding the pulmonary 
circulation.  
 















THE PULMONARY CIRCULATION 
The main function of the pulmonary circulation is to transport deoxygenated blood from the 
RV into the lungs, where oxygen uptake and carbon dioxide elimination takes place through 
the alveolar-capillary membrane. After that, the oxygenated blood is transported to the LV 
and is distributed to all organs by the systemic circulation.  The pulmonary circulation is 
characterized as a low pressure, high flow system. The RV, generating this low pressure, is 
characterized by a crescent shape and thin muscular wall when compared to the LV. (5–7) The 
present thesis focuses on a disease affecting the pulmonary circulation; pulmonary 
hypertension.  
 
PULMONARY HYPERTENSION AND THE RIGHT VENTRICLE 
Pulmonary hypertension (PH) is a hemodynamic condition characterized by an elevated mean 
pulmonary artery pressure (mPAP). During the first World Symposium on PH in 1973 in 
Geneva, PH has been defined as a mPAP ≥ 25 mmHg measured during a right heart 
catheterization (RHC).(8) In 2018, this definition was revised after Kovacs et al. demonstrated 
in a systematic review that healthy individuals had a resting mPAP of 14.0±3.3 mmHg, leading 
to an upper limit of normal of >20 mmHg.(8,9)  
 
The pathophysiological process behind the development of PH is dependent of the 
underlying etiology. Despite the fact that all PH entities are characterized by an increased 
mPAP and pulmonary vascular resistance (PVR), prognosis and treatment strategies vary 
significantly. Therefore, PH is categorized in five main subtypes based their clinical, 
pathophysiological and therapeutic characteristics, as can be observed in Table 1.1. (8) The 
most common forms are PH due to left heart diseases and PH due to lung diseases. 
Regardless of the underlying entity, patients with PH presen with non-specific symptoms such 
as exertional dyspnea, exercise intolerance, palpitations and syncope. As a result, patients are 
often diagnosed by the time their disease is already in an advanced state. Even in the modern 
treatment era, survival rates are still unsatisfactory low in all groups.(10–13)  
 
Pulmonary arterial hypertension (PAH, group 1) is a diagnosis per exclusionem and cannot 
coexist with the other PH subtypes. PAH is characterized by excessive pulmonary vascular 
remodeling and proliferation, resulting in a progressive increase in PVR. To maintain stroke 
volume and cardiac output, the RV has to undergo morphological and functional adaptation. 
As a comparison, the LV has to cope with a 50% increase in pressure in systemic hypertension, 
while the RV in PAH has to cope with a 400-500% increase in pressure.(14) When faced with 
this increased load, the RV initially adapts by increasing its contractility via the enhancement 
of intrinsic contractile properties of the cardiomyocyte and via muscular hypertrophy.(14,15) 
However, as the load progressively increases, the hypertrophic response will be hampered 
and a vicious circle of RV dilatation, RV systolic dysfunction and RV diastolic dysfunction is 
 
 
entered (Figure 1.2). Right heart failure is the main cause of death in PAH, and markers of RV 
adaptation and failure are of great prognostic value in PAH-patients.(16–19) 
 
Intriguingly, the response to rather than the amount of pressure overload determines the fate 
of the RV in PAH patients.(17) Although it is currently unknown what the transition from an 
adaptive to failing RV triggers, several mechanisms could play a role. In this thesis, we focus 
on the possible roles of genetics, the neurohormonal system and sex. 
 
Table 1.1 – Clinical classification of pulmonary hypertension as proposed on the Sixth World 
Symposium on Pulmonary Hypertension (8) 
 
THE GENETICS OF PULMONARY ARTERIAL HYPERTENSION 
Hereditary PAH-patients (Group 1.2) have a younger age at diagnosis, often present with 
worse hemodynamic features and have a worse prognosis compared to idiopathic PAH-
patients.(20,21) In 2000, Deng et al. and Thomson et al. identified the first gene to cause 
pulmonary hypertension: the Bone Morphogenetic Protein Receptor type 2 (BMPR2), a 
member of the Transforming Growth Factor ß (TGF-ß) superfamily.(22,23) To date, the BMPR2 
mutation remains the most common mutation, with mutations in 53-86% of patients with a 
family history and in 14-35% of patients with IPAH.(24,25) Transmission occurs in an autosomal 
dominant manner. Interestingly, BMPR2 mutations have incomplete penetrance, estimated to 
be 14% for males and 42% for females.(26) In recent years, sixteen additional genes in which 
mutation may cause PAH are identified. Remarkably, the vast majority of these genes 
participate in the TGF-ß/BMPR2 pathway and lead to a relative increase in TGF-ß activity. It 
is known that TGF-ß activity is pivotal to protect the heart against dilatation and matrix 
1. Pulmonary Arterial Hypertension 
1.1 Idiopathic PAH 
1.2 Heritable PAH 
1.3 Drugs and toxins induced 
1.4 Associated with: 
1.4.1 Connective tissue disease 
1.4.2 Human immunodeficiency virus (HIV) infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart disease 
1.4.5 Schistosomiasis 
1.5 PAH long-term responders to calcium channel blockers 
1.6 PAH with over features of venous/capillaries (PVOD/PCH) involvement 
1.7 Persistent PH of the newborn syndrome 
2. Pulmonary Hypertension due to left heart disease 
3. Pulmonary Hypertension due to lung diseases and/or hypoxia 
4. Chronic Thromboembolic Pulmonary Hypertension and other pulmonary artery 
obstructions 
5. Pulmonary hypertension with unclear and/or multifactorial mechanisms 
 
 
degeneration in case of a pressure-overload. However, it is unknown what the effects of the 
BMPR2 mutation is on RV function and adaptation. Excessive TGF-ß signaling might be 
detrimental in case of a pressure-overloaded RV, because of maladapted hypertrophy and 
myocardial dysfunction.(27,28) 
 
THE NEUROHORMONAL SYSTEM IN PULMONARY ARTERIAL HYPERTENSION 
To maintain cardiac output and enhance contractility and hypertrophy in the short term, the 
sympathetic nervous system is upregulated and overstimulated in PAH.(29,30) However, in 
the long term, overstimulation of the sympathetic nervous system proved to be detrimental. 
In preclinical studies, a partial restoration of the sympathetic overdrive by beta-blocker 
therapy led to an improved systolic and diastolic RV function and thereby a survival 
benefit.(31,32) 
 
Figure 1.2 – The Right Ventricle in Pulmonary Arterial Hypertension, adapted from Vonk 
Noordegraaf et al.(14)  
 
Unfortunately, a randomized, placebo-controlled trial did not favor the use of bisoprolol in 
IPAH.(33) Less studied is the counterpart of the sympathetic nervous system, the 
parasympathetic nervous system. The both systems are connected in such a way that 
increased activity in one will result in reduced activity in the other. In PAH-patients, markers 
of parasympathetic activity are strong predictors of prognosis.(34) However, it is currently 
unknown whether enhancing the parasympathetic activity might play a beneficial role in 
preventing the transition from RV adaptive remodeling to RV failure.  
 
THE ROLE OF SEX IN PULMONARY ARTERIAL HYPERTENSION 
The prevalence of PAH in females is known to be two times higher than in males. However, 
survival of female patients is significantly higher dan in males. (11,35,36) Previous studies 
 
 
suggest that this survival benefit might be explained by a differential response of the RV to 
the altering afterload. (35) Estrogens, androgens and their precursors 
(dehydroepiandrosterone sulfate, DHEAs), are known to be involved in RV adaptation and 
maladaptation to a pressure overload.  Due to fluctuating sex hormones, specifically estrogen, 
in premenopausal women, clinical studies and analyses are challenging. Therefore, the exact 
interplay between sex hormones and RV adaptation and maladaptation currently remains 
elusive.  
 
TREATMENT RESPONSE IN PULMONARY ARTERIAL HYPERTENSION 
Conventionally, management of PAH-patients is based on functional (i.e. six-minute walking 
distance, New York Heart Association (NYHA) -classification) and invasive measurements 
obtained during right heart catheterization (RHC). However, as previously mentioned, non-
invasive measurements obtained via CMR are of great predictive value in PAH-patients. (16–
18,37,38). The non-invasive character of CMR may provide a more patient-friendly routine 
follow-up in PAH-patients with minimal risks. Whether CMR is a suitable modality to monitor 
idiopathic PAH-patients in comparison to invasive and/or functional measurements remains 
to be established.  
   
OUTLINE OF THIS THESIS 
In Part I, we aimed to identify possible factors affecting the transition of RV adaptation towards 
RV failure in PAH.  In Chapter 2, we investigated RV function in PAH-patients with and without 
the BMPR2 mutation by combining in vivo measurements with molecular and histological 
analysis of human RV and LV tissue. In Chapter 3, the relationship between parasympathetic 
activity and RV function in PAH-patients was studied. In addition, the potential therapeutic 
effects of pyridostigmine were studied in experimental PH. Pyridostygmine is an oral drug 
stimulating the parasympathetic activity via acetylcholinesterase inhibition, and is currently 
prescribed to patients with Myasthenia Gravis. Whether sex and age influence the RV 
response to pressure-overload was studied in Chapter 4. In Chapter 5, we provide a 
perspective on the mechanisms of RV adaptation in PAH and discuss which mechanisms play 
a role in the transition from RV adaptation to RV failure by comparing different etiologies of 
RV pressure overload.  
In Part II of this thesis we focus on novel insights in (assessing) treatment response in PAH. In 
Chapter 6, we aimed to compare non-invasive and invasive follow-up in PAH-patients. In 
Chapter 7, we investigated whether the hemodynamic and cardiac responses to PAH-specific 
therapy are different between patients with IPAH patients and a severely reduced diffusion 
capacity of the lung for carbon monoxide compared to IPAH patients with a more preserved 
diffusion capacity of the lung for carbon monoxide. Lastly, in Chapter 8, we discuss the 





1.  West J. The Human Pulmonary Circulation: 
Historical Introduction. In: Textbook of 
Pulmonary Vascular Disease. 2011.  
2.  Singer C. A short history of anatomy and 
physiology from the Greeks to Harvey. Dover, 
New York; 1957.  
3.  Harvey W. The works of William Harvey. 
Philadelphia: University of Pennsylvania Press; 
1989.  
4.  Young J. Malphigi’s De Pulmonibus. In: R Soc 
Med Proc 23:1: 1-11. 1929.  
5.  Vonk Noordegraaf A, Chin KM, Haddad F, 
Hassoun PM, Hemnes AR, Hopkins SR, e.a. 
Pathophysiology of the right ventricle and of 
the pulmonary circulation in pulmonary 
hypertension: an update. Eur Respir J. januari 
2019;53(1).  
6.  Naeije R, Vanderpool R, Peacock A, 
Badagliacca R. The Right Heart-Pulmonary 
Circulation Unit: Physiopathology. Heart Fail 
Clin. juli 2018;14(3):237–45.  
7.  Haddad F, Doyle R, Murphy DJ, Hunt SA. Right 
ventricular function in cardiovascular disease, 
part II: pathophysiology, clinical importance, 
and management of right ventricular failure. 
Circulation. 1 april 2008;117(13):1717–31.  
8.  Simonneau G, Montani D, Celermajer DS, 
Denton CP, Gatzoulis MA, Krowka M, e.a. 
Haemodynamic definitions and updated 
clinical classification of pulmonary 
hypertension. Eur Respir J [Internet]. 1 januari 




9.  Kovacs G, Berghold A, Scheidl S, Olschewski 
H. Pulmonary arterial pressure during rest and 
exercise in healthy subjects: a systematic 
review. Eur Respir J. 1 oktober 
2009;34(4):888–94.  
10.  Benza RL, Miller DP, Barst RJ, Badesch DB, 
Frost AE, McGoon MD. An evaluation of long-
term survival from time of diagnosis in 
pulmonary arterial hypertension from the 
REVEAL Registry. Chest. augustus 
2012;142(2):448–56.  
11.  Humbert M, Sitbon O, Chaouat A, Bertocchi 
M, Habib G, Gressin V, e.a. Survival in patients 
with idiopathic, familial, and anorexigen-
associated pulmonary arterial hypertension in 
the modern management era. Circulation. 13 
juli 2010;122(2):156–63.  
12.  Gall H, Felix JF, Schneck FK, Milger K, Sommer 
N, Voswinckel R, e.a. The Giessen Pulmonary 
Hypertension Registry: Survival in pulmonary 
hypertension subgroups. J Heart Lung 
Transplant Off Publ Int Soc Heart Transplant. 
september 2017;36(9):957–67.  
13.  Wijeratne TD, Lajkosz K, Brogly SB, Lougheed 
MD, Jiang L, Housin A, e.a. Increasing 
Incidence and Prevalence of WHO Groups 1–
4 Pulmonary Hypertension: A Population-
Based Cohort Study in Ontario, Canada. Circ 
Cardiovasc Qual Outcomes. februari 
2018;11(2):e003973.  
14.  Vonk Noordegraaf A, Westerhof BE, Westerhof 
N. The Relationship Between the 
Right Ventricle and its Load in 
Pulmonary Hypertension. J Am Coll Cardiol. 
17 januari 2017;69(2):236–43.  
15.  van der Bruggen CEE, Tedford RJ, Handoko 
ML, van der Velden J, de Man FS. RV pressure 
overload: from hypertrophy to failure. 
Cardiovasc Res. 1 oktober 
2017;113(12):1423–32.  
16.  van Wolferen SA, Marcus JT, Boonstra A, 
Marques KMJ, Bronzwaer JGF, 
Spreeuwenberg MD, e.a. Prognostic value of 
right ventricular mass, volume, and function in 
idiopathic pulmonary arterial hypertension. 
Eur Heart J. mei 2007;28(10):1250–7.  
17.  van de Veerdonk MC, Kind T, Marcus JT, 
Mauritz G-J, Heymans MW, Bogaard H-J, e.a. 
Progressive right ventricular dysfunction in 
patients with pulmonary arterial hypertension 
responding to therapy. J Am Coll Cardiol. 6 
december 2011;58(24):2511–9.  
18.  Swift AJ, Capener D, Johns C, Hamilton N, 
Rothman A, Elliot C, e.a. Magnetic Resonance 
Imaging in the Prognostic Evaluation of 
Patients with Pulmonary Arterial Hypertension. 




19.  Courand P-Y, Pina Jomir G, Khouatra C, 
Scheiber C, Turquier S, Glérant J-C, e.a. 
Prognostic value of right ventricular ejection 
fraction in pulmonary arterial hypertension. 
Eur Respir J. januari 2015;45(1):139–49.  
20.  Sztrymf B, Coulet F, Girerd B, Yaici A, Jais X, 
Sitbon O, e.a. Clinical outcomes of pulmonary 
arterial hypertension in carriers of BMPR2 
mutation. Am J Respir Crit Care Med. 15 juni 
2008;177(12):1377–83.  
21.  BMPR2 mutations and survival in pulmonary 
arterial hypertension: an individual participant 
data meta-analysis. - PubMed - NCBI 




22.  Deng Z, Morse JH, Slager SL, Cuervo N, Moore 
KJ, Venetos G, e.a. Familial primary 
pulmonary hypertension (gene PPH1) is 
caused by mutations in the bone 
morphogenetic protein receptor-II gene. Am J 
Hum Genet. september 2000;67(3):737–44.  
23.  Thomson JR, Machado RD, Pauciulo MW, 
Morgan NV, Humbert M, Elliott GC, e.a. 
Sporadic primary pulmonary hypertension is 
associated with germline mutations of the 
gene encoding BMPR-II, a receptor member 
of the TGF-beta family. J Med Genet. oktober 
2000;37(10):741–5.  
24.  Southgate L, Machado RD, Gräf S, Morrell NW. 
Molecular genetic framework underlying 
pulmonary arterial hypertension. Nat Rev 
Cardiol. 12 augustus 2019;1–11.  
25.  Machado RD, Southgate L, Eichstaedt CA, 
Aldred MA, Austin ED, Best DH, e.a. 
Pulmonary Arterial Hypertension: A Current 
Perspective on Established and Emerging 
Molecular Genetic Defects. Hum Mutat. 
december 2015;36(12):1113–27.  
26.  Larkin EK, Newman JH, Austin ED, Hemnes 
AR, Wheeler L, Robbins IM, e.a. Longitudinal 
analysis casts doubt on the presence of 
genetic anticipation in heritable pulmonary 
arterial hypertension. Am J Respir Crit Care 
Med. 1 november 2012;186(9):892–6.  
27.  Koitabashi N, Danner T, Zaiman AL, Pinto YM, 
Rowell J, Mankowski J, e.a. Pivotal role of 
cardiomyocyte TGF-β signaling in the murine 
pathological response to sustained pressure 
overload. J Clin Invest. juni 2011;121(6):2301–
12.  
28.  Dobaczewski M, Chen W, Frangogiannis NG. 
Transforming growth factor (TGF)-β signaling 
in cardiac remodeling. J Mol Cell Cardiol. 
oktober 2011;51(4):600–6.  
29.  Bristow MR, Ginsburg R, Umans V, Fowler M, 
Minobe W, Rasmussen R, e.a. Beta 1- and beta 
2-adrenergic-receptor subpopulations in 
nonfailing and failing human ventricular 
myocardium: coupling of both receptor 
subtypes to muscle contraction and selective 
beta 1-receptor down-regulation in heart 
failure. Circ Res. september 1986;59(3):297–
309.  
30.  Ciarka A, Doan V, Velez-Roa S, Naeije R, van 
de Borne P. Prognostic significance of 
sympathetic nervous system activation in 
pulmonary arterial hypertension. Am J Respir 
Crit Care Med. 1 juni 2010;181(11):1269–75.  
31.  de Man FS, Handoko ML, van Ballegoij JJM, 
Schalij I, Bogaards SJP, Postmus PE, e.a. 
Bisoprolol delays progression towards right 
heart failure in experimental pulmonary 
hypertension. Circ Heart Fail. januari 
2012;5(1):97–105.  
32.  Bogaard HJ, Natarajan R, Mizuno S, Abbate A, 
Chang PJ, Chau VQ, e.a. Adrenergic receptor 
blockade reverses right heart remodeling and 
dysfunction in pulmonary hypertensive rats. 
Am J Respir Crit Care Med. 1 september 
2010;182(5):652–60.  
33.  van Campen JSJA, de Boer K, van de 
Veerdonk MC, van der Bruggen CEE, Allaart 
CP, Raijmakers PG, e.a. Bisoprolol in 
idiopathic pulmonary arterial hypertension: an 
explorative study. Eur Respir J. 
2016;48(3):787–96.  
34.  Minai OA, Gudavalli R, Mummadi S, Liu X, 
McCarthy K, Dweik RA. Heart rate recovery 
predicts clinical worsening in patients with 
pulmonary arterial hypertension. Am J Respir 
Crit Care Med. 15 februari 2012;185(4):400–8.  
35.  Jacobs W, van de Veerdonk MC, Trip P, de 
Man F, Heymans MW, Marcus JT, e.a. The 
right ventricle explains sex differences in 
survival in idiopathic pulmonary arterial 
hypertension. Chest. juni 2014;145(6):1230–6.  
 
 
36.  Shapiro S, Traiger GL, Turner M, McGoon MD, 
Wason P, Barst RJ. Sex differences in the 
diagnosis, treatment, and outcome of patients 
with pulmonary arterial hypertension enrolled 
in the registry to evaluate early and long-term 
pulmonary arterial hypertension disease 
management. Chest. februari 
2012;141(2):363–73.  
37.  van de Veerdonk MC, Marcus JT, Westerhof N, 
de Man FS, Boonstra A, Heymans MW, e.a. 
Signs of right ventricular deterioration in 
clinically stable patients with pulmonary 
arterial hypertension. Chest. april 
2015;147(4):1063–71.  
38.  Swift AJ, Rajaram S, Campbell MJ, Hurdman J, 
Thomas S, Capener D, e.a. Prognostic value of 
cardiovascular magnetic resonance imaging 
measurements corrected for age and sex in 
idiopathic pulmonary arterial hypertension. 































RIGHT VENTRICULAR ADAPTATION IN 



























BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE II 
MUTATION IN PULMONARY ARTERIAL 
HYPERTENSION: 









CEE van der Bruggen & CM Happé, P Dorfmüller, P Trip, OA Spruijt, N Rol, FP 
Hoevenaars, AC Houweling, B Girerd, JT Marcus, O Mercier, M Humbert, ML 









Background:  The effect of a mutation in the bone morphogenetic protein receptor 2 gene 
(BMPR2) gene on right ventricular (RV) pressure overload in patients with pulmonary arterial 
hypertension (PAH) is unknown. Therefore, we investigated RV function in PAH-patients with 
and without BMPR2 mutation by combining in vivo measurements with molecular and 
histological analysis of human RV and left ventricular (LV) tissue.  
 
Methods & Results: In total, 95 idiopathic or familial PAH patients were genetically screened 
for the presence of a BMPR2 mutation: 28 patients had a BMPR2 mutation, 67 patients did 
not have a BMPR2 mutation. In vivo measurements were assessed using right heart 
catheterization (RHC) and cardiac magnetic resonance imaging. Despite a similar mean 
pulmonary artery pressure (non-carriers 54±15 vs. mutation carriers 55±9 mmHg) and 
pulmonary vascular resistance (755 (483-1043) vs. 931 (624-1311) dynes*s/cm⁵ ), mutation 
carriers presented with a more severely compromised RV function (RV ejection fraction: 
37.6±12.8 vs. 29.0±9 %: p<0.05, cardiac index 2.7±0.9 vs. 2.2±0.4 l/min/m²). Differences 
continued to exist after treatment. To investigate the role of TGF-β and BMPRII signaling, 
human RV and LV tissue were studied in controls (n=6), mutation carriers (n=5) and non-
carriers (n=11). However, TGF-β and BMPRII signaling, as well as hypertrophy, apoptosis, 
fibrosis, capillary density, inflammation and cardiac metabolism were similar between 
mutation carriers and non-carriers.  
 
Conclusion: Despite a similar afterload, RV function is more severely affected in mutation 
carriers compared to non-carriers. However, these differences cannot be explained by a 























Pulmonary arterial hypertension (PAH) is a rapidly progressive and lethal disease, 
characterized by an increase in resistance of the pulmonary arterioles, causing an increased 
right ventricular (RV) afterload. 1–3 The RV adapts to this increased load via several 
compensatory mechanisms but these are not sufficient to prevent progression to RV 
dysfunction and failure, which is the predominant cause of death in PAH. 4 Intriguingly, this 
clinical observation suggests that the response to rather than the amount of pressure overload 
determines the fate of the RV in PAH-patients.  
Patients with PAH may have an underlying genetic predisposition, in particular a mutation in 
the bone morphogenetic protein receptor type 2 (BMPR2) gene. 5–11 BMPR2 mutations are an 
autosomal dominant cause of PAH with reduced penetrance (14% in men, 42% in women) 
clinically characterized by a younger age and a more severe hemodynamic compromise at 
presentation compared to idiopathic PAH patients. 10,12–15 The bone morphogenetic protein 
receptor II (BMPRII) encoded by the BMPR2 gene belongs to the transforming growth factor 
β (TGF-β) superfamily and mutations have been shown to result in a disturbed BMP/TGF-β 
balance. 16–18 Decreased BMPRII activity leads to an overactivated TGF-β signaling, which 
stimulates vasculogenesis, intimal hyperplasia and medial smooth muscle growth in the 
pulmonary vasculature. 19,20 In addition, growing evidence suggests a key role for TGF-β 
signaling in the response to pressure overload of the heart. 21–23 
While TGF-β signaling is necessary to protect the heart against uncontrolled matrix 
degradation and dilatation, excessive TGF-β signaling might be detrimental due to 
maladapted hypertrophy and myocardial dysfunction, as previously described in left heart 
failure. 21–23 Furthermore, a recent study by Hemnes et al. showed that the RV hypertrophic 
response was disturbed in pulmonary hypertensive mice carrying a BMPR2 mutation. 24 
However, whether RV function and adaptation in PAH-patients carrying a BMPR2 mutation 
differs from PAH-patients without identified BMPR2 mutation remains currently elusive. 
Therefore, the aim of this study was two-fold: 1) to determine the effects of a BMPR2 mutation 
on RV function in PAH patients and 2) to compare the histological and morphological 





Clinical study: We retrospectively reviewed PAH patients seen at the VU University Medical 
Center (Amsterdam, the Netherlands) between March 1995 and October 2014. Patients were 
eligible for this study when the results from BMPR2 mutation analysis were available. In total, 
123 PAH-patients were genetically screened for the presence of a BMPR2 mutation. After the 
exclusion of 28 patients, 95 patients were included in this study. 28 patients were carriers of 
a BMPR2 mutation (mutation carriers) and no BMPR2 mutation was identified in 67 sporadic 
 
 
PAH patients (non-carriers). Patients with a family history of PAH with no evidence of a BMPR2 
mutation (n=3) or patients with a genetic mutation linked to pulmonary hypertension other 
than the BMPR2 mutation (n=5) were excluded from the analysis to avoid the risk of 
misclassification in the BMPR2 non-carriers group. For comparison a group of 15 control 
subjects without PAH family history was included in this study. Controls were selected from 
referred patients suspected with PAH but in whom the condition was ruled out after right 
heart catheterization (RHC).  A subset of patients was eligible for treatment response analysis. 
(Figure 2.1)  Patients were diagnosed with idiopathic PAH according to current clinical 
guidelines, by means of RHC and by ruling out all associated conditions of PH by a 
multidisciplinary team. 25 All genetically tested patients signed written informed consent and 
received genetic counseling.  
Because the MRI and RHC data were obtained for clinical purposes and analyzed 
retrospectively, the Medical Ethics Review Committee of the VU University Medical Center 
did not consider this study to fall within the scope of the Medical Research Involving Human 
Subjects Act. Therefore, no additional approval was acquired. 
 




Schematic overview of study populations. PH: pulmonary hypertension; IPAH: idiopathic pulmonary 
arterial hypertension, HPAH; hereditable pulmonary arterial hypertension, BMPR2: bone 




Cardiac tissue samples: Explanted RV and LV tissue samples were collected from PAH patients 
undergoing heart/lung transplantation in the French Referral Centre for Pulmonary 
Hypertension (Université Paris-Sud, France) (mutation carriers n=5, non-carriers n=11). Control 
RV and LV tissue was obtained from non-failing donors (n=6). Human cardiac tissue collection 
and use by collaborating universities (VU Medical Center, Amsterdam) was approved by the 
Human Research Ethics Committee of the Université Paris-Sud - Inserm U999 (ID RBC 2008-
A00485-50). Written informed consent was obtained. All samples were stored in paraffin.  
 
Genetic analysis of the BMPR2 gene 
Genomic DNA was extracted from peripheral blood samples after the patients gave informed 
consent. The coding sequences and the surrounding splice sites of the BMPR2 gene were 
amplified by polymerase chain reaction (PCR). PCR amplification was performed using a 
PE9700 thermocycles (Applied Biosystems, Forster City, CA, USA). Sequencing reactions were 
performed using the Big Dye Terminator system (Applied Biosystems, Forster City, CA, USA) 
and run on an ABI 3100XL or ABI3730 genetic analyzer (Applied Biosystems, Forster City, CA, 
USA).  To detect deletions and duplications of one or more exons MLPA analysis was 
performed using MLPA kit P093-A (MRC-Holland, Amsterdam, The Netherlands).   
 
Hemodynamic measurements 
A 7-F balloon-tipped Swan Ganz catheter (131HF7, Baxter Healthcare Corp., Irvine, CA, USA) 
was inserted via the jugular or femoral vein and brought into position under local anesthesia 
during continuous electrocardiographic monitoring. The following variables were recorded: 
mean pulmonary artery pressure (mPAP), right atrial pressure (RAP), pulmonary arterial wedge 
pressure (PAWP), mixed venous oxygen saturation (SvO2) and heart rate (HR). PVR was 
calculated via the following formula: 80*(mPAP-PAWP)/cardiac output (CO). CO was 
determined by either the Fick method or thermodilution and stroke volume (SV) was 
calculated as CO divided by HR. Both CO and SV were indexed for body surface area (BSA), 
shown as respectively cardiac index (CI) and SV index (SVI).  
 
Cardiac magnetic resonance imaging 
Cardiac magnetic resonance imaging (MRI) was performed on a Siemens 1.5-Tesla Avanto or 
1.5-Tesla Sonato scanner (Siemens Medical Solutions, Erlangen, Germany), equipped with a 
6-element phased-array coil. A stack of short-axis images were obtained at breath-hold per 
slice, with a slice thickness and interslice gap of 5 mm, fully covering both ventricles from base 
to apex.  
On end-diastolic images (first cine after R-wave trigger) and end-systolic images (cine with 
visually the smallest cavity area), endocardial and epicardial contours were manually drawn 
using MASS software (Department of Radiology, Leiden University Medical Center, Leiden, 
The Netherlands) to obtain RV end-diastolic volume (RVEDV), RV end-systolic volume (RVESV) 
and RV mass. Volume measurements and RV mass were indexed for BSA. Papillary muscles 
 
 
and trabeculae were included in RV mass. RV ejection fraction (RVEF) is calculated as (RVEDV-
RVESV)/RVEDV*100%. 
 
Histology and morphometry 
Paraffin embedded cardiac sections (5μm) were histochemically stained with Hematoxylin-
Eosin (HE) and Picrosirius Red using standard methods. Analysis of the cross sectional area 
(CSA) was performed by randomly selecting 20 transversally cut cardiomyocytes (CMC) in RV 
and LV (40x magnification) and tracing the exterior of the cell with image analysis software. 
(Image J 1.45S, National institute of Health, USA). Collagen content was expressed as a 
percentage collagen positive tissue-area per total field of view, as measured in 5 randomly 
selected fields (40x magnification).  
Immunofluorescent staining was performed using standard methods. Briefly, sections were 
deparaffinized followed by epitope retrieval with antigen unmasking solution (H3300, Vector 
Laboratories, USA). Blocking steps with 3% H2O2 for endogenous peroxidase and 1% bovine 
serum albumin (BSA) were performed before labeling with the primary antibodies O/N; 
phosphorylated (p) SMAD1,5,8 (CS9511, 1:200), p-SMAD2 (CS8828s, 1:100),  Von Willebrand 
Factor (VWf) (used for capillary density analysis) (A0082, DAKO, 1:100) , CD45+ (used for 
inflammation analysis) (M0701, DAKO, 1:200). Subsequent labeling with appropriate FITC-
conjugated secondary antibody followed VWf  and CD45 labeling. Both p-SMAD1,5,8 and p-
SMAD2 sections were labeled with appropriate HRP-conjugated secondary antibodies 
followed by tyramide signal amplification (TSA) (NEL700A001KT, Perkin Elmer, USA). All 
sections were counterstained with wheat germ agglutinin (W32464, Life technologies, USA) 
and 4’,6-diamidino-2 phenylindole (DAPI) (H-1200, Vector labs, USA). Image acquisition was 
performed on a ZEISS Axiovert 200M Marianas inverted microscope. A minimum of 5 fields 
per section was randomly acquired for analysis. Slidebook 5.5 imaging analysis software 
(Intelligent Imaging Innovations, Denver, CO) was used to quantify for positive p-SMAD1,5,8 
and p-SMAD2 nuclei and expresses as total number of p-SMAD-positive nuclei vs. total nuclei 
count. CD45+ cells positive cells were expressed as number of positive cells per area. 
Capillaries (VWF staining) and CMC were semi-automatically counted and expressed as a 




RNA was isolated from paraffin embedded RV and LV tissues according to the manufacturer’s 
protocol (73504, Qiagen, Venlo, The Netherlands) followed by purification (74204, Qiagen, 
Venlo, The Netherlands). Subsequently RNA concentration and purity was assessed using a 
Nanodrop spectrophotometer (Nanodrop 1000, Thermo Scientific, Breda, The Netherlands). 
Equal concentrations of RNA of all individual samples was reversely transcribed and amplified 
(3312-48, NuGEN, Leek, The Netherlands). Differential gene expression was assessed by qRT-
PCR using Takyon PCR mastermix (UF-LSMT-B0705, Eurogentec, Maastricht, The 
 
 
Netherlands) and the CFX96 Touch detection system (Bio-Rad, Veenendaal, The 
Netherlands). Relative levels of gene expression were obtained using 18s rRNA as reference 
gene. Data is shown as fold change ± standard error of the mean (SEM). Target genes, primers 
sequences and annealing temperatures are shown in Table 2.1. 
 
Statistical analysis 
Statistical analyses was performed using Prism 5 for Windows (GraphPad Software Inc, San 
Diego, CA).  The data are presented as means ± SEM or median (25-75%), dependent on 
normal distribution. Normal distribution was tested using the D’Agostino and Pearson 
omnibus normality test. Values of p<0.05 were considered significant. 
Differences in patient characteristics, hemodynamics, RV function and RV histology were 
tested using a one-way ANOVA or Kruskal-Wallis test with proper post-hoc comparison, 
depending on normal distribution. To compare categorical variables, a chi-squared test was 
used.  Linear regression analysis was used to correct differences in RV function for PVR. 
Treatment response analysis was performed using a two-way analysis of variance with 
Bonferroni’s multiple comparison test. 
Cross sectional area was analyzed using multilevel analysis to correct for nonindependence 
of successive measurements per patients (MLwiN 2.02.03, Center for Multilevel Modeling, 
Bristol, UK).  
 


















Abbreviations: Bmpr2, bone morphogenetic protein receptor 2; Tgfbr1, transforming growth factor 
beta receptor 1; Fas, Fas cell surface death receptor; ANP, atrial natriuretic peptide; Glut1, glucose 









Clinical characteristics of patients seen at the VU University Medical Center are presented in 
Table 2.2 and supplementary Table 1. No differences between carriers and non-carriers were 
found in sex or 6 minute walking distance (6MWD). Mutation carriers tended to present at a 
younger age compared to non-carriers. 
 
BMPR2 mutations 
BMPR2 mutations were identified in 15 of 82 (18%) sporadic PAH patients and 13 of 21 (61%) 
familial PAH patients. Familial patients without BMPR2 mutation were excluded. Twenty 
different germline BMPR2 mutations were identified in the mutation carriers, including three 
large rearrangements  (corresponding to an exon 1 deletion, a deletion from exon 4 to 12 
and a deletion of exon 10 to 13) and one duplication of exon 8. (Table 2.3) 
 







































Data are presented as mean±SD  or median (25-75%), dependent on normal distribution. 6MWD: 6 
minute walk distance,  HR: heart rate; mPAP: mean pulmonary artery pressure; mRAP: mean right atrial 
pressure; SvO2: mixed venous oxygen saturation; PAWP: pulmonary arterial wedge pressure; PVR: 
pulmonary vascular resistance; CI: cardiac index; SVI: stroke volume index; RVEDVI: right ventricular 
end-diastolic volume index; RVESVI: right ventricular end-systolic volume index; RVEF: right ventricular 
ejection fraction; LVEDVI: left ventricular end-diastolic volume index; LVESVI: left ventricular end-
systolic volume index; LVEF: ejection fraction. P-value: comparison mutation carriers-non-carriers.  
 




To assess whether initial changes between mutation carriers and non-carriers at baseline 
remain after PAH-specific treatment, we performed a treatment response analysis in a 
subgroup of patients (Supplementary Table 2). Median time between baseline and follow-up 
was similar for non-carriers and mutation carriers (1.9 years (interquartile range 1.0-4.7) and 
1.2 years (interquartile range 0.8-5.1) respectively). Time between RHC and MRI was 2±7 days 
in mutation carriers and 1±6 days in non-carriers.  As can be appreciated from Supplementary 
Table 3, both groups were treated equally. Initial differences between mutation carriers and 






Figure 2.2 – Hemodynamic measurements and cardiac function at baseline 
 
 
mPAP: mean pulmonary artery pressure, PVR: pulmonary vascular resistance, HR: heart rate, CI: 
cardiac index, SVI: stroke volume index, RVEF: right ventricular ejection fraction. Hemodynamic 
measurements: controles: n=15, non-carriers: n=65, carriers n=28. RVEF: controls n=15, non-carriers 
n=40, carriers n-21. Data are presented as mean±SEM. Controls vs. non-carriers or carriers: *; p<0.05, 
**: p<0.01, ***: p<0.001, non-carriers vs. carriers: #: p<0.05 
 
The effects BMPR2 mutations on TGF-β/BMP signaling, RV adaptation and cardiac 
metabolism   
To investigate whether the differences observed in the clinical data could be explained by 
differences in TGF-β or BMP signaling in cardiomyocytes, immunofluorescent stainings and 
RNA analyses were performed in LV and RV tissue obtained from controls, mutation carriers 
and non-carriers. Hemodynamic characteristics of tissue samples donors can be observed in 
Table 2.4. Tissue samples of mutation carriers and non-carriers were matched on pulmonary 
vascular resistance (PVR) in order to avoid load-dependent differences.   
 
TGF- β/BMP signaling 
To assess BMP signaling, the first downstream effector of the BMP signaling cascade was 
stained, phosphorylated SMAD1,5,8 (p-SMAD1,5,8) (Figure 2.3A). No difference was 
observed in p-SMAD1,5,8 expression in RV tissue of PAH and controls or between BMPR2 
mutation carriers and non-carriers. However, expression of p-SMAD1,5,8 was significantly 
reduced in LV tissue of PAH-patients in comparison to controls, although again no difference 
was found between BMPR2 mutation carriers and non-carriers.  
To assess TGF-β activity, the expression of phosphorylated SMAD2 (p-SMAD2) was 
determined (Figure 2.3B). Expression of p-SMAD2 was significantly reduced in PAH in 
 
 
comparison in both RV and LV tissue. However, no differences in p-SMAD2 activity were 
observed between BMPR2 mutation carriers and non-carriers.   
No differences were observed in RNA expression of BMPR2 and the TGF-β type I receptor 
(TβRI) (Figure 2.4A), indicating that TGF-β and BMP activity is similar in cardiomyocytes in 
BMPR2 mutation carriers and non-carriers and that other factors may play a role in the 
different RV adaptation in mutation carriers and non-carriers.    
 
Table 2.4 – Cardiac tissue samples – Patient characteristics RV tissue samples  
 
Data are presented as mean±SD or median (25-75%), dependent on normal distribution. NYHA class: 
New York Heart Association Functional class, mPAP: mean arterial pressure, PVR: pulmonary vascular 
resistance, CI: cardiac index. P-value: comparison mutation carriers – non-carriers. Comparison to 
controls: †p<0.05, ‡ p<0.01. 
 
RV adaptation 
To obtain more insight into the mechanisms of RV and LV adaptation, morphological 
characteristics of both non-carriers and mutation carriers were assessed. RV hypertrophy and 
LV atrophy was observed in all PAH-patients in comparison to controls, without differences 
between mutation carriers and non-carriers (Figure 2.5A). In line with these data, increased 
expression of ANP was observed in PAH-patients compared to controls, while expression was 
similar in carriers and non-carriers (Figure 2.4B).    
RV fibrosis was increased in PAH-patients in comparison to control (Figure 5B). However, no 
differences were observed in RV fibrosis, capillary density, or CD45 expression in both RV and 
LV tissue of mutation carriers and non-carriers. (Figure 2.5B, 2.6).  
In addition, apoptotic rate (expression of caspase 3 and fas cell surface death receptor) was 








To determine whether changes in metabolism may explain the differences in RV function 
between mutation carriers and non-carriers, we subsequently assessed RNA expression of 
key-components of glucose metabolism (GLUT1, hexokinase 1/2) and fatty acid oxidation 
(fatty acid binding protein 3 (FABP3), CD36, carnitine palmitoyltransferase 1/2). Although 
significant increases in expression of GLUT 1, FABP3 and CPTB1 were observed in PAH tissue 
in comparison to control, no differences were identified between mutation carriers and non-
carriers.  (Figure 2.7) 
 
DISCUSSION 
By combining in vivo measurements of RV function with molecular and histological analyses 
of unique RV and LV tissue of PAH-patients and controls, we were able to demonstrate that:  
1) Despite a similar afterload, RV function is more severely compromised in BMPR2 
mutation carriers compared to non-carriers. Differences continue to exist after PAH-
specific treatment. 
2) TGF-β and BMP signaling is similar in LV and RV cardiomyocytes of BMPR2 mutation 
carriers and non-carriers. 
3) The amount of RV hypertrophy, LV atrophy, fibrosis, apoptosis, inflammation, capillary 
density and cardiac metabolism is similar between BMPR2 mutation carriers and non-
carriers, indicating an equal RV and LV adaptation. 
 
Impaired RV function in BMPR2 mutation carriers 
Previous large retrospective studies have demonstrated the increased hemodynamic burden 
in PAH-patients carrying a BMPR2 mutation, accompanied by a shorter time to death or lung 
transplantation. 13,14,26–28 Until now, differences in survival and disease severity were mainly 
explained by a more severe pulmonary vascular involvement, leading to a more severe and 
faster disease trajectory. However, combining the fact that RV function is the main 
determinant of prognosis and disease severity and that the BMPR2 gene is also expressed in 
the RV, it can be speculated that RV function plays a role in the differential clinical phenotypes 
of mutation carriers and non-carriers. 4,9,29,30 Accordingly, a recent study by Brittain et al. 
revealed an out of proportion RV dysfunction in HPAH patients at baseline. 27 However, these 
differences should be interpreted with caution, as the afterload of mutation carriers was 
significantly higher in comparison to non-carriers. 
An interesting finding in our present study is the comparable afterload of BMPR2 mutation 
carriers and non-carriers, suggesting a distinct clinical phenotype of BMPR2 mutation carriers 
in the Netherlands. A possible explanation is the relatively high percentage of cytoplasmic 
tail mutation carriers in our cohort, which is 25%, compared to 13% in the French PAH registry. 
31 As cytoplasmic tail mutations carriers present hemodynamically similar to non-carriers, this 
may have contributed to the observed phenotype of our patient cohort. Despite these 
similarities, we observed a decreased RV function in mutation carriers. This reduction was not 
 
 
explained by differences in PVR or a more severe state of disease at presentation. These 
findings suggest a negative effect of BMPR2 mutations on RV function in PAH-patients. 
 
TGF-β/BMP balance in PAH  
Significant progress in the knowledge about the role of TGF-β in the response to pressure 
overload has been achieved by studies in left heart failure. Whilst it is known that TGF-β is 
associated with maladaptive hypertrophy, inflammation and fibrosis in various models and 
diseases, the study of Koitabashi et al was the first to show that TGF-β plays a central role in the 
cardiac maladaptive response to pressure-overload.32–36 However, as the left ventricle has a 
different embryological origin and the amount of pressure overload in right and left heart failure 
is not comparable, these results cannot directly be extrapolated. 37,38 
Until recently, little was known about the effects of BMPR2 mutations on RV adaptation in PAH. 
First, Megalou et al. showed the importance of TGF-β in the hypertrophic response in the 
myocardium of pulmonary hypertensive monocrotaline rats, and more recently Hemnes et al. 
demonstrated impaired hypertrophy due to an altered cardiac energy metabolism in the RV of a 
transgenic mice model expressing mutant BMPRII. 24,39 However, the effects of BMPR2 mutations 
in human cardiomyocytes remain elusive. Therefore, we studied the TGF-β-BMP signaling in 
cardiomyocytes of PAH patients with and without BMPR2 mutation and characterized hypertrophy, 
capillarization, inflammation and fibrosis. Surprisingly, our study did not reveal any differences in 
neither TGF-β nor BMP signaling between carriers and non-carriers, although it corresponds to a 
previous study of Atkinson et al., in which they show a decreased BMPRII receptor expression in 
the pulmonary vasculature of both mutation carriers and non-carriers. 16 Interestingly, we were 
able to demonstrate significant differences in BMPR2 expression and metabolic adaptation 
between non-carriers and controls, suggesting a potential dysfunctional compensatory signaling 
underlying the functional differences between mutation carriers and non-carriers.   
We were not able to confirm the previous observed RV maladaptive response in BMPR2 mice in 
our human RV tissue. One explanation might be the difference between rodents and human 
cardiac physiology. Another explanation could be the end-stage right heart failure of the patient 
samples used for our histomorphological analysis of the RV. There may be important differences 
in myocardial structure of failing and adapting RV, but due to the inherent difficulties of obtaining 
biopsies (reported high complication rates) from adapted patients this is problematic to assess.   
 
Study limitations 
We were only able to include a small number of RV and LV tissue samples of PAH-patients and 
controls. This may have limited our statistical power to identify differences between mutation 
carriers and non-carriers. However, we were able to confirm known differences in hypertrophy, 
fibrosis and cardiac metabolism, which were described previously in animal models. 40–42 These 
findings suggest, that although the number of subjects was small, it was sufficient to identify 







Although a direct relation between RV function and a BMPR2 mutation was not revealed in this 
study, our findings suggest that BMPR2 mutations lead to an impaired RV function in symptomatic 
PAH. Our results raise the question whether clinical status and time to death or lung 
transplantation in BMPR2 mutation carriers could be improved using the RV as a therapeutic 
target. Furthermore, our results provide rationale for closely monitoring RV function in BMPR2 
mutation carriers in PAH referral centers and subsequently timely referral for lung transplantation. 
Further therapeutic studies targeting the disturbed TGF-β/BMP pathway will reveal the clinical 
implications of  this disturbed balance in the RV of PAH patients.  
 
Conclusions 
We demonstrated that PAH patients carrying a BMPR2 mutation have a decreased RV function 
compared to PAH patients without BMPR2 mutation at presentation, which persisted after PAH 
specific treatment. We revealed that there are no alterations in TGF-β and BMP induced SMAD 
phosphorylation in cardiomyocytes of PAH patients with or without mutation. Furthermore, we 
demonstrated that RV and LV adaptation is not different between BMPR2 mutation carriers and 


























Figure 2.3  - Expressions of p-SMADs in the right and left ventricle,  legend page 44 
 
 




Figure 2.5 – Cross-sectional area (A) and fibrosis (B) in the LV and RV, legend page 44 
 
 
Figure 2.6 – CD-45 expression (A) and capillary density (B) in the RV and LV – legend page 44 
 
 







Figure 2.3:  
Percentage of a) p-SMAD1,5,8 activated nuclei per total nuclei in the left ventricle (LV) and right 
ventricle (RV), b) percentage of p-SMAD2 activated nuclei per total nuclei in the LV and RV. Controls 
n=6, non-carriers n=11, carriers n=5. Control values are normalized to 100%. Data are presented as 
mean±SEM. *: p<0.05, **: p<0.01, ***: p<0.001 
 
Figure 2.4: 
RNA-expression of RV a) the TGF-ß/BMP axis, b) hypertrophy and c) apoptosis and LV d) TGF-ß/BMP 
axis, e) hypertrophy and f) apoptosis. BMPR2: Bone Morphogenetic Protein Receptor 2, TGF-ßR1: 
Transforming Growth Factor -ß1, ANP: atrial natriuretic peptide, FAS: Fas Cell Surface Death 
Receptor, CASP3: Caspase 3. Controls n=6, non-carriers n=11, carriers n=5. Data are presented as 
mean±SEM. Control values are normalized to 1. *<0.05, **<:p<0.01 
 
Figure 2.5: 
Percentage of a) cross-sectional area and b) fibrosis in both the LV and RV. Control values are 
normalized to 100%. Controls n=6, non-carriers n=11, carriers n=5. Data are presented as 
mean±SEM. *:p<0.05, **: p<0.01, ***: p<0.001 
 
Figure 2.6: 
Percentage of a) CD45 expression and b) capillary density in both LV and RV. Control values are 




RNA expression of metabolic markers. GLUT1: glucose transporter 1; HK2: hexokinase 2, HK1: 
hexokinase 1, FABP3: fatty acid binding protein 3, CPT: carnitine palmitoyltransferase. Controls n=6, 
non-carriers n=11, carriers n=5. Data are presented as mean±SEM. Control values are normalized to 
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Table S1 – Clinical study – ethnicities 
 
 




Table S3 – PAH-specific therapy at follow-up 
 
PAH=pulmonary arterial hypertension, PDE-5-inhibitors: phosphodiesterase type 5 inhibitors; ERAs: 












































CONTRIBUTION OF IMPAIRED PARASYMPATHETIC 
ACTIVITY IN RIGHT VENTRICULAR DYSFUNCTION 
AND PULMONARY VASCULAR REMODELING IN 












D da Silva Gonçalves Bos, CE van der Bruggen, K Kurakula, XQ Sun, KR Casali, AG 
Casali, N Rol, R Szulcek, C dos Remedios, C Guignabert, L Tu, P Dorfmuller, M 
Humbert, PJM Wijnker, DWD Kuster, J van der Velden, MJ Goumans, HJ Bogaard, A 








Background:  Beneficial effects of parasympathetic stimulation have been reported in left 
heart failure, however, whether it would be beneficial for pulmonary arterial hypertension 
(PAH) remains to be explored. Here, we investigated the relationship between 
parasympathetic activity and right ventricular (RV) function in PAH-patients, and the potential 
therapeutic effects of pyridostigmine (PYR), an oral drug stimulating the parasympathetic 
activity through acetylcholinesterase (AchE) inhibition, in experimental pulmonary 
hypertension (PH). 
 
Methods: Heart rate recovery (HRR) after maximal cardiopulmonary exercise test was used as 
a surrogate for parasympathetic activity. RV ejection fraction (RVEF) was assessed in 112 PAH-
patients. Expression of nicotinic (α-7nAchR) and muscarinic (m2AchR) receptors, and AchE 
activity were evaluated in RV (n=11) and lungs (n=7) from PAH-patients undergoing heart/lung 
transplantation and compared with tissue obtained from controls. In addition, we investigated 
the effects of PYR (40 mg/kg/day) in experimental PH. PH was induced in male rats by SU5416 
(25 mg/kg; s.c.) injection followed by 4 weeks of hypoxia. In a subgroup 
sympathetic/parasympathetic modulation was assessed by power spectral analysis. At week 
6, PH status was confirmed by echocardiography, and rats were randomized to vehicle or 
treatment (both n=12). At the end-of-study, echocardiography was repeated, with additional 
RV pressure-volume measurements, along with lung, RV histological and protein analyses. 
 
Results: PAH-patients with lower RVEF (<41%) had a significantly reduced HRR in comparison 
to patients with higher RVEF. In PAH RV-samples, α-7nAchR was increased and AchE activity 
was reduced versus controls. No difference in m2AchR expression was observed. Chronic 
PYR-treatment in PH-rats normalized the cardiovascular autonomic function, demonstrated by 
an increase in parasympathetic activity and baroreflex sensitivity. PYR improved survival, 
increased RV contractility, and reduced RV stiffness, RV hypertrophy, RV fibrosis, RV 
inflammation, as well as RV α-7nAchR and m2AchR expression. Furthermore, PYR reduced 
pulmonary vascular resistance, RV afterload and pulmonary vascular remodeling, which was 
associated with reduced local and systemic inflammation. 
 
Conclusion: RV dysfunction is associated with reduced systemic parasympathetic activity in 
PAH-patients, with an inadequate adaptive response of the cholinergic system in the right 
ventricle. Enhancing parasympathetic activity by PYR improved survival, RV function and 











Pulmonary arterial hypertension (PAH) is characterized by progressive pulmonary vascular 
remodeling and increased right ventricular (RV) afterload, which eventually leads to right heart 
failure.1 Despite the significant progress in the treatment of PAH, its prognosis remains grim.2, 
3 
 
Cardiovascular autonomic dysfunction, or more specifically, increased sympathetic nervous 
system activity4, 5, parasympathetic nervous system withdrawal6 and blunted baroreflex 
sensitivity7, 8 are associated with disease progression and poor prognosis in PAH. It has 
however, never been directly related with RV function.7, 9 We and others have demonstrated 
that targeting the sympathetic nervous system could be a promising therapy to improve RV 
function and pulmonary vascular remodeling.10-12 Hypothetically, autonomic function can also 
be restored via parasympathetic stimulation. However, this has not been investigated yet in 
the context of PAH. 
 
Local cardiac parasympathetic activity is mediated via two types of receptors, the nicotinic 
receptors (at the preganglionic level) and the muscarinic receptors (postganglionic level). 
Nicotinic receptors are activated by acetylcholine released from parasympathetic nerve 
terminals at the preganglionic level, and subsequently the muscarinic receptors are activated 
at organ level.13 Increased expression of the nicotinic receptor was observed in the left 
ventricle in a pressure-overload rat model.14 This finding suggests a compensatory cholinergic 
response to reduced parasympathetic activity. Another study in experimental left heart failure 
provided evidence that pyridostigmine (PYR), an oral drug which stimulates the 
parasympathetic nervous system through acetylcholinesterase inhibition, was able to improve 
autonomic and left ventricular function.15, 16 Furthermore, donepezil, a different 
acetylcholinesterase inhibitor which crosses the blood-brain barrier, was also shown to 
improve cardiac function in left heart failure17 and attenuated the development of 
hypertension in spontaneously hypertensive rats.18 In the present study we choose to use PYR, 
a long approved drug for myasthenia gravis, with a more favorable pharmacological profile 
compared to donepezil, to activate the parasympathetic nervous system. 
 
Here, we aim to investigate the relationship between parasympathetic activity and RV function 
in idiopathic/hereditary PAH-patients. In addition, we aim to determine the potential 
therapeutic effects of parasympathetic activity stimulation by pyridostigmine in an 









Parasympathetic nervous system activity and RV function in pulmonary arterial hypertension 
patients 
We retrospectively reviewed 112 idiopathic and hereditary PAH-patients seen at the VU 
University Medical Center (Amsterdam, the Netherlands) between 2002 and 2015, who 
underwent a maximal cardiopulmonary exercise test and cardiac magnetic resonance imaging 
(CMR) for clinical reasons. Eight healthy volunteers who underwent a maximal 
cardiopulmonary exercise test were used as a control group. Heart rate recovery (HRR) was 
used as a surrogate of parasympathetic activity.19 HRR was defined as the difference in heart 
rate at the maximum workload and at 30 seconds, 60 seconds and 120 seconds after 
completion of the cardiopulmonary exercise test. RV ejection fraction (RVEF) was used as a 
parameter of RV function, and the cutoff value of 41% was selected based on the median. 
 
Table 3.1 – General characteristics and hemodynamics 
 
Data are presented as mean±SD or median (25%–75%), dependent on normal distribution. RVEF 
indicates right ventricular ejection fraction. Compares RVEF<41% and RVEF≥41%. 
 
Human RV and Lung samples 
Explanted RV tissue samples were collected from PAH-patients undergoing heart/lung 
transplantation (PAH-patient; n=11) and compared with RV tissue obtained from non-failing 
controls (control; n=9).20 Human cardiac tissue collection was approved by the Human 
Research Ethics Committee of The University of Sydney (AU/1/961515) and the Université 
Paris-Sud-Inserm U999 (ID RBC 2008-A00485-50). Control lung tissues and pulmonary arteries 
were obtained from patients undergoing surgery for lung carcinoma (control; n=4). Samples 
 
 
were obtained distant from the malignant lesion and were dissected by a pathologist. Lung 
tissues and pulmonary arteries were also obtained from PAH-patients undergoing lung 
transplantation (PAH-patient; n=7). Lung sample collection was approved by the local ethics 
committees (Comité de Protection des Personnes, Sud-Ouest et Outre-mer III, Bordeaux, 
France; and Comité de Protection des Personnes, IIe de France, VII, Le Kremlin Bicêtre, 
France). 
 
Cholinergic system in human samples 
Acetylcholinesterase (AchE) activity (supplemental methods) and protein expression of 
cholinergic receptors were evaluated in RV, pulmonary artery and lung homogenates from 
PAH and control patients by Western blot analyses. In the current study, we evaluated the 
expression of the following cholinergic receptors: the alpha-7 nicotinic acetylcholine receptor 
(α-7nAchR; 1:1000; AB24644; Abcam), a receptor which can activate the anti-inflammatory 
cholinergic pathway21, and muscarinic acetylcholine type 2 receptor (m2AchR; 1:1000; MA3-
044; Thermo Scientific), a receptor related to negative inotropic effects via inhibition of 
adenylate cyclase.22 Moreover, α-7nAchR was evaluated by immunofluorescence in lung 
sections from PAH and control patients. 
 
Cell proliferation assay of PAH-patients 
Pulmonary microvascular endothelial cells (MVECs) were isolated from patients that 
underwent lobectomy. The study was approved by the Institutional Review Board of the VU 
University Medical Center (Amsterdam, the Netherlands). Endothelial cell isolation and culture 
of the smallest pulmonary vessels were performed as previously described.23 Cell proliferation 
was assessed by the MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) 
(Sigma-Aldrich) assay as described previously.24 Cells were seeded in a 96-well plate at a 
density of 3 × 103 cells/well and incubated overnight. Cells were made quiescent by 
incubation in medium without fetal calf serum (FCS) for 2 h. Cells were then treated with 
vehicle or various concentrations of PYR for 2 h followed by FCS (10 % v/v) stimulation for 24 
h. After the incubation, cells were incubated with 10 μL of MTT reagent (5 mg/ml) for 2.5 h at 
37°C. The MTT reagent was removed and 100 μL of isopropanol was added to each well. 
Plate was wrapped in an aluminium foil and incubated for 15 min on a shaker. Colorimetric 
analysis was performed with an ELISA plate reader. This experiment (in quadruplicate) was 
repeated at least three times. 
 
Human 3D-engineered heart tissue 
For regulatory reasons, we were not permitted to include a PYR-control group in the main 
experimental study. Therefore, we included a study on the effects of PYR on 3D-engineered 
heart tissue (EHT), generated from iCell® cardiomyocytes^2 (Cellular Dynamics International), 
which are human induced pluripotent stem cell-derived cardiomyocytes, mixed with 
 
 
MatrigelTM (Corning, 354234), bovine fibrinogen (Sigma, F8630) plus aprotinin (Sigma, A1153), 
and thrombin (Sigma, T7513) (for details see Supplement).25 
 
Experimental pulmonary hypertension 
All animal experiments were approved by the Institutional Animal Care and Use Committee 
of the VU University, Amsterdam, the Netherlands. 
 
Figure 3.1 - Heart rate recovery and local change in the cholinergic system in PAH-patients 
 
 
(A) Heart rate recovery (HRR) after the cardiopulmonary exercise test at 30, 60 and 120 seconds. PAH-
patients with lower right ventricle (RV) function (RV ejection fraction or RVEF <41%) had a significant 
reduced HRR in comparison to patients with higher RV function (RVEF >41%). Control: n=8, PAH RVEF 
>41% (n=56), PAH RVEF <41% (n=56). **p<0.01, ***p<0.001, versus PAH RVEF >41%. RVEF=right 
ventricle ejection fraction. (B) Representative RV protein expression from alpha-7 nicotinic acetylcholine 
receptor ( -7nAchR) and (C) muscarinic acetylcholine receptor (m2AchR). (D) Acetylcholinesterase 
(AchE) activity in RV homogenates from PAH-patients. Control: n=9 and PAH-patients: n=11. (E) AchE 
activity in pulmonary artery homogenates. Control: n=4 and PAH-patients: n=7. (F) AchE activity in 
microvascular endothelial cells from Control: n=3 and PAH-patients: n=3. *p<0.05, **p<0.01 versus 
Control. 
 
Sugen/hypoxia-rat model of pulmonary hypertension 
Male Sprague Dawley rats were used (n=31, 125-150 g; Charles River, Sulzfeld, Germany). 
One week before PH-induction, a pressure telemetry device (TA11PA-C40, Data Science 
International, St. Paul, MN) was implanted in the abdominal aorta in a subgroup of rats (n=4-
6) for heart rate and blood pressure variability analysis.26 PH was induced by a single 
subcutaneous injection of a vascular endothelial growth factor inhibitor (SU5416, 25 mg/kg 
body mass; Tocris Bioscience, Bristol, UK) dissolved in 0.5% carboxymethylcellulose, followed 
by 4 weeks of hypoxia exposure (10% oxygen; Biospherix Ltd, New York, NY) maintained by 
 
 
a nitrogen generator (Avilo, Dirksland, The Netherlands) and re-exposed to normoxia for 
maximally 10 weeks. The control group (controls; n=7) received a carboxymethylcellulose 
injection and was housed in normoxic condition until the end-of-study (Supplement Figure 
S1).27 
 
Pyridostigmine treatment and hemodynamic measurements 
Pyridostigmine (PYR) dose (Sigma Aldrich, 40 mg/kg) was determined in a pilot study as the 
minimal dose able to reduce heart rate by 10% and increase parasympathetic activity, with 
minimal effects on systolic arterial pressure or animal activity (Supplement Figure S2). At week 
6, PH status was confirmed by echocardiography, and animals were randomized into: PH 
(n=12) or PH-PYR (n=12). PYR was delivered in drinking water. At the end-of-study, week 10, 
or earlier when animals developed signs of right heart failure, defined as > 10% of body 
weight reduction, cyanosis, dyspnea and/or lethargy, echocardiography and RV 
catheterization with pressure-volume analyses were performed as described before (see also 
Supplement, Figure S1).12, 28 
 
Heart rate and blood pressure variability analysis 
Cardiovascular autonomic function was assessed by power spectral analysis, applied to pulse 
interval (PI) and systolic arterial pressure (SAP) series. Heart rate variability (HRV) and blood 
pressure variability (BPV) were evaluated at spectral domain using an autoregressive algorithm 
on stationary sequences of 200 beats. The low-frequency (0.25-0.75 Hz) and high-frequency 
(0.75-3.0 Hz) bands, represented the sympathetic and parasympathetic modulation and were 
expressed in both absolute (HRV: ms2, BPV: mmHg2) and normalized units. The ratio between 
low-frequency and high-frequency components (low-frequency/high-frequency index) was 
considered a synthetic expression of the sympathovagal balance.29, 30 The alpha-index was 
obtained from the square root of the ratio between the PI interval and the SAP variability 
within the low-frequency ranges,31 and it was used to estimate spontaneous baroreflex 
sensitivity.32, 33 
 
Histology of heart and lungs 
After hemodynamic evaluation, rats were euthanized under isoflurane by exsanguination (by 
dissecting the abdominal aorta and inferior vena cava) with immediate removal of the vital 
organs. Heart and lungs were harvested and frozen. Cardiomyocyte cross-sectional area, 
cardiac fibrosis and relative wall thickness of pulmonary arterioles, were determined (see 
Supplement). Furthermore, RV capillary density, leukocytes infiltration, α-7nAchR and 
m2AchR were measured by immunofluorescence (see Supplement). 
 
Cholinergic system in experimental-PH 
RV tissue of the rats was homogenized in radioimmunoprecipitation assay (RIPA) buffer 
containing phosphatase and protease inhibitors (Sigma-Aldrich). The protein concentration 
 
 
was quantified by the Pierce 660 nm protein assay kit (Thermo Scientific, Rockford, USA). 10µg 
of protein was used to detect the expression of cholinergic receptors: α-7nAchR (1:1000; 
AB24644; Abcam) and m2AchR (1:1000; MA3-044; Thermo Scientific). The protein amount 
was normalized by GAPDH as loading control (1:50000; G9295, Sigma-Aldrich). In addition, 
AchE activity (supplemental methods) was measured in plasma and RV homogenates. 
 
Statistical analysis 
Statistical analyses were performed using Prism for Windows (GraphPad 6 Software). Data are 
presented as mean±SEM, p-values < 0.05 were considered significant. Normality of data was 
checked and either log-transformation or non-parametric testing was performed if data was 
not normally distributed. Unpaired t-test was used to compare the general characteristics of 
PAH-patients and to compare acetylcholinesterase levels and cholinergic receptors 
expression between control and PAH-patients. The X2 test was used for categorical variables. 
The survival estimates were performed by Kaplan-Meier analysis, with post-hoc comparison 
by log rank (Mantel-Cox) test between PH rats with/without PYR treatment. Two-way ANOVA 
for repeated measurements followed by Bonferroni post-hoc test was used for: heart rate 
recovery, echocardiography and cell proliferation assay. One-way ANOVA with Bonferroni 
post-hoc comparison between PH and PH-PYR was used for: pressure-volume relationships, 
autopsy data, histology data and protein analyses. Kruskal-wallis test followed by Dunn’s 
multiple comparison test was used for: heart rate variability and blood pressure variability 
analyses. The heart rate and blood pressure variability data are presented in delta percentage 




Reduced parasympathetic activity was associated with reduced RV function in PAH-patients 
To investigate whether parasympathetic activity is associated with RV function in 
idiopathic/hereditary PAH patients, we assessed heart rate recovery after the 
cardiopulmonary exercise test as a measure of parasympathetic activity and RVEF as a 
measure of RV function assessed by cardiac magnetic resonance imaging (CMR). General 
patient characteristics and hemodynamics are presented in (Table 1). The median RVEF was 
41%. Patients with lower RVEF had increased NT-proBNP levels, lower exercise capacity, 
higher resting heart rate, increased mean pulmonary artery pressure and pulmonary vascular 
resistance (Table 3.1). 
 
PAH-patients had an impaired HRR at 30 and 60 seconds after maximal exercise, in 
comparison to control subjects (Figure 3.1A). Importantly, in patients with low RVEF, heart 
rate recovery (at both 60 and 120 seconds) was lower compared to patients with higher RVEF 
(Figure 3.1A). These results indicate that reduced parasympathetic activity in PAH-patients is 
associated with a reduced RV function. 
 
 
Local changes in the cholinergic system in PAH-patients 
Acetylcholine is the main parasympathetic nerve neurotransmitter and exerts its effect by 
binding to its nicotinic and muscarinic receptors. To investigate the local changes in the 
cholinergic system in the right ventricle, expression of the nicotinic (α-7nAchR), muscarinic 
receptors (m2AchR) and acetylcholinesterase (AchE) activity were assessed in RV tissue of 
PAH-patients and controls. We observed that α-7nAchR expression was upregulated in RV 
tissue from PAH-patients versus controls (Figure 3.1B), whereas no difference in m2AchR 
expression was found (Figure 3.1C). In addition, AchE activity was reduced in RV tissue of 
PAH-patients (Figure 3.1D). 
 
To determine the local changes in the cholinergic system in the lung, we assessed the 
expression of α-7nAchR, m2AchR and AchE activity in whole lung tissue and pulmonary artery 
of PAH-patients and controls. Both α-7nAchR and m2AchR expression were similar in lung 
homogenates of control and PAH-patients (Figure S3A-B). However, because our 
immunofluorescence staining suggested higher α-7nAchR expression around the pulmonary 
arteries from PAH-patients (Figure S3C), we further investigated the expression of α-7nAchR 
in pulmonary artery homogenates from PAH-patients versus controls, and again no significant 
difference was observed (Figure S3D). In addition, m2AchR expression was also not significant 
different in pulmonary artery homogenates from PAH-patients in comparison to controls 
(Figure S3E). Moreover reduced AchE activity was observed in MVECs and pulmonary arteries 
of PAH-patients (Figure 3.1E,F). 
 
Based on these data we hypothesize that the observed reduction in AchE activity may be an 
adaptive mechanism to the known autonomic imbalance observed in PAH-patients. However, 
as patients still suffer from an autonomic imbalance, this adaptation can be regarded as 
insufficient. The association of reduced parasympathetic activity with RV dysfunction and local 
changes in cholinergic signaling in the RV and lungs in PAH-patients were the rationale to 
study the role of parasympathetic activity in more detail in an experimental model of PH. 
 
Effects of PYR in control animals and in human 3D-engineered heart tissue 
In a pilot study (supplemental material and methods, pilot dose finding), we found that PYR-
treatment at 40 mg/kg had no significant effects in RV end-systolic and end-diastolic pressures 
(Figure S4) in healthy rats. In addition, no relevant differences on dP/dt maximum or dP/dt 
minimum was observed after PYR-treatment (Figure S4). Furthermore, the effects of PYR were 
investigated in human engineered 3D-heart tissue (EHT, supplemental material and methods). 
Functional measurements in EHT were obtained at baseline, 15 and 60 minutes after 
acetylcholine or PYR treatment. As observed in (Figure S4E) we confirmed that PYR and 
acetylcholine significantly reduced the heart rate on spontaneous beating EHTs. PYR also 
reduced the relaxation velocity after 60 min (Figure S4F). In addition, no significant effects of 
 
 
PYR-treatment on maximum force and contraction velocity were observed (Figure S4G-H). 
These results confirmed that PYR had no relevant hemodynamics effect in controls. 
 
Figure 3.2 - Pyridostigmine improved cardiovascular autonomic function and reduced 
acetylcholinesterase activity in rats 
 
Relative changes at end-of-study (week 10) compared to baseline (week 6) on heart rate (HRV) and 
blood pressure variability (BPV). In summary, PYR restores the sympathovagal balance and thus 
(partially) normalized the cardiovascular autonomic function in experimental PH. (A-B) Typical examples 
of a power spectrum (amplitude by heart rate frequency domains) that is the basis for the HRV analysis: 
the low frequency (low-frequency) component is a reflection of sympathetic activity and the high 
frequency (high-frequency) component reflects parasympathetic activity. The dashed lines represent 
the data at start of treatment and the continuous lines indicate the data at the end-of-study. As can be 
appreciated, high-frequency-component increases after PYR (arrow in Figure 2B). PYR reduced heart 
 
 
rate (C) and increased the parasympathetic activity (high-frequency-component) after the treatment (D). 
(E-F) Data derived from the BPV analysis; the sympathetic vascular component is the low-frequency-
component from the BPV (in analogy of the low-frequency-component of HRV), and the lowering effect 
of PYR in PH on this parameter is demonstrated (E); Spontaneous baroreflex sensitivity ( -index) is 
calculated by the square root of the ratio between the pulse interval and the systolic arterial pressure 
variability within the low-frequency-components (sympathetic), the lowering effect of PYR on this 
parameter is demonstrated in (F). Biochemical analysis confirmed that PYR intervention reduced plasma 
acetylcholinesterase (AchE) activity (G) and no effect in RV AchE activity (H). Control: n=4, PH: n=4-6, 
PH-PYR: n=4-6; *p<0.05, **p<0.01, ***p<0.001 versus PH. 
 
Pyridostigmine improved cardiovascular autonomic function in experimental PH 
To establish that PYR effectively stimulated parasympathetic activity in our PH-rat model, the 
cardiovascular autonomic function was assessed by heart rate and blood pressure variability 
analysis (Supplement: Table S1). Typical power spectrum before and after the treatment from 
PH and PH-PYR groups can be appreciated at (Figure 3.2A,B), the low-frequency-component 
represents sympathetic activity and high-frequency-component represents parasympathetic 
activity. PYR significantly reduced the heart rate in comparison to vehicle (Figure 3.2C and 
significantly increased the parasympathetic activity, measured by the high-frequency-
component of the heart rate variability obtained by spectral analysis (Figure 3.2D). Moreover, 
no significant changes in systemic arterial pressure (Supplement: Figure S5A) and daily activity 
(Supplement: Figure S5B) were observed with the dose used. Through the blood pressure 
variability analysis we observed that PYR reduced the sympathetic vascular component (Figure 
3.2E) and improved the spontaneous baroreflex sensitivity (Figure 3.2F). In addition, PYR 
effectively reduced plasma AchE activity in our experimental-PH (Figure 3.2G). No significant 
effects on AchE activity after PYR-treatment was observed in RV homogenates (Figure 3.2H). 
These results confirmed that PYR-treatment reduced plasma AchE activity and partially 
normalized cardiovascular autonomic function in our PH-rat model, without adverse side 
effects. 
 
Pyridostigmine delayed progression towards right heart failure 
PH was confirmed before the start of PYR-treatment in all PH-rats (Supplement: Table S2). 
Survival analysis demonstrated that PYR significantly delayed the time to manifest right heart 
failure in comparison to PH-rats (Figure 3.3A). This finding was confirmed by serial 
echocardiographic analysis, where PYR-treatment maintained RV systolic function, measured 
by TAPSE, stroke volume (Supplement: Table S3) and cardiac output (Figure 3.3B,C). In 
addition, PYR reduced the pulmonary vascular resistance, RV wall thickness and RV end-
diastolic diameter (Figure 3.3D-F). 
 
Pyridostigmine improved RV function 
To determine the effect of PYR on load-independent parameters of RV function, RV pressure-
volume analyses were performed at the end-of-study (representative examples: Figure 3.4A-
C). PYR significantly increased RV contractility (Ees), reduced RV diastolic stiffness (Eed) and 
 
 
also reduced RV afterload (Ea, Figure 3.4D-F), resulting in a partial normalization of RV-arterial 
coupling (Ees/Ea: 0.86±0.09 vs. 0.37±0.09; p<0.05). 
 
Figure 3.3 - Pyridostigmine delayed progression towards right heart failure 
 
Pyridostigmine (PYR) treatment delayed time to manifest right heart failure (A). PYR treatment improved 
RV function (B) and cardiac output (C). PYR reduced significantly the pulmonary vascular resistance (D), 
RV wall thickness (E), RV end-diastolic diameter (F). Data presented as mean ± SEM. Control: n=7, PH: 
n=8, PH-PYR: n=12; Arrows represent significant interaction of the two way ANOVA. ##p<0.01, 
###p<0.001, versus control; *p<0.05, **p<0.01, ***p<0.001, versus PH. TAPSE= tricuspid annular 
plane systolic excursion, CO= cardiac output, PVR= pulmonary vascular resistance, RVWT= right 
ventricle wall thickness, RVEDD=right ventricle end-diastolic diameter. 
 
 
Pyridostigmine reduced RV remodeling and inflammation 
RV histological analyses were performed to analyze structural changes in the right ventricle. 
RV cardiomyocyte cross-sectional area (Figure 3.5A,E,I) and RV fibrosis were decreased with 
PYR (Figure 3.5B,F,J). Although RV myocardial capillary density was reduced in PH-rats in 
comparison to controls, it was not significantly different after PYR (Figure 3.5C,G,K). RV 
myocardial leukocyte infiltration was observed in PH-rats, which was not present in the left 
ventricle (Supplement: Table S4). PYR significantly reduced RV myocardial leukocyte 
infiltration (Figure 3.5D,H,L). 
 
Furthermore, we evaluated changes in the cholinergic receptors after PYR. Western blot and 
immunofluorescent analysis revealed that PYR reduced α-7nAchR and m2AchR expression in 
the RV (Figure 3.6A-D). These findings suggest that the improvement in RV function by 
increased parasympathetic activity may be related to a decreased expression of cholinergic 




Figure 3.4 - Pyridostigmine improved RV function 
 
Representative examples of pressure-volume relationship for control, PH and PH-pyridostigmine (PYR) 
groups. By preload reduction, multiple end-systolic pressure/volume points were obtained, from which 
the RV end-systolic pressure-volume relationship was derived (depicted by the solid rising line). Its 
slope is a load-independent measure for RV contractility (Ees). Similarly, by preload reduction RV end-
diastolic pressure-volume relationship and RV stiffness (Eed) were derived. RV afterload (Ea) was 
measured by RV end-systolic pressure at steady state divided by stroke volume (descending solid line; 
A-C). PYR significantly improved the RV contractility (D) and reduced RV stiffness (E). Moreover, PYR 
reduced RV afterload (F) Control: n=7, PH: n=8, PH-PYR: n=12. *p<0.05 versus PH 
 
Pyridostigmine reduced pulmonary vascular remodeling 
Pulmonary histology was subsequently performed to study structural changes that may 
explain the observed reduction in RV afterload. Histological analyses from pulmonary 
arterioles indicated a significant reduction in media and intima wall thickness after PYR 
treatment (Figure 3.7A-E). Moreover, PYR decreased the formation of occlusive vascular 
lesions (Figure 3.7F). To further investigate the effects of PYR on intima proliferation, we 
evaluated different PYR concentrations on proliferation of microvascular endothelial cells 
(MVECs) derived from control and PAH-patients. Our in vitro study confirmed that PYR 
reduced the MVECs proliferation (Figure 3.7G, Supplement: Figure S6). Taken together, these 










Figure 3.5 - Pyridostigmine reduced right ventricle hypertrophy and fibrosis 
 
Representative examples for control, PH and PH-PYR groups of right ventricle (RV) cross sectional area 
(hematoxilin and eosin, 400X magnification, A,D), fibrosis (picrosirius red, 100X magnification, B,E) and 
CD31 (myocardial capillary density, 100X magnification, C,F). CD31 (green), WGA (red), nuclei (DAPI). 
Scale bar 20µm. PYR reduced significantly the RV cross sectional area (G) and RV fibrosis (H). No 
difference was observed in RV capillary density (I). Data presented as mean ± SEM. Control: n=7, PH: 
n=8 and PH-PYR: n=12. **p<0.01, ***p<0.001, versus PH. 
 
Pyridostigmine reduced systemic and pulmonary inflammation 
To assess the anti-inflammatory effects of PYR, we measured systemic and local inflammation 
in the lung. In plasma, lower levels of IL-6 (730±24 vs. 843±42, p=0.01; pg/ml) and MCP-1 
(1913±273 vs. 3646±542, p=0.002; pg/ml) were observed in PH-PYR compared to the PH-
group. In addition, we observed a reduction in lung perivascular CD45+ cells infiltration in 
PH-PYR group (293±44 vs. 439±37, p=0.02; CD45+/mm2). To assess whether the changes on 
pulmonary vasculature and inflammation could be explained by changes in the cholinergic 
signaling, the expression levels of α-7nAchR and m2AchR were measured by 
immunofluorescence in the pulmonary vasculature. However, no significant changes in α-
7nAchR and m2AchR expression were observed (Figure 3.7H-I, Supplement: Figure S7) after 
PYR. Downstream signaling of α-7nAchR was further analyzed.34 Western blot analysis 
revealed no significant differences on phosphorylated-ERK, total-ERK and NF-κB p65 
expression in lung homogenates by PYR (Supplement: Figure S8). These findings suggest that 







Figure 3.6 - Pyridostigmine improved cholinergic system in RV 
 
Representative RV immunofluorescence staining for alpha-7 nicotinic acetylcholine receptor ( -7nAchR; 
A) and muscarinic acetylcholine type 2-receptor (m2AchR; B) for control, PH and PH-PYR groups.  -
7nAchR and m2AchR (white), WGA (red),  -actinin (green) and nuclei (DAPI). Scale bar 20µm. Western 
blot analyses revealed significant reduction of cholinergic  -7nAchR (C) and m2AchR (D) expression in 
the right ventricle (RV) homogenates after PYR-treatment. Protein expression was normalized by 




In this translational study we demonstrated the clinical relevance of impaired parasympathetic 
activity in RV dysfunction and pulmonary vascular remodeling in pulmonary arterial 
hypertension. 
We were able to provide evidence that: 
1. In PAH-patients, reduced parasympathetic activity was associated with reduced RV 
function; 
2. In our PAH-rat model, increase in parasympathetic activity by PYR delayed the 
progression towards right heart failure; 
3. PYR improved RV function, which was related to a reduction of inflammation, fibrosis 
and normalization of cholinergic receptors in the right ventricle; 
4. PYR also reduced RV afterload and pulmonary vascular remodeling, which was 
associated with direct anti-proliferative and -inflammatory effects of PYR. 
 
 
Figure 3.7 - Pyridostigmine effects on pulmonary vascular remodeling, MVECs proliferation and 
cholinergic receptors in pulmonary vasculature 
 
Representative images of pulmonary arterioles (elastica von Gieson, 40X magnification) for control, PH 
and PH-PYR groups (A-C). PYR improved significantly the wall thickness of the pulmonary arterioles, as 
observed by media (D), intima thickness reduction (E) and formation of occlusive vascular lesions (F). In 
addition PYR reduced human microvascular endothelial cells (MVECs) proliferation in vitro from control 
and pulmonary arterial hypertension (PAH) cells (G). Data presented as mean ± SEM. PO: partially 
obliterated vessels; FO: fully obliterated vessels. *p<0.05, **p<0.01 comparison between 0 mM dose 
versus 10 mM. n =2 in each condition. Control: n=7, PH: n=8 and PH-PYR: n=12. **p<0.01, ***p<0.001, 
versus PAH. Immunofluorescence quantification for alpha-7 nicotinic acetylcholine receptor ( -7nAchR; 
H) and muscarinic acetylcholine type 2-receptor (m2AchR; I). There was no difference on receptors 
density after PYR-treatment. Control: n=4, PH: n=4 and PH-PYR: n=4. 
 
Sympathovagal imbalance and RV dysfunction in PAH 
Previous studies have demonstrated impaired cardiovascular autonomic function and reduced 
parasympathetic nerve system activity in PAH-patients.7, 35 Evaluation of parasympathetic 
activity in patients is challenging, but it can be indirectly assessed by heart rate variability 
spectral analysis, heart rate recovery after exercise and by evaluating the reflexes involved in 
heart rate changes, such as baroreflex sensitivity.19 Lower high-frequency-component of 
 
 
spectral analysis7, impaired heart rate recovery6, 35 and depressed baroreflex sensitivity7, 8 have 
been described in PAH-patients. In addition, these parameters have been related to worse 
exercise capacity7 and prognosis.6 In the present study, we demonstrated that patients with 
reduced parasympathetic activity had a lower RVEF. In addition, we provide direct evidence 
that local parasympathetic activity of the RV is significantly changed. These findings suggest 
an important pathophysiological role of the parasympathetic nervous system. However, until 
now no systematic evaluation in the context of PAH has been performed. 
In (right) heart failure, an autonomic nervous system imbalance develops characterized by 
sympathetic over-activity and parasympathetic withdrawal. At the tissue level, the RV 
responds by reducing beta-adrenergic receptor expression, and increasing nicotinic and/or 
muscarinic receptor expression. The preganglionic part of the parasympathetic system is 
mainly mediated by nicotinic receptors and the postganglionic part is mainly mediated by 
muscarinic receptor, while the pre- and postganglionic neurons are connected in series. Our 
finding that nicotinic receptor expression was increased and AchE activity were reduced in 
the right ventricle in PAH (Figure 3.1) is consistent with an adaptive, albeit inadequate, 
response to reduced parasympathetic signaling (Figure 3.8). This is further supported by the 
finding that treatment with PYR in PH-rats resulted in a further reduction of AchE activity in 
plasma (Figure 3.2G). 
 
The involvement of the α-7nAchR in the ‘cholinergic anti-inflammatory pathway’ is well-
described. Via this pathway, the vagal nerve exerts its anti-inflammatory effects by release of 
acetylcholine and the activation of this specific receptor. Vang et al. also found evidence of 
increased α-7nAchR expression in a cigarette smoke model. Furthermore, they observed that 
increased cardiac fibroblast proliferation and collagen content in RV of this mouse model was 
mediated via α-7nAchR.36 This is in line with our observations and suggests that the 
improvement in RV remodeling and RV inflammation by PYR could be mediated via the α-
7nAchR. 
It would be of interest to explore potential differences in RV α-7nAchR expression, local AchE 
activity and RVEF efficiency in PAH-patients with an adapted right ventricle (RVEF>40%) 
versus patients with right heart failure (RVEF <40%). Unfortunately, the hemodynamic data 
from the RV tissue were not available. Also, all RV tissue samples were obtained from PAH-
patients with end-stage right heart failure and a RVEF far below 40%, as they were all eligible 
for heart-lung transplantation. 
In a recent paper by DeMazumder et al., a relationship between the muscarinic receptor and 
beta-adrenergic receptor at myocardial level was described.22 As an (initial) compensatory 
mechanism, the downstream effect of the beta-adrenergic receptor was attenuated by the 
upregulation of the muscarinic receptors in their model of pacing-induced heart failure, which 
resulted in less calcium influx. Even though this protected the heart from arrhythmias; it also 
resulted in impaired contractility due to reduced PKA-mediated phosphorylation. We 
 
 
previously demonstrated that PKA-phosphorylation is impaired in experimental and clinical 
PAH.12, 37 
Based on these studies, we propose that impaired parasympathetic activity observed in the 
present study may be a consequence of increased sympathetic nervous system and renin 
angiotensin-aldosterone system activities, which were previously described in PAH-patients.5, 
28, 38 Sympathetic and parasympathetic activities are linked in such a way that increased 
sympathetic activity results in reduced parasympathetic activity. Increased RV wall stress and 
reduced RV function are triggers for the increased neurohormonal activation observed in PAH-
patients. Thus, reduced parasympathetic activity may be a direct consequence of the 
increased sympathetic activation in PAH-patients. We postulate that PYR not only enhances 
parasympathetic activity, but also reduces sympathetic activity, and therefore may restore the 
autonomic imbalance in PAH. 
 
Sympathovagal imbalance, inflammation and pulmonary vascular remodeling in PAH 
Increased levels of pro-inflammatory markers have been reported in PAH-patients.39 In 
addition, these high levels of inflammatory mediators were associated with worse prognosis40, 
41, suggesting an important role of inflammation in PAH pathogenesis. Previous studies in 
animal models of inflammation and left heart failure have described the beneficial effects of 
vagal nerve42, 43 and cholinergic stimulation on the inflammatory response.44, 45 However, until 
now the anti-inflammatory effect of cholinergic stimulation in PAH was unknown. In the current 
study, we provided evidence that parasympathetic nervous system activation reduced 
systemic and local pro-inflammatory cytokine production, resulting in reduced RV and 
pulmonary vascular inflammation. The anti-inflammatory effect of a restoration of 
parasympathetic activity is mainly regulated via cholinergic stimulation mediated by nicotinic 
receptor activation and inhibition of NF-κB pathway.46, 47 However, direct effects of 
acetylcholine on chemokine production in tumor necrosis factor-treated macrophages42 and 
endothelial cells have been described.43 In our study, nicotinic receptor expression in the 
pulmonary vasculature was unaltered. Moreover, downstream signaling of α-7nAchR in lung 
homogenates was unchanged after PYR-treatment. Therefore, the anti-inflammatory and anti-
proliferative effects of parasympathetic stimulation observed in the pulmonary vasculature are 
unlikely mediated via α-7nAchR. 
 
Clinical relevance 
In this study, we show that enhancing parasympathetic nervous system activity, by PYR is 
beneficial in experimental PH. PYR is a long-approved drug, used in myasthenia gravis 
patients, with a favorable pharmacological profile. Although no major side effects were 
observed in our experimental PH-model, the safety and efficacy of PYR in PAH-patients should 
be investigated. Currently, we are designing a proof-of-principle pilot study to investigate the 
acute effects of PYR on the pulmonary vasculature and RV function of PAH-patients. Also, 
 
 
other approaches to alter parasympathetic activity, like vagal nerve stimulation or other drugs 
may be of interest. 
 
Figure 3.8 – Summary of findings 
(A) Parasympathetic-related abnormalities in PAH-patients; (B) Proposed mechanism for improved RV 
function, reduced RV afterload and improved survival after pyridostigmine treatment. PAH= pulmonary 




We did not include a PYR-control group in our main experimental study, based on evidence 
in prior studies that PYR does not have significant hemodynamic effects,15, 48 and anticipated 
difficulties obtaining ethical approval for use of animals in studies of this nature. We 
acknowledge that PYR has not been studied specifically for the right ventricle. However, our 
dose-finding study confirmed that PYR (40 mg/kg) did not have any relevant effect on RV 
function in controls. In addition, our novel data in human EHT, also revealed no relevant effect 
of PYR on maximal force and force development. 
 
 
In addition, we acknowledge that the exact mechanism by which parasympathetic activity is 
reduced in PAH remains unclear. The focus of this study was on the consequences of reduced 
parasympathetic activity and the therapeutic potential of (pharmacologically) enhancement. 
 
Conclusion 
In this translational study, we demonstrated that reduced RV function in PAH-patients is 
associated with reduced parasympathetic activity. In addition, α-7nAchR is upregulated in the 
right ventricle from PAH-patients. Furthermore we also demonstrated reduced AchE activity 
in RV and MVECs from PAH-patients. These results are suggestive of an local adaptive 
response to reduced parasympathetic activity in PAH-patients. However, this compensatory 
mechanism may be insufficient, with persistence in autonomic dysfunction. Chronic 
parasympathetic nervous system stimulation in experimental-PH can improve survival, RV 
function and reduce pulmonary vascular remodeling. The beneficial effects of PYR may be 
associated with reduced inflammation and normalized RV cholinergic receptors expression. 
Our findings revealed a novel potential therapeutic target in PAH, and provide evidence that 
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CONTRIBUTION OF IMPAIRED PARASYMPATHETIC 
ACTIVITY IN RIGHT VENTRICULAR DYSFUNCTION 
AND PULMONARY VASCULAR REMODELING IN 

















Pyridostigmine pilot dose finding 
5 male Sprague Dawley rats were used to identify the optimal pyridostigmine (PYR) dose. 
Previous to the treatment, an aorta telemetry device (TA11PA-C40, Data Science 
International, St. Paul, MN) was implanted for heart rate, systolic arterial pressure and animal 
activity measurements. After animal recovery from the telemetry surgery, PYR-treatment was 
initiated for 5 days, at different doses (25, 31 and 40mg/kg/day). The 40 mg/kg was the 
optimal dose able to reduce the heart rate by 10% and increase the parasympathetic 




Rats were evaluated by echocardiography prior to PYR-treatment and at the end of study. 
Transthoracic echocardiographic measurements (ProSound SSD-4000 system equipped with 
a 13-MHz linear transducer UST-5542, Aloka, Tokyo, Japan) were performed under 
anesthetized and spontaneously breathing rats (isoflurane 2.0% in 1:1 O2/air mix; 
Pharmachemie, Haarlem, The Netherlands).1 Analyses were performed off-line (Image-Arena 
2.9.1, TomTec Imaging Systems, Unterschleissheim, Munich, Germany). Parameters for right 
ventricular (RV) function were: cardiac output (Doppler-derived stroke volume, heart rate), and 
tricuspid annular plane systolic excursion (TAPSE). Parameters for RV remodeling were: RV 
end diastolic diameter (RVEDD) and RV wall thickness. Pulmonary vascular resistance (PVR) 
was estimated by Poiseuille’s law.2-4 
 
Right ventricle catheterization 
At the end of study rats were anesthetized with isoflurane (induction: 4.0% in 1:1 O2/air mix; 
maintenance: 2.0% in 1:1 O2/air mix), intubated (16G Teflon tube) and attached to a 
mechanical ventilator (Micro-Ventilator, UNO, Zevenaar, The Netherlands; ventilator settings: 
breathing frequency 75/min, pressures 9/0 cmH2O, inspiratory/expiratory ratio 1:1). Rats were 
placed on a warming pad to maintain body temperature, and open-chest RV catheterization 
was performed. For the RV catheterization, the thorax was opened and the heart exposed, a 
temporary suture was placed around the inferior vena cava and a (23G needle) puncture in 
the right ventricle was performed. A combined pressure-volume catheter (SPR-869, Millar 
Instruments, Houston TX) was inserted into the right ventricle and positioned in the long axis. 
The signals (processed by MPVS-300, Millar Instruments), obtained at steady state (at least 
10s) and during temporary vena cava occlusion were digitally recorded (2.0 kHz sampling rate; 
Chart 5.5.6, ADInstruments, Sydney, Australia) and analyzed off-line, using (LabChart 8, 
ADInstruments, Sydney, Australia) with custom-made algorithms (programmed in MATLAB 
R2007b, The MathWorks, Natick MA). Stroke volume (in RVU) derived from the conductance 




RV pressure-volume relationships 
Using custom made algorithms (programmed in MATLAB 2007b, The MathWorks, Natick, 
MA) RV (peak-) systolic pressures and RV end-diastolic pressures were automatically 
determined from steady state measurements, as well as arterial elastance (Ea), a measurement 
of RV afterload.6 From vena cava occlusion, end-systolic elastance (Ees; RV contractility) and 
end-diastolic elastance (Eed; RV stiffness) were determined.5 These parameters represent the 
slope of end-systolic and end-diastolic pressure-volume relationships, and are considered 
load independent measurements for cardiac contractility (Ees) and stiffness (Eed).7 The ratio 
Ees/Ea was calculated, and it represents the RV-arterial coupling. 
 
Histomorphometric analyses of heart and lungs 
After the hemodynamic evaluation, rats were euthanized (by exsanguination under isoflurane), 
and heart, lungs and other major organs were harvested. Lungs were weighted; left lobe was 
filled by 1:1 mix of saline and cryofixative (Tissue-Tek O.C.T. compound, Sakura, Fintek, 
Europe, Zoeterwolde, The Netherlands), and snap frozen in liquid nitrogen. The heart was 
perfused, weighted, dissected and snap-frozen in liquid nitrogen. Images were collected 
using a Motic microscope (BA210, Wetzlar, Germany) and a digital tablet camera (VisiCam ® 
TC10, VWR International B.V, Amsterdam, The Netherlands). ImageJ for Windows 1.48 
software (National Institutes of Health, USA) was used for image analysis, taking the pixel-to-
aspect ratio into account. 
 
Cardiomyocyte cross-sectional area 
Hematoxylin & eosin (HE)-stained cardiac cryosections (5 μm) were used to determine left 
ventricular (LV) and RV cardiomyocyte cross-sectional area (CSA). Cardiomyocyte size for each 
ventricle was expressed as the average CSA of minimally twenty transversally cut 
cardiomyocytes at the level of the nucleus, randomly distributed over the ventricles. 
 
Cardiac fibrosis 
Picrosirius red staining (5 μm cryosections) was used for analysis of cardiac fibrosis. LV and RV 
fibrosis were expressed as the percentage tissue area positive for collagen, measured over 
minimally five randomly areas per ventricle. 
 
Relative wall thickness of pulmonary arterioles 
Lung cryosections (5 μm) were stained with Elastica van Giesson for morphometric analysis of 
vascular dimensions. Minimally fifty transversally pulmonary arterioles cut, with an outer 
diameter between 25 and 100 μm, randomly distributed over the lungs, were measured. 





RV and lung immunofluorescence 
Cryosections of RV apex (5μm) were blocked with 1% bovine serum albumin (BSA) in 
phosphate-buffered saline (PBS), and incubated for 60 min or overnight with primary 
CD31/CD45 (1:35; sc-1506-R, sc-53045, Santa Cruz Biotechnology, Dallas, TX), alpha-7 
nicotinic acetylcholine receptor (α-7nAchR; 1:50; ANC-007; Alomone, Jerusalem, Israel) and 
muscarinic acetylcholine type 2 receptor (m2AchR; 1:50; M9558, Sigma-Aldrich, St. Louis, 
MO), followed by appropriate secondary antibody (Invitrogen, MA) for 1 hour. Sections were 
also incubated with WGA (glycocalyx), α-actinin (1:1000; A7732 Sigma-Aldrich, St. Louis, MO) 
and DAPI (nuclei) counterstaining. 
Lung cryosections (5μm) were also blocked with 1% BSA in PBS and incubated overnight with 
the same α-7nAchR and m2AchR-antibodies followed by appropriated secondary antibody. 
Lung sections were also incubated with anti α-smooth muscle actin- Cy3 antibody (1:100; 
Sigma-Aldrich, St. Louis, MO), von willebrand factor (1:200; AB8822; Abcam; Cambridge, UK) 
and DAPI (nuclei) counterstaining. 
 
Immunofluorescence quantification 
Image acquisition was performed on a Marianas digital imaging microscopy workstation 
(Intelligent Imaging Innovations (3i), Denver, CO). SlideBook imaging analysis software 
(SlideBook 6, 3i) was used to semi-automatically quantify the images. Capillary density and 
leukocyte infiltration was expressed as the number of capillaries and of positive CD45-nuclei 
per area, measured over three randomly areas per ventricle. Lung α-7nAchR and m2AchR 




Cytokine levels in rat plasma were measured by ELISA for IL-6 and MCP-1 (Ready-SET-Go!, 
eBioscience) according to the manufacturers’ instructions. In addition, acetylcholinesterase 
activity was measured in plasma, MVECs, RV, lung and pulmonary artery homogenates from 
PAH-patients, PH-rats and controls by ELISA (ThermoFisher Scientific, A12217) according to 
the manufacturers’ instructions. 
 
Protein expression by Western Blot in Lung Homogenates 
To evaluate the downstream signalling of the α-7nAchR in lung homogenates from 
experimental-PH, the expression of the phosphorylated form of-ERK (p-ERK; 1:2000; CS9106; 
Cell Signaling), total protein expression of ERK (tERK; 1:1000; CS9102; Cell Signaling) and 







Human engineered heart tissue generation, treatment, contraction measurements 
Human engineered heart tissue (EHT) was prepared as previously described, with small 
modifications.9, 10 Briefly, iCell® cardiomyocytes^2 (Cellular Dynamics International), which 
are human induced pluripotent stem cell (HiPSC)-derived cardiomyocytes, were thawed 
according to manufacture instructions. HiPSC-EHT reconstitution mix was prepared with 
3.5x105 cardiomyocytes per 70 μl HiPSC-EHT. EHT was generated in agarose molds with solid 
silicone racks as previously described.11, 12 Cells were mixed with 100 µl/ml MatrigelTM 
(Corning, 354234), 5 mg/ml bovine fibrinogen (Sigma, F8630; 200 mg/ml in 0.9% NaCl plus 
0.5 µg/mg aprotinin; Sigma, A1153), 2×DMEM (matching the volume of fibrinogen and 
thrombin for isotonisation) and EHTs were generated with 70 µl per EHT (3.5x105 cells), and 
3 U/ml thrombin (100 U/ml; Sigma, T7513). The cell mix was pipetted into the agarose casting 
molds around the silicone posts. After fibrin polymerization (37°C, 2h) the silicone racks were 
transferred to a new 24-wells plate filled with culture medium, consisting of  Dulbecco’s 
modified Eagle’s medium (DMEM; Biochrom, F0415), 1% penicillin/streptomycin, 10% horse 
serum (Gibco, 26050), 10 μg/ml insulin (Sigma, I9278) and 33 μg/ml of aprotinin, and 
maintained in the incubator (37°C, 21% O2, 7% CO2). Culture medium was changed 3 times 
a week. After 10-14 days, human EHTs displayed spontaneous coherent contractions. 
Contractile analysis was performed on 20-35-day-old EHTs in serum-free culture medium, 
supplemented with 10 mM HEPES for pH-steadiness, pre-incubated at 37°C, 21% O2, 7% CO2 
for 2 h. EHTs were treated with 10 μM acetylcholine (Sigma Aldrich, A2661) or 10 mM 
pyridostigmine (Sigma Aldrich, P9797). Contractility measurements were performed at 
baseline, 15 minutes and 60 minutes after the respective treatment. Force was measured 
based on automated video-optical recording and EHT contour recognition as described (EHT 
Technologies, A0001).4 Values for beating frequency (heart rate), maximal force, contraction 
velocity (dF/dt max) and relaxation velocity (dF/dt min) were calculated with a specific custom-























SUPPLEMENTAL TABLES AND FIGURES 
 




All data are presented as mean ± SEM. Delta (Δ) percentage (%) between PH and PH-PYR; Mann-
Whitney test. Abbreviations: PYR= pyridostigmine; HR= heart rate; HRV_var= heart rate variability; LF= 

















Table S2 - Baseline echocardiography characteristics 
 
 
All data are presented as mean ± SEM; One-way ANOVA followed by Bonferroni correction; 
Abbreviations: PYR= pyridostigmine; TAPSE= tricuspid annular plane systolic excursion; RVEDD= right 
ventricular end-diastolic diameter; PAAT/cl= pulmonary acceleration time divided by cycle length; 
eRVSP= estimated right ventricular systolic pressure; PVR= pulmonary vascular resistance. 
 
 
Table S3 - Echocardiographic characteristics at the end of the study 
 
 
All data are presented as mean ± SEM; One-way ANOVA followed by Bonferroni correction; 
Abbreviations: PYR= pyridostigmine; TAPSE= tricuspid annular plane systolic excursion; RVEDD= right 
ventricular end-diastolic diameter; PAAT/cl= pulmonary acceleration time divided by cycle length; 









Table S4 - Autopsy and hemodynamic data 
 
 
All data are presented as mean ± SEM. One-way ANOVA followed by Bonferroni correction; 
Abbreviations: PYR= pyridostigmine; tl= tibia length; RV=right ventricle; LV + S=left ventricle (including 
septum); RV/(LV+S)= RV over LV (including septum) mass ratio; RVESP= right ventricular end-systolic 
pressure; RVEDP= right ventricular end-diastolic pressure. 
 
 






















SU5416 combined with chronic hypoxia: Study design of SU5416 combined with chronic hypoxia, as 
PH-experimental model. Control: n=7, PH: n=12, PH-PYR: n=12; Week 0: SU5416 (25 mg/kg, s.c.) or 
0.5% carboxymethylcellulose (CMC) injection and placed in hypoxia (10% oxygen) for 4 weeks. At week 
 
 
6 (normoxia), echocardiogram (Echo) followed by PYR-treatment (40mg/kg). At the end of study, at 
week 10 or when animals develop signs of heart failure, echocardiogram and right ventricle (RV) 
catheterization (cath.) were performed 
 
 
Figure S2 – Pyridostigmine pilot dose finding 
 
 
Telemetry results from previous pilot study using 5 male Sprague Dawley rats. The same animals were 
treated with pyridostigmine at different doses for five days (with a washout in between). The 40mg/kg 
dose significantly reduced heart rate by 10% (A) and significantly increase the parasympathetic 
modulation (B) without relevant effect in systolic arterial pressure (C) or in daily activity (D). One-way 
ANOVA for repeated measurement followed by Bonferroni corrected post-hoc analysis. **p<0.01, 
















Figure S3 – Cholinergic signaling in pulmonary vasculature and lung homogenates from PAH-
patients 
Representative western blot analyses from alpha-7 nicotinic acetylcholine (Ach) receptor (α-7nAchR; A) 
and muscarinic acetylcholine type 2-receptor (m2AchR; B) expression in lung homogenates from 
controls and PAH-patients. Representative immunofluorescence staining for α-7nAchR (C) for control 
and PAH-patients; α-7nAchR (red), α-smooth muscle actin (green), lectin (white) and nuclei (DAPI, blue). 
Western blot analyses from α-7nAchR (D) and m2AchR (E) expression in pulmonary artery (PA) 
homogenates for control and PAH-patients. Acetylcholinesterase (AchE) activity in whole lung 
homogenates from PAH-patients and controls. (F) Unpaired t-test, no significant differences were 
observed between PAH-patients versus controls.  
 
 
Figure S4 – Effects of PYR in control animals and in human 3D engineered heart tissue 
 
Effect of PYR in control rats in RV function. (A) RV end-systolic pressure, (B) RV end-diastolic pressures, 
(C) RV contractility and (D) RV relaxation. From E-H: effect of PYR in healthy human 3D engineered 
heart tissue (EHT). (E) Effect of acetylcholine (Ach) and PYR on heart rate; 2-way ANOVA for repeated 
measurements followed by Bonferroni corrected post-hoc analysis. (F) Relaxation velocity corrected by 
heart rate after 15 and 60 min of PYR treatment. (G) Maximum force after 15 and 60 min of PYR 
treatment. (H) Contraction velocity after 15 and 60 min of PYR treatment. G-H: One-way ANOVA for 
repeated measurement followed by Bonferroni corrected post-hoc analysis. * p<0.05 vs. baseline 




Figure S5 – Effects of chronic pyridostigmine treatment on systolic arterial pressure and daily 
activity 
 
Telemetry results from chronic pyridostigmine treatment. (A) No significant effects on systolic arterial 
pressure or daily activity (B) were observed by PYR treatment. One-way ANOVA for repeated 
measurement followed by Bonferroni corrected post-hoc analysis. 
 
 










Different concentrations of pyridostigmine (PYR) reduced human microvascular endothelial cells 
(MVECs) proliferation in vitro from pulmonary arterial hypertension (PAH) cells. analysis; *p<0.05, 
**p<0.01 comparison between 0 mM dose. n =2 in each condition. 2-way ANOVA for repeated 












Figure S7 - Representative immunofluorescence staining for cholinergic receptors in the 
pulmonary vasculature from experimental-PH 
Representative immunofluorescence staining for alpha-7 nicotinic acetylcholine receptor ( -7nAchR; 
A) and muscarinic acetylcholine type 2-receptor (m2AchR; B) for control, PH and PH-PYR groups.  -








































Figure S8 – Downstream signaling of alpha-7 nicotinic acetylcholine receptor in lung 
homogenates from experimental PH 
 
Representative example of protein expression of alpha-7 nicotinic acetylcholine receptor downstream 
targets on whole lung homogenates. No significant differences were observed in phosphorylated-ERK 
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Aim: To investigate the association between altered sex hormone expression and long-term 
right ventricular (RV) adaptation and progression of right heart failure in a Dutch cohort of 
Pulmonary Arterial Hypertension (PAH)-patients across a wide range of ages.  
 
Methods: In this study we included 306 PAH-patients, of which 196 females and 110 males. 
From 55 patients and 15 controls we collected plasma samples for sex hormone analysis. In 
280 patients, right heart catheterization (RHC) and/or cardiac magnetic resonance (CMR) 
imaging was performed at baseline. For longitudinal data analysis we selected patients that 
underwent a RHC and/or CMR maximally 1,5 years prior to an event (death or transplantation, 
N=49).  
 
Results: Dehydroepiandrosterone-sulfate (DHEA-S) levels were reduced in both male and 
female PAH-patients compared to controls, whereas androstenedione and testosterone were 
only reduced in female patients. Interestingly, low DHEA-S and high testosterone levels were 
correlated to worse RV function in male patients. Subsequently, we analyzed prognosis and 
RV adaptation in females stratified by age. Females≤45years had best prognosis in 
comparison to females≥55years and males. No differences in RV function at baseline were 
observed, except higher pressure-overload in females≤45years. Longitudinal data 
demonstrated a clear distinction in RV adaptation over time. Although females≤45years had 
an event at a later time point, RV function was more impaired at end-stage disease. 
 
Conclusions: RV dysfunction in male PAH-patients was associated with altered androgen 
expression. Females PAH-patients had lower expression of androgens. Females≤45years 
could persevere pressure-overload for a longer time, but had a more severe RV phenotype at 







Pulmonary arterial hypertension (PAH) is a progressive disease characterized by narrowing of 
pulmonary arterioles and right heart failure[1-3]. Although females are more prone to develop 
PAH (female: male prevalence ~2:1), their survival is significantly better than male patients[4-
8]. Previous studies showed that this survival benefit in females may be explained by a 
different RV response to treatment[4, 9]. 
Sex differences are common in cardiovascular physiology and disease. The multi-ethnic study 
of atherosclerosis (MESA) in 4000 healthy community-based participants revealed that RV 
mass and volume are smaller in females, while RV ejection fraction (RVEF) is higher compared 
to age-matched males[10]. To a great extent, this distinction was explained by differences in 
sex hormone levels, especially estrogens[11]. Higher RVEF and lower RV end-systolic volume 
were associated with higher estrogen serum levels in healthy postmenopausal women using 
hormone replacement therapy (HRT)[11].  
Different expression levels of sex hormones have also been observed in PAH[12-17]. 
Especially high estradiol and reduced dehydroepiandrosterone-sulfate (DHEA-S) have been 
associated to PAH-severity in male and postmenopausal females. In addition, several animal 
studies have been performed to investigate the effect of sex hormones on pulmonary vascular 
remodeling and right heart failure[12]. However, due to conflicting data between patients and 
animal models, and due to limited data in younger females of productive age,  the exact 
association between sex hormones and RV adaptation remains elusive. In addition, most data 
on sex hormones has been obtained in US centers. With the known differences in 
demographic characteristics and use of hormone replacement therapy between US and 
European patients, it is of importance to investigate sex hormones in a non-US PAH-cohort 
as well[18]. Finally, the majority of data is cross-sectional or at one time-point during the 
disease course, whereas longitudinal data of RV function during progression towards right 
heart failure is pivotal to understand differential RV adaptation patterns between male and 
female patients. Therefore, in this study we aimed to investigate the association between 
altered sex hormone expression levels and RV adaptation and to assess progression of right 
heart failure over time in a Dutch cohort of patients with a wide range of ages. We performed 
a translational study in which we combined cross-sectional analyses of sex hormones with 
longitudinal analyses of RV adaptation and histopathological analyses of RV tissue from 










Study design and patients for RV function assessment 
We included PAH-patients diagnosed according to European Respiratory Society (ERS) and 
European Society of Cardiology (ESC) guidelines at Amsterdam UMC (location VUmc) 
between March 1996 and September 2019 (N=306). From 55 patients and 15 controls we had 
collected plasma samples on which we performed sex hormone analysis (Medical Ethics 
Approval Numbers 2015.220-Liquid Biopsy and 2017.318-DOLPHIN). We retrospectively 
assessed patient charts for contraceptive and/or hormone replacement therapy use. In 280 
patients, right heart catheterization (RHC) and/or cardiac magnetic resonance (CMR) imaging 
was performed within a maximum interval of one month at baseline prior to receiving PAH-
specific therapy. In addition, of 49 patients that had an event (death or transplantation), a last 
RHC and/or CMR measurement was available with a maximum of 1.5 years before the event. 
From these patients we also collected RHC/CMR data at earlier time points during the 
disease. Lastly, in explanted and post-mortem RV tissue of male and female patients (N=8) 
and controls (N=5), we assessed histopathological differences. The Medical Ethics Review 
Committee of Amsterdam UMC did not consider the current study to fall within the scope of 
the Medical Research Involving Human Subjects (WMO), therefore informed consent was not 
required (approval number 2012288). Approval from the Sydney Heart Bank was received for 
use of RV samples (HREC #2814; HREC #7326). The use of human RV autopsy samples was 
approved by and performed according to guidelines of the ethics committee of Amsterdam 
UMC, location VUmc, and conformed to the Declaration of Helsinki principles.  
 
Table 4.1 – Characteristics of the subgroup of patients and controls in the sex hormone analysis 
 
Characteristic Control F PAH F Control M PAH M P-value 
Number 10 36 5 19 
 
Age at visit, years 48 (20) 51 (16) 46 (19) 50 (14) NS 
BSA, m2 1.7 (0.1) 1.8 (0.2) # 2.0 (0.2) 2.0 (0.2) <0.001 
BMI, kg/m2 24 (3) 26 (5) 26 (5) 25 (4) NS 
NYHA FC 
     
















4 (21) NS 
NTproBNP, ng/L 
 
202 [111 - 399] 
 









48 (13) NS 
mRAP, mmHg 
 
7 [6 - 9] 
 





11 (2) NS 
PVR index, WU*m2 
 
4 [2 - 6] 
 
3 [2 - 4] NS 




3.0 (0.9) NS 
CMR 
     
Heart rate, bpm 72 (9) 72 (12) 59 (10) 72 (13) NS 
RVEDV index, ml/m2 66 (17) 89 (27) ‡ 77 (23) 99 (20) <0.01 
RVESV index, ml/m2 30 (14) 48 (22) 29 (12) 61 (24) * <0.01 
SV index, ml/m2 40 (6) 40 (11) 53 (11) 40 (11) NS 
RVEF, % 59 (6) 48 (11) # 63 (6) 40 (14) <0.001 
 
 
RV mass index, g/m2 25 (2) 43 (14) ‡ 18 (4) 52 (15) * <0.001 
Therapy 
     
















3 (16) NS 
Medication type 
     




17 (90) NS 




11 (58) NS 




4 (21) NS 
Hormonal treatment 
     
Contraceptive use, n (%) 1 (10) 6 (17) 
   
Hormone replacement therapy, 
n (%) 
0 (0) 1 (3) 
   
 
Data is presented as mean (SD) or as median [IQR] or as n (%). # Male vs. female PAH patients ‡Female 
PAH patients vs. Female controls * Male PAH patients vs. Female control. 
 
Figure 4.1 – Flow chart 
 
Schematic overview of study populations used for each analysis. PAH = Pulmonary Arterial 
Hypertension; HIV = Human Immunodeficiency Virus; F≤45 = Females ≤45 years; F≥55 = Females ≥55 
years; RV = Right Ventricular; M = Male; F = Female.  
 
 
Sex Hormone Analysis 
All samples were analyzed at the Endocrine Laboratory of Amsterdam UMC. DHEA-S, 
testosterone and androstenedione were measured in plasma using isotope diluted liquid 
chromatography mass spectrometry (ID-LC-MS/MS)[19, 20]. Sex hormone-binding globulin 
(SHBG) was measured using an automated immunoassay (Architect, Abbott Diagnostics). Free 




Right heart catheterization 
Hemodynamic assessment was performed using a balloon-tipped, flow-directed 7.5-F triple 
lumen Swan-Ganz catheter (Edwards Lifesciences LLC, Irvine, CA, USA), as previously 
described[22].  
 
Cardiac Magnetic Resonance Imaging 
Measures of RV function and volumes were taken using CMR imaging. Scans were obtained 
using a Siemens 1.5-T Sonata or Avanto scanner (Siemens Medical Solutions, Erlangen, 
Germany). Acquisition of images and post-processing was carried out as reported[23].  
 
Immunohistofluorescence 
RV paraffin-embedded tissue of PAH-patients (N=3 females, N=3 males) and controls (N=3 
females, N=3 males) were sectioned and stained for CD31, rhodamine Ulex europaeus 
agglutinin I (Ulex), and wheat germ agglutinin (WGA). Tissue apoptosis was assessed by 
Terminal deoxynucleotidyl transferase dUTP Nick-End Labeling (TUNEL) assay. Images were 
captured under a laser confocal microscope (Nikon A1R). Quantitative histological 
measurements were assessed through ImageJ (NIH) with at least 10 random fields/patient. 
 
Statistical analysis 
Data are presented as mean (standard deviation) or median [interquartile range]. Transplant-
free differences in survival were assessed using Kaplan-Meier curves and log-rank test with 
Bonferroni-corrected pairwise comparison. For normally distributed continuous variables, 
group differences were assessed using one-way ANOVA and post-hoc unpaired t-tests with 
Bonferroni correction. For non-normally distributed data, logarithmic transformation was 
applied prior to testing or Kruskal-Wallis test and post-hoc testing with pairwise Mann–
Whitney U-tests was performed. For categorical variables, group differences were assessed 
with Pearson’s χ2 test or Fisher’s exact test. Univariate and multivariate linear regression was 
used to assess the relation between two or more continuous variables. Confounding by age 
and Body Mass Index (BMI) were checked and corrected for when necessary. A p-value of 





PAH-induced sex differences in survival, RV function and adaptation 
We included 258 idiopathic PAH, 37 hereditable PAH, 10 drug- and toxin-induced PAH and 
1 PAH patient associated with HIV-infection, resulting in 110 male and 196 female patients in 





Low DHEA-S and high testosterone levels associated with worse RV function in male PAH 
To investigate the association of RV adaptation and sex hormones, we quantified plasma 
levels of sex hormones in a subgroup of patients. We cross-sectionally determined levels of 
precursors to estrogens and androgens (Figure 4.1 Supplementary) in 19 male and 36 female 
PAH-patients, and 5 male and 10 female healthy controls. Characteristics of the cross-
sectional cohort are presented in Table 4.1 and compared to the main cohort in 
Supplementary Table 4.1. No differences were observed in therapy or medication type at 
time of blood sampling.  
 
Figure 4.2 – Lower DHEA-S and lower testosterone in PAH-patients compared to contols 
Cross-sectional hormone analysis of male and female PAH-patients and controls for DHEA-S (A), 
Androstenedione (B), Total testosterone (C) and Calculated free testosterone (D) levels. * P<0.05; ** 
P<0.01; *** P<0.001. DHEA-S = Dehydroepiandrosterone-sulfate; F = Females; PAH = Pulmonary 
Arterial Hypertension; M = Males.  
 
Levels of DHEA-S were reduced in both female and male PAH-patients compared to controls 
(Figure 4.2A). Intriguingly, androstenedione levels, as well as total and free testosterone 
levels, were significantly lower in female patients compared to controls, but did not differ 
between male patients and controls (Figure 4.2B-D). In addition, we investigated the 
association between sex hormone levels and RV functional parameters. Interestingly, the 
relationship between DHEA-S or total testosterone with RV function was different for male 
and female patients: lower DHEA-S and higher testosterone levels were correlated to worse 
RV function in males, whereas no correlations were observed in females (Figure 4.3A, B, D). 
 
 
In both male and female patients, lower levels of DHEA-S were related to higher levels of 
NTproBNP (Figure 4.3C). These data indicate that the association between DHEA-S and 
testosterone with RV function is different in male and female patients.   
 
Figure 4.3 - Sex hormones are differently related to RV function in PAH males and females 
Relationship between levels of DHEA-S and RVEF in (A), DHEA-S and SV in (B), DHEA-S and NTproBNP 
in (C), and between total testosterone and RVEF (D), in both male and female PAH-patients. DHEA-S 
= Dehydroepiandrosterone-sulfate; RVEF = Right Ventricular Ejection Fraction; SV = Stroke Volume; 
















Table 4.2 - Baseline characteristics of PAH patients with females divided on age. 
 
Characteristic Females ≤45 y Females ≥55 y Males P-value 
Number 73 97 110 
 
Age at Diagnosis, y 34 (8) 68 (8) 61 (17) <0.001 
BSA, m2 1.9 (0.3) 1.9 (0.2) * 2.0 (0.2) <0.01 
BMI, kg/m2 28 (7) 28 (5) * 26 (4) <0.01 
sABP, mmHg 125 (16) 134 (25) 127 (20) <0.05 
dABP, mmHg 76 (12) 75 (15) 76 (14) NS 
NYHA FC 
    
Class I, n (%) 5 (8) 1 (1) 3 (4) 
 
Class II, n (%) 17 (29) 21 (28) 27 (34) 
 
Class III, n (%) 29 (49) 42 (57) 39 (49) 
 
Class IV, n (%) 8 (14) 10 (14) 11 (14) NS 
6MWD, m 448 [335-497] #‡ 314 [218-415] 330 [186-456] <0.001 
NTproBNP, ng/L 813 [355-1932] 1269 [369-2945] 1090 [299-2870] NS 
HPAH BMPR2, n (%) 15 (21) # 6 (6) 10 (9) <0.05 
Low DLCO, n (%) 0 (0) ‡ 14 (14) * 35 (32) <0.001 
Comorbidities 
    
Smoking, n (%) 25 (36) #‡ 46 (54) 64 (65) <0.01 
Coronary Artery 
Disease, n (%) 
0 (0) # 13 (15) * 25 (25) <0.001 
Hypertension, n (%) 8 (12) # 37 (44) 30 (30) <0.001 
Diabetes, n (%) 3 (4) # 25 (29) 18 (18) <0.001 
RHC 
    
sPAP, mmHg 88 (23) #‡ 80 (19) 78 (19) <0.001 
dPAP, mmHg 38 (13) #‡ 31 (10) 32 (10) <0.001 
mPAP, mmHg 57 (15) #‡ 49 (12) 49 (12) <0.001 
mRAP, mmHg 9 [5 - 11] 8 [6 - 11] 7 [5 - 11] NS 
PAWP, mmHg 9 (3) 11 (3) * 9 (3) 0.001 
PVR index, WU*m2 5.8 [3.4 - 7.6] ‡ 4.8 [3.1 - 7.7] 4.3 [3.1 - 5.9] 0.04 
Cardiac index, L/m2 2.5 (0.8) 2.5 (0.9) 2.4 (0.8) NS 
CMR 
    
Heart rate, bpm 82 (14) 78 (10) 77 (15) NS 
RVEDV index, ml/m2 83 (21) 79 (30) 87 (23) NS 
RVESV index, ml/m2 56 (19) 51 (28) 61 (24) NS 
SV index, ml/m2 27 (8) 28 (8) 28 (8) NS 
RVEF, % 33 (11) 37 (13) 33 (12) NS 
 
 
RV mass index, g/m2 53 (14) 47 (13) 56 (15) <0.05 
Therapy  
    
Monotherapy, n (%) 45 (63) 60 (62) 70 (64) 
 
Dual therapy, n (%) 23 (32) 33 (34) 32 (29) 
 
Triple therapy, n (%) 2 (3) 1 (1) 1 (1) NS 
Medication type 
    
ERA, n (%) 42 (58) 63 (65) 59 (54) NS 
PDE5, n (%) 28 (39) 56 (58) 59 (54) <0.05 
Prostacyclin, n (%) 21 (30) # 6 (6) 15 (14) <0.05 
 
Data is presented as mean (SD) or as median [IQR] or as n (%) #Females ≤45 vs. females ≥55 ‡Females 
≤45 vs. males * Females≥55 vs. males.   
 
Superior RV adaptation in females of reproductive age 
Several indications in literature point to the direction of estrogen as a main regulator of RV 
adaptation in PAH. However, since estrogen levels are variable throughout the menstrual 
cycle, it is challenging to interpret estrogen plasma levels in females[17], and as estrogen 
levels are known to drop around the age of 50 years[24]. Therefore, to get a general idea on 
the contribution of estrogens to RV adaptation, we stratified the female cohort on age: 
females of reproductive age (N=73, ≤45 years), and females of postmenopausal age (N=97, 
≥55 years old). The male cohort was included as a reference group and was not stratified on 
age. Baseline characteristics are presented in Table 4.2. Females≤45years had a higher BMI 
and BMPR2 mutations were more prevalent. A low diffusing capacity of the lung for carbon 
monoxide (DLCO) (≤45%) and comorbidities were more prevalent in male PAH-patients. The 
frequency distribution of mono-, duo- and triple therapy was comparable between the 
groups, although PDE5 inhibitors were more frequently provided to male PAH and 
females≥55years and prostacyclin therapy was more frequent in females≤45years.   
 
At baseline, no differences were observed in hemodynamic or RV imaging data, besides a 
significantly higher mean pulmonary artery pressure and pulmonary vascular resistance in 
females≤45years in comparison to females≥55years and males. As can be appreciated in 
Figure 4.4A, females≤45years had the best prognosis, whereas males had the worse 
prognosis. 
 
To investigate the difference in RV adaptation over time towards end-stage disease in more 
detail, we subsequently performed longitudinal analyses on RHC and CMR data. For this 
purpose, we selected patients that underwent a RHC and/or CMR maximally 1,5 years prior 
to an event (death or transplantation). Subsequently, we analyzed CMR and/or RHC data at 
three earlier time-points during the disease including a baseline scan. Median time from last 
follow-up to event was similar for all patients (females≤45years: 0.47 vs females≥55years: 0.77 
vs males: 0.52 years, P=0.42), whereas median time from baseline to last follow-up was 
 
 
different, as expected from the survival curve (females≤45years: 5.2 vs females≥55years: 2.0 
vs males: 1.8 years, respectively, P<0.05). Figure 4.5 shows the longitudinal data of RHC and 
CMR of PAH-patients with an event. Intriguingly, although females≤45years have an event at 
a later time-point than male and females≥55years, RV function has significantly deteriorated 
over time in comparison to baseline values. In contrast, in males and females≥55years no 
drop in RV function in comparison to baseline was observed. These data suggest that females 
of reproductive age can persevere pressure-overload for a longer time, but have a worse RV 
phenotype at end-stage disease. 
 
Figure 4.4 - Five-year survival of PAH patients and hemodynamics and RV phenotype at baseline 
Females are stratified on age into females of reproductive age (≤45 years) and females of 
postmenopausal age (≥55 years). Sex and age differences in the 5-year transplant-free survival 
probability in male and female PAH patients in (A). Baseline measurements of mPAP in (B), SVi (C), 
RVEDVi (D) and RVEF (E) in PAH females≤45 years compared to females≥55 years and males. ** 
P<0.01; *** P<0.001.  F≤45 = Females ≤45 years; F≥55 = Females ≥55 years; M = Males; mPAP = 
mean Pulmonary Arterial Pressure; RVEDVi = Right Ventricular End-Diastolic Volume index; SVi = Stroke 
Volume index; RVEF = Right Ventricular Ejection Fraction. 
 
 
Figure 4.5 – Change in hemodynamics, RV morphology and function over time from baseline to 
last follow-up before an event 
 
Change in measurements from baseline over time of mPAP (A), RVEDVi (B), SVi (C) and RVEF (D) to last 
follow-up with a maximum of 1.5 years before an event in PAH females of reproductive age (≤45 years) 
compared to females of postmenopausal age (≥55 years) and to males. * P<0.05 at last follow-up vs 
baseline. F≤45 = Females ≤45 years; F≥55 = Females ≥55 years; M = Males; mPAP = mean Pulmonary 
Arterial Pressure; RVEDVi = Right Ventricular End-Diastolic Volume index; SVi = Stroke Volume index; 
RVEF = Right Ventricular Ejection Fraction. 
 
Sex differences in end-stage RV tissue 
Lastly, we investigated sex differences in end-stage RV tissue of PAH-patients. Post-mortem 
and transplanted RV tissue was used to investigate RV hypertrophy, capillary density and 
apoptosis (Figure 4.6), in male and female end-stage PAH-patients and controls. All female 
tissue was obtained of patients with an age<55 years old. Although no statistical analyses 
could be performed due to the limited number of tissue samples per group, representative 
images and quantification suggest a more pronounced capillary rarefaction and endothelial 
cell apoptosis in female RV tissue in comparison to males also indicating a more severe RV 












Figure 4.6 – Histopathological analyses in RV tissue of PAH-patients and controls 
 
RV cardiomyocyte cross-sectional area quantification (Hypertrophy, A) and representative pictures for 
cell membrane counterstaining (WGA; B-E). Vascular density quantification (F) and illustrative overviews 
(CD31, green; G-I). Vascular apoptosis quantification (K) and characteristic stainings (L-O) against 
apoptotic nuclei (TUNEL, grey) and vessels (Ulex, green). White arrowheads indicate apoptotic 
cardiomyocytes, while green arrowheads indicate apoptotic vessels. Nuclei were counterstained with 
Hoechst 33342 (blue, B-E and L-O) and WGA (red). N=3 subjects/group and ≥10 fields/subject. Scale 
bars= 50µm. RV = Right Ventricular; PAH = Pulmonary Arterial Hypertension; CD31= cluster of 





Using a comprehensive set of hormone analyses combined with longitudinal imaging and 
hemodynamic data, we were able to demonstrate that:  
1. For the first time, we show a link between androgen levels and worse RV function in 
male PAH-patients. 
2. DHEA-S plasma levels are reduced in male and female PAH-patients across a wide 
range of ages, whereas reduced testosterone and androstenedione levels are 
observed in female patients only.  
3. Females of reproductive age may tolerate RV pressure-overload for a longer period of 
time resulting in a more severe RV phenotype at end-stage disease. 
 
Beneficial effect of DHEA-S on RV adaptation to pressure-overload 
In contrast to the controversial findings on estrogens in animal and human studies, DHEA-S 
has consistently shown to be beneficial in RV adaptation [25-27]. First, DHEA-S levels of 
healthy subjects were associated to larger RV volumes and mass in females, with a trend in 
males [10]. Second, DHEA-S levels were reduced in both postmenopausal female and older 
male PAH-patients, and throughout the menstrual cycle in a small study of reproductive PAH 
females [15-17]. Furthermore, DHEA-S levels were associated with disease severity, 
progression and survival. Third, DHEA-S treatment in experimental PAH improved both 
systolic and diastolic RV function, and reduced RV maladaptive remodeling [25, 27]. In our 
study, we could confirm the reduced expression of DHEA-s in a Dutch cohort of male and 
female PAH-patients across a wide range of ages. This further supports the rationale of a 
phase two clinical trial currently being conducted to study the effects of DHEA 
supplementation on RV functional parameters (EDIPHY trial: NCT03648385). Interestingly, in 
our cohort the relation of DHEA-S with RV dysfunction was more pronounced in male PAH-
patients. Therefore, sex-specific analyses of treatment effects of DHEA-S supplementation 
would be of interest.  
 
Possible detrimental relation between androgens and RV adaptation  
Androgens may also be involved in RV adaptation to pressure-overload. Elevated levels of 
androgens are associated with higher RV mass and volumes in males[11]. Interestingly, we 
show for the first time that plasma testosterone is differentially associated to RV dysfunction 
in males and female PAH-patients. Similar to previous studies in PAH, we only detect lower 
plasma levels of testosterone in PAH females[15]. Nevertheless, testosterone levels were 
associated to RV dysfunction in male PAH-patients, suggesting that testosterone levels may 
negatively affect RV adaptation in males. This is in line with experimental data in which 
testosterone was associated with dysfunctional RV hypertrophy and excessive RV fibrosis in 
male mice with pulmonary artery banding [28], suggesting that androgens may have a 
detrimental effect on RV adaptation to pressure-overload, predisposing to an earlier onset of 
 
 
RV failure and possibly resulting in worse survival in males. Therefore, a lack of testosterone 
may be protective in females.  
 
Worse end-stage disease phenotype in PAH females 
Female PAH-patients have a better prognosis and, at the same time, the worst RV phenotype 
at end-stage disease, which can be appreciated by more RV dilation and worse RV function 
shortly before death or transplantation. Our histopathologic results evidenced more 
hypertrophy, decreased capillary density and increased apoptosis in the PAH RV tissue. 
Unfortunately, it is difficult to draw definite conclusions with limited number of human end-
stage RV samples; thus, novel translational tools, like cardiac tissue engineered models, are 
highly necessary. Hence, increased estrogen or reduced testosterone levels may protect the 
female heart and allow better endurance to increased afterload, subsequently resulting in a 
worse stage of RV failure at a later point in time. The remaining question is whether the 
younger female heart is intrinsically better to adapt to these pressures and maintain cardiac 
function, or whether older female and male patients die at an earlier stage due to other causes 
than RV failure. The latter may be plausible, as older patients from our cohort more frequently 
had comorbidities, such as smoking, previously associated with worse survival in PAH [29]. 
Nevertheless, as we were unable to retrieve cause of death in all patients, no definite 
conclusions can be drawn. 
 
Limitations and strengths 
One of the limitations of this study is the relatively small sample size of male patients 
compared to female patients. Nonetheless, the smaller representation of males is reflective 
of the PAH patient population. Furthermore, we were unable to measure estrogen levels of 
patients in our cohort, hence, we could not study direct associations of estrogen and RV 
adaptation. Lastly, as availability of human end-stage disease RV tissue samples is limited, 
numbers were small, and we could not match patient samples on age, the histopathological 
analyses suggest more capillary rarefaction in females, providing a hypothesis for future 
studies. Although our clinical cohort mostly consisted of idiopathic and hereditary PAH-
patients, CHD RV tissue samples were useful to study pressure-overloaded RV failure. Again, 
new approaches are necessary to overcome limited RV tissue availability, but also to 
investigate the direct effect of sex hormones on the right ventricle throughout in vitro cardiac 
models to study the cardiomyocyte/endothelial cell interaction in females in more detail. 
However, even with limited numbers, we have provided insight into the underlying 
pathophysiological mechanisms of RV failure in end-stage disease of PAH-patients. The 
strength of our study is the combination of RHC and CMR longitudinal functional data with 
cross-sectional sex hormone data and histopathological analyses of end-stage disease RV 
tissue. Importantly, we show that previous findings on sex hormone alterations in PAH can be 
extrapolated to a European cohort of PAH-patients across a wide range of ages. In addition, 
we used ID-LC-MS/MS for quantification of sex hormone levels, which has shown to be more 
 
 
reliable and accurate compared to immunoassays[30]. Finally, although follow-up is 
performed on a regular basis in our clinic, additional follow-up may have been indicated only 





In a large Dutch cohort of PAH-patients across a wide range of ages, we show for the first 
time a link between androgens and worse RV function in male PAH-patients. While DHEA-S 
levels were decreased in both male and female patients, reduced androstenedione and 
testosterone levels were observed in females only. Our longitudinal data suggest that females 
of reproductive age may persevere pressure-overload for a longer time period resulting in a 
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INTERPLAY OF SEX HORMONES AND LONG-TERM 
RIGHT VENTRICULAR ADAPTATION IN A DUTCH 



















Right heart catheterization 
Hemodynamic assessment was performed using a balloon-tipped, flow-directed 7.5-F triple 
lumen Swan-Ganz catheter (Edwards Lifesciences LLC, Irvine, CA, USA), as previously 
described [1]. Measurements of mPAP, right atrial pressure (RAP), pulmonary artery wedge 
pressure (PAWP) and cardiac output (CO) were taken at baseline and follow-up visits. CO 
measurements were obtained using the thermodilution or the direct Fick method. PVR was 
determined using the formula: (mean PAP-PAWP)/CO. 
 
Cardiac Magnetic Resonance Imaging 
Measures of RV function and volumes were taken using CMR imaging. Scans were obtained 
using a Siemens 1.5-T Sonata or Avanto scanner (Siemens Medical Solutions, Erlangen, 
Germany). Acquisition of images and post-processing was carried out as previously reported 
[2]. RV end-diastolic and end-systolic endocardial and epicardial contours were manually 
drawn using Mass Analysis software (MEDIS Medical Imaging Systems, Leiden, the 
Netherlands). End-diastole was determined using the onset of the R-wave in the ECG. 
Volumes and mass were indexed to body surface area (BSA) using the Mosteller formula. 
Stroke volume (SV) was determined according to left ventricular volumes (left ventricular end-
diastolic volume (LVEDV) - left ventricular end-systolic volume (LVESV)). 
 
Sex Hormone Analysis 
All samples were analyzed at the Endocrine Laboratory of the Amsterdam UMC. DHEAS, 
testosterone and androstenedione were measured in plasma using isotope diluted liquid 
chromatography mass spectrometry (ID-LC-MS/MS), as described earlier [3, 4]. DHEAS was 
measured using Isotope-Dilution Liquid Chromatography Tandem Mass Spectrometry (ID-LC-
MS/MS), slightly adapted from before[4]. In short, a deuterated internal standard ([2H6] 
DHEAS) (Sigma-Aldrich) was added to the serum sample and a protein precipitation step took 
place using acetonitrile. The supernatants were analyzed on a LC-MS/MS (Acquity, Waters 
Corp., Milford, MA). The lower limit of quantitation was 0.1 µmol/L. The intra-assay variation 
was 4% to concentrations of 4.2 and 8 µmol/L. The inter-assay variation was <6% over the 
whole concentration range. 
 
Testosterone and androstenedione were also measured using ID-LC-MS/MS, as published 
before (method C)[3]. In short, a deuterated internal standard [d3-testosterone and d7-
androstenedione) (both CDN isotopes) were added to the serum sample and later protein 
precipitation using acetonitrile. Samples were extracted using Porvair Sciences P3 filtration 
plates. Samples were analyzed on a LC-MS/MS (Xevo TQS, Waters Corp., Milford, MA). The 
lower limit of quantitation was 0.1 nmol/L for testosterone and 0.1 nmol/L for 
androstenedione. For testosterone the intra-assay variation was 6.5% in the female 
 
 
concentration range and 4.1% in the male concentration range. For androstenedione the 
intra-assay variation was 4.3%. The inter-assay variation was <7.6% over the whole 
concentration range for both testosterone and androstenedione. SHBG was measured using 
an automated immunoassay (Architect, Abbott Diagnostics, Chicago, IL, USA). The lower limit 
of quantitation was 2 nmol/L. The intra-assay CV was 6.3% and 4.9% at concentrations of 34 
and 134 nmol/L respectively. Free testosterone levels were calculated according to the 
Vermeulen formula using the total testosterone and SHBG measurement and using a fixed 
albumin concentration of 43 g/dl [5]. A fixed albumin concentration was used as it was not 
measured in all patients. However, in the patients where albumin measurements were 
available, the mean concentration was 39 g/dl.  
 
RV paraffin-embedded tissue of PAH-patients (N=3 females, N=3 males) and controls (N=3 
females, N=3 males) were sectioned and stained for CD31, rhodamine Ulex europaeus 
agglutinin I (Ulex), and wheat germ agglutinin (WGA). Tissue apoptosis was assessed by 
Terminal deoxynucleotidyl transferase dUTP Nick-End Labeling (TUNEL) assay. Images were 
captured under a laser confocal microscope (Nikon A1R). Quantitative histological 
measurements were assessed through ImageJ (NIH) with at least 10 random fields/patient. 
 
Immunohistofluorescence  
Right ventricle tissue from deceased healthy subjects (N=3 females, N=3 males) and both 
deceased or transplanted PAH patients (N=3 females, N=3 males ) were fixed in 4% 
paraformaldehyde in phosphate-buffered saline (PBS, pH 7.4) for 24 h, and embedded into 
paraffin. Afterwards, the paraffin block was cut into 5-µm sections and mounted into the slide 
with 3-aminopropyl-triethoxysilane (APES). 
Tissue sections were dewaxed with two 3-min xylene washes, one 3-min xylene:ethanol, 3-
min graded ethanol washes of 100% (twice), 95%, 70%, and 50% followed by running cold 
tap water. Next, sections were steamed in antigen retrieval EDTA-based pH=9 solution 4 
times 5 minutes. The sections were permeabilized, blocked and incubated at 4°C overnight 
with the primary antibody. Sections were stained for cluster of differentiation 31 (also known 
as Platelet endothelial cell adhesion molecule (PECAM-1)) (CD31, diluted 1:50; Santa Cruz 
Biotechnologies). Samples were then incubated for 1 h at room temperature with anti-mouse 
secondary antibody conjugated with Alexa-488 (diluted 1:500; Abcam). The sections were 
counterstained with Hoechst 33342 nuclear dye (diluted 1:500; Santa Cruz Biotechnology), 
rhodamine Ulex europaeus agglutinin I (Ulex, diluted 1:200; Vectorlabs), and Alexa-647 
conjugated wheat germ agglutinin (WGA, diluted 1:300; Thermo Fisher Scientific). Finally, 
samples were coverslipped with ProLong™ Gold Antifade Mountant (Thermofisher Scientific). 
Cell apoptosis was assessed by Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End 
Labeling (TUNEL) assay using the In situ cell death detection kit fluorescein (Roche) following 
manufacturer’s protocol. Images were captured at 20x, 40x and 60x magnifications under a 
laser confocal microscope (Nikon A1R). Whole-slide image acquisition was performed on 
 
 
Vectra Polaris (Akoya) at 10x and 20x magnifications. Quantitative histological measurements 
(cardiomyocyte cross-sectional area, vessel density and apoptotic nuclei) were assessed 
through ImageJ analysis software (NIH) with at least 10 random fields averaged per patient. 
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Overview of sex hormone pathway and findings in our PAH cohort of reduced DHEAS levels in both 
male (blue arrow) and female patients (pink arrow), and reduced androstenedione and testosterone 
















Table S1 - Characteristics general cohort compared to cross-sectional sex hormones cohort 
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RIGHT VENTRICULAR PRESSURE OVERLOAD:  


























In pulmonary arterial hypertension (PAH), right ventricular (RV) adaptation is essential to 
overcome the chronic increases in RV pressure overload. Ultimately, RV compensatory 
mechanisms are not sufficient and patients succumb to RV failure. The processes underlying 
the transition of RV adaptation to RV failure are not well understood. In this review, we 
propose that important insights in RV adaptation processes can be obtained by comparing 
different etiologies of PAH, namely patients with PAH secondary to Eisenmenger syndrome, 
patients with PAH secondary to systemic sclerosis and patients where no cause is identified: 
idiopathic PAH. Although the amount of RV afterload does not differ between these patient 
groups, their prognosis is distinctly different. We will show that an adaptive RV phenotype, as 
is observed in Eisenmenger patients, coincides with RV hypertrophy, increased RV 
contractility, low RV fibrosis and low RV diastolic stiffness. Whereas a phenotype of RV failure, 
as is observed in patients with PAH-secondary to systemic sclerosis, is characterized by 

































The first systematic explanation of the cardiopulmonary circulation was provided by the 
Roman scientist and philosopher Galen in the second century AD. He claimed that the liver-
produced blood would flow into the right ventricle, where it would move directly to the left 
ventricle (LV) via invisible holes in the interventricular septum. After that, the blood would flow 
to the local tissue in need, where it would disappear.1,2 Despite the discovery of Ibn al-Nafis 
in the 13th century that blood from the right ventricle passes through the lungs before 
returning to the LV, Galen’s theory dominated and influenced Western medical science for 15 
centuries.3  In 1628, William Harvey published his ‘Exercitatio Anatomica de Motu Cordis et 
Sanguinis in Animalibus’, where he was the first to describe the importance of right ventricular 
(RV) function by arguing; ‘If Nature does nothing in vain, she would not have added the right 
ventricle for the sole purpose of nourishing the lungs, but to propel blood through the lungs 
into the cavity of the LV’.2  Ever since, significant progress has been made in understanding 
the right ventricle, both in physiological and pathophysiological circumstances. In recent 
years, it has become clear that RV function is a significant determinant of prognosis and 
symptomatology in many cardiovascular diseases such as left-sided heart failure, congenital 
heart disease or pulmonary arterial hypertension (PAH).4,5 Therefore, understanding the right 
ventricle has become increasingly relevant to researchers and clinicians alike.  
In PAH, RV afterload increases due to progressive remodeling and proliferation of the 
pulmonary vasculature.  Even though RV adaptation mechanisms initially suffice, the 
progressive increases in pressure-overload leads almost inevitably to RV failure and death.6 
Except for lung transplantation, no curative treatment is available. Currently available 
vasodilators can only achieve a partial afterload reduction, but typically not enough to prevent 
RV failure, leading to an unsatisfactory median survival of 7 years.7 Interestingly, there is a 
wide heterogeneity in the time between RV adaptation to RV failure, which is independent of 
the pressure-overload.8 This observation suggests that the response of the RV rather than the 
amount of pressure-overload defines the fate of the RV in PAH. In aortic stenosis (AS), the LV 
equivalent of a chronic pressure overloaded ventricle, mechanisms underlying the conversion 
of LV adaptation towards LV failure have been more robustly studied. 9-15 However, despite 
the apparent resemblances between chronic RV and LV pressure overload, it is important to 
remember the relative increase in pressure overload is roughly two times higher in PAH than 
in AS. Additionally, while in both situations the ventricles adapt by increasing their mass, only 
the LV succeeds in normalizing the wall stress. 16-18  For these reasons and others, processes 
known to play a role in the transition from LV adaptation to LV failure can not necessarily be 
extrapolated to the RV. In this review, we will provide a perspective on the mechanisms of RV 
adaptation in PAH and discuss which mechanisms play a role in the transition from RV 





Possible mechanisms underlying transition of RV adaptation to RV failure 
To preserve cardiac output and thus systolic function in PAH, the RV initially adapts by 
increasing its contractility via the enhancement of intrinsic contractile properties and via 
muscular hypertrophy.19,20 However, as the load progressively increases, the hypertrophic 
response will be hampered and a vicious cycle of RV dilatation, RV systolic and diastolic 
dysfunction ensues.16,20-22  Although it is unknown what triggers the transition from an adaptive 
to maladaptive state, several mechanisms that could play a role have been proposed 





The most common genetic cause of PAH are loss-of-function mutations in the Bone 
Morphogenetic Protein Receptor type 2 (BMPR2) gene.26,27 The BMPR2 receptor is a member 
of the transforming growth factor β (TGF-β) superfamily, and mutations have been shown to 
result in a disturbed TGF-β/BMP balance. Also less common genetic causes of PAH have their 
origin in the TGF-β superfamily (mutations in the activin receptor-like kinase 1 (ALK1), 
BMPR1B, caveolin-1, and SMAD9 ).28-30  In the pulmonary vasculature, the over-activity of the 
TGF-β signaling leads to intimal hyperplasia, smooth muscle cell proliferation and apoptosis 
resistance.31-34  From a clinical perspective, it is known that patients with a BMPR2 mutation 
present at a younger age, with more severe hemodynamic derangements.35  
Most importantly, BMPR2 mutation carriers carry a worse prognosis – either dying at a 
younger age or requiring earlier lung transplantation, as elegantly shown in a recent meta-
analysis by Evans and coworkers.36 In addition, the authors conclude more severe RV 
dysfunction in BMPR2 mutated patients is responsible for the disparate outcomes. Other 
clinical studies have also revealed advanced RV dysfunction (as measured by stroke work 
index, stroke volume and  cardiac index) at time of diagnosis in BMPR2 mutation carriers.35,37,38  
Most convincingly, a recent study found that  BMPR2 mutation carriers have a reduced RV 
ejection fraction compared to patients without a BMPR2 mutation, both at baseline and after 
PAH-specific therapy, despite similar RV afterload.39 This points towards an important role of 
the TGF-β/BMP balance in RV adaptation during a chronic pressure-overload.  
In the heart, the BMPR2 receptor is expressed by cardiomyocytes and the ventricular 
endocardium.40-42 Signalling is activated to modulate angiogenic activity, cell growth, cell 
behaviour and survival.41-44 However, the cause of BMPR2 mutation-induced maladaptive RV-
remodeling is still unknown. From left heart failure, it is known that TGF-β overactivation in 
pressure-overloaded hearts directly lead to maladaptive hypertrophy, fibrosis and 
hypertrophy.45-48 Although LV and RV pressure-overload are distinctly different as discussed 
above, Megalou et al. demonstrated in a monocrotaline-induced PAH-rat model that TGF-β 
blockage indeed attenuated PAH by both lowering RV afterload and improving RV function.49 
Moreover, Hemnes et al. has shown in multiple experimental models that the BMPR2 mutation 
 
 
can result in a disturbed hypertrophic response.50 These data suggest that the complex 
cardiac metabolic program of fatty acid oxidation and glycolysis is impaired in PAH, evident 
from lipid accumulation and RV lipotoxicity.50-52 By comparing human RV tissue of healthy 
controls and PAH patients with and without BMPR2 mutation, our group observed increased 
mRNA levels of both the glycolysis and fatty acid oxidation pathway in PAH-patients without 
BMPR2 mutation. This might suggest that an impaired metabolic compensatory mechanism 
plays a role in the maladaptive hypertrophic response in the BMPR2. In addition, we were 
able to demonstrate that PAH-patients, independent of their BMPR2 mutation status, both 
show signs of cardiac fibrosis, inflammation and angiogenic alterations in terms of capillary 
density. No differences were seen between BMPR2 mutation carriers and non-carriers.39  
 
Neurohormonal activation 
As a response to the chronic pressure-overload in PAH neurohormonal systems are activated, 
in particular the sympathetic and renin-angiotensin-aldosterone-system (RAAS).53-55  Although 
important for maintaining cardiac output via the enhancement of contractility and hypertrophy 
in the short term, autonomic dysregulation might be a key player in transition of RV adaptation 
to RV failure in PAH.56  
 
Sympathetic nervous system 
Although it still has to be clarified when in the course of PAH sympathetic overstimulation in 
the RV begins, it has been shown that increased sympathetic activity is associated with a 
reduced chronotropic response to exercise, a delayed heart rate recovery and an increased 
mortality.57,58  In 1986, Bristow et al. showed reduced β1-adrenoreceptor density in the PAH-
patients.53 Later, this finding was confirmed an experimental study of Piao et al., where the 
authors demonstrate a downregulation of mRNA and protein expression of the adrenergic 
receptors in a sugen-hypoxia and pulmonary artery banding model.59 As a consequence, less 
protein kinase A (PKA) will be activated through the binding of norepinephrine to the β1-
adrenoreceptor, resulting in less PKA-mediated phosphorylation of key proteins involved in 
calcium handling and myofilament function.60 As a result, increased diastolic stiffness in the 
RV of PAH-patients is observed due to interstitial and perivascular fibrosis as well as stiffening 
of the RV cardiomyocyte caused by hypophosphorylation of titin.21 
In experimental studies a (partial) restoration of the sympathetic overdrive by beta-blocker 
therapy led to a survival benefit as well as improved systolic and diastolic RV function, by 
restoring PKA-signaling.61,62 Despite the common use in left heart failure treatment, the PAH 
field has been reluctant to study the therapeutic potential of β-blocker therapy in patients 
because of the potential negative inotropic effects and further impairment of exercise 
capacity.63,64 In recent years, several retrospective studies reported no detrimental effects of 
β-blockage in terms of hemodynamics, clinical and functional outcomes, paving the way for 
a prospective randomized controlled trials assessing the safety and efficacy of β-blockers in 
PAH.65,66 Explorative studies enrolling relatively small numbers of PAH-patients show trends 
 
 
towards better cardiac function yet mixed results in terms of exercise tolerance and 
hemodynamic improvements.67,68  
 
Parasympathetic activity 
Sympathetic nerve system activity is closely related to parasympathetic activity, in such a way 
that increased activity in one will result in reduced activity in the other. Little data exist about 
the contribution of parasympathetic activity in PAH-induced right heart failure.  
In PAH-patients reduced heart rate recovery, a marker of parasympathetic activity, is a strong 
predictor of prognosis and is associated with reduced exercise capacity.69,70  Although not 
well studied in PAH, targeting impaired parasympathetic signaling in left heart failure is 
beneficial, with previous studies showing improvement in LV function and survival after 
applying electric vagal stimulation and acetylcholinesterase inhibitors.71-73 In addition, 
preliminary data of our own group demonstrate potential therapeutic effects of enhancing 
parasympathetic activity in an animal model of PAH (da Silva Gonçalves Bos, D et al. Am J 
Resp Crit Care Med 2016;193:A3878, abstract). Future experimental studies should reveal 
whether restoring the sympatho-vagal balance via parasympathetic stimulation is a new 
potential treatment target in PAH.   
 
RAAS-system 
Increases in RV wall stress and RV dysfunction lead to the release of renin secondary to 
chronically reductions in kidney perfusion. Consequently, the RAAS-system is constitutively 
activated in PAH and its degree of activation has been associated with disease progression 
and worse prognosis.74 There is even some data to suggest that the pulmonary effects of 
RAAS-activation are even greater than the cardiac effects, and it has been demonstrated that 
several RAAS-inhibiting agents affect RV adaptation.75 For example, chronic angiotensin II 
type 1 (AT1)-receptor blocker treatment restores RV-arterial coupling, RV dilatation and RV 
diastolic stiffness in a monocrotaline PAH-model.74 In addition, renal denervation (affecting 
both the sympathetic and RAAS system) not only demonstrated improvement in 
hemodynamics, but also a significant reduction in RV fibrosis and diastolic stiffness.76  
Aldosterone inhibitors, which are currently a maintstay of therapy for symptomatic left 
ventricular failure, have shown promise in RV failure due to PAH.77 In retrospective cohort 
study combining an aldosterone-inhibitor with an endothelin-receptor antagonist lead to 
more significant improvements in functional status and cardiac function compared to 
endothelin-receptor antagonists alone.78 The results of a large randomized controlled trial 
assessing the effects of aldosterone-inhibitor spironolactone treatment in PAH-patients are to 
be expected soon (Clinicaltrials.gov NCT01468571).  
 
Ischaemia 
A hallmark in the transition of RV adaptation to RV failure is the occurrence of capillary 
rarefaction.79-81 In the pressure-overloaded RV, oxygen demand increases due to higher RV 
 
 
wall stress. To preserve the oxygen consumption/oxygen supply balance, the RV has to 
increase its myocardial efficiency and blood supply.  Initially, these mechanisms are effective, 
as is proven by the fact that RV hypertrophy alone is not associated with worse survival.82 
However, at a certain point capillary density and myocardial efficiency decrease and the RV 
begins to fail. 81,83  Ruiter et al. demonstrated that despite similar capillaries per myocyte in 
PAH versus controls, capillary density is actually less given the hypertrophied RV 
cardiomyocytes.81 Preserved capillary density is associated with HIF-1α and PGC-1α encoding 
for VEGF expression and therefore angiogenesis. As a consequence, HIF-1α- and PGC-1α-
related capillary angiogenesis are reduced in RV failure, but not in well adapted RV.84 The loss 
of myocardial capillaries and loss of integrity in the remaining capillaries lead to microvascular 
RV dysfunction, apoptosis and inflammation. A recent experimental study underlines the 
importance of the reduced capillary density in a maladapted pig model, where a mismatch 
between capillary density and workload was associated with increased myocardial fibrosis and 
worse RV failure.85 An additional factor hampering myocardial blood supply in PAH patients 
may be reduced flow in the right coronary artery, a consequence of low systemic pressures, 
high RV pressures and myocardial systolic compression.86 Reduced flow is correlated to RV 
mass and RV systolic pressures, indicating more ischemia as pressure afterload further 
increases. Although Brooks et al. showed an strong correlation between occlusion of the right 
coronary artery and RV contractility, the functional consequences in a chronic pressure-
overload RV are still to be investigated.87-90   
Taken this together, a reduced myocardial efficiency, reduced right coronary artery flow and 
capillary rarefaction occur during the transition from RV adaptation to RV failure.  
 
WHAT CAN WE LEARN FROM THE COMPARISON OF DIFFERENT ETIOLOGIES OF RV 
PRESSURE OVERLOAD? 
Determining the relevance and causality of the above described pathophysiological 
mechanisms is difficult. Although there are several animal models available  which allow one 
to study the pathophysiological mechanisms in more detail, there are significant differences 
between the human and rodent heart and the difference in disease progression (human: years, 
rats: weeks) making it difficult to translate the results to the human applications.91 In addition, 
mice are resistant to the development of  severe PH and RV pressure overload, limiting the 
use of genetic mice models. In future, cardiac specific gene therapy in rats may provide a 
solution.92 
Ideally, a comparison of protein changes in RV biopsies at different stages of the disease 
would define the key pathomechanisms. However, due to the high trabeculation and the 
thickness of the RV free wall,  the technical complexity in addition to the non-negligible risk 
of a ruptured RV free wall makes the procedure too challenging.93 An alternative could be to 
obtain a biopsy of the interventricular septum at the side of the RV, assuming that wall tension 
is similar around the RV cavity. The wall tension of the right ventricular free wall may differ 
from the tension in the interventricular septum, because of the structure of the right ventricle. 
 
 
Therefore, cardiomyocytes from the interventricular septum may or may not be comparable 
to cardiomyocytes from the right ventricular free wall.  
 




Summary of the proposed pathophysiological mechanisms contributing to the transition of RV 
adaptation to RV failure. Right ventricular adaptation to the increased pressure overload occurs in 
patients with Eisenmenger Syndrome by adaptive right ventricular hypertrophy.103 In patients with 
idiopathic pulmonary arterial hypertension, RV hypertrophy is not sufficient to cope with the increased 
pressure overload, and ischemia79-81 and intrinsic cardiomyocyte dysfunction19,21,109-112 have been 
described. In addition, RV adaptation can further be hampered due to genetic mutation in the bone 
morphogenetic protein receptor 2 (BMPR2).26,27,39 RV maladaptation in patients with systemic sclerosis 
is characterized by excessive RV fibrosis115,120,121, inflammation125 and disturbed contractile reserve53-55 
which is more pronounced than in patients with idiopathic pulmonary arterial hypertension. 
Abbreviations: PAH, pulmonary arterial hypertension; RV, right ventricular. 
 
At least one study suggests that the gene expression of alpha-myosin heavy chain is 
expressed in all ventricular regions in nonfailing human ventricular myocardium, signifying 
that biopsies of the interventricular septum could be used as a surrogate for the RV free wall.94 
However, a recent study in PAH-rats showed that important pathophysiological characteristics 
such as fibrosis, hypertrophy and capillary rarefaction may not be comparable between the 
RV free wall and RV septum.95 Therefore, current tissue analysis is limited to the comparison 
of end-stage disease. Nevertheless, important insights may be obtained when different 


















































(idiopathic PAH), PAH secondary to systemic sclerosis and PAH secondary to Eisenmenger 
syndrome. Epidemiological studies show that these 3 etiologies of PAH differ significantly in 
prognosis. As is shown in Figure 5.2, patients with PAH secondary to Eisenmenger syndrome 
have the best outcome with a 3-years survival of 85%, whereas this is only 63% in patients 
with idiopathic PAH and even worse in PAH-secondary to systemic sclerosis in which 3-years 
survival is only 52%.96 Furthermore, data suggest that these survival differences cannot be 
described to the severity of the pulmonary vascular remodelling, but is most likely ascribed 
to differences in the RV response to pressure overload.97,98 The magnitude of RV pressure 
overload is similar among the groups, or even lower in the PAH-patients with systemic 
sclerosis, but the adaptation of the right ventricle differs significantly. Therefore, these three 
PAH etiologies could be divided into 3 phenotypes of RV adaptation to increased pressure 
overload: 1. Eisenmenger patients represents a phenotype with RV adaptation; 2. Patients 
with PAH-secondary to systemic sclerosis represents a phenotype of RV failure; 3. idiopathic 
PAH-patients have a mixed phenotype of RV adaptation and RV failure. 
 
 
Idiopathic pulmonary arterial hypertension 
When during clinical assessment no cause of pulmonary hypertension is found (such as left 
heart failure, pulmonary embolism, chronic obstructive pulmonary disease, etcetera), the 
diagnoses of idiopathic PAH is made.99 The disease is further characterized by the relative 
young age of patients (average 49 years) and the female predominance (~80%).100 PAH is 
caused by excessive remodelling of the pulmonary vasculature, due to increased proliferation 
of the endothelial and smooth muscle cells of the small pulmonary arterioles. As a 
consequence of the pulmonary vascular remodelling, resistance in the pulmonary vasculature 
is increased resulting in elevated pulmonary artery pressure and pressure overload.  
 
PAH secondary to systemic sclerosis 
Systemic sclerosis is an autoimmune disorder which is characterized by increased 
inflammation and fibrosis formation in skin and visceral organs. Two forms of systemic 
sclerosis have been described: 1. Limited systemic sclerosis, in which the disease mainly 
affects the skin of the face, hands and feet, and; 2. Diffuse systemic sclerosis, in which the 
disease also affects the visceral organs such as kidneys, heart, lungs and gastrointestinal tract. 
The prevalence of PAH in systemic sclerosis patients is estimated around 12%, and is more 
common in patients with limited systemic sclerosis than in patients with diffuse systemic 
sclerosis.101 The development of PAH in systemic sclerosis has been ascribed to severe fibrotic 
and hypertrophic remodelling of the pulmonary arterioles. In addition, PAH is a principle 






PAH secondary to Eisenmenger syndrome 
Eisenmenger syndrome occurs in patients with a congenital heart defect, and is characterized 
by severe PAH with dilatation of the central pulmonary arterial, and reversal of a previous left-
to-right shunt at the atrial and ventricular or aorta-pulmonary level.102 Eisenmenger syndrome 
is mostly prevalent in patients with a shunt or defect distal to the tricuspid valve. Defects 
located proximal to the tricuspid valve include all atrial septum defects, sinus venosus defects 
and common atria, whereas post-tricuspid defects include all ventricular septum defects, 
single ventricles and aortapulmonary communications.103 Eisenmenger syndrome only occurs 
in patients with a large defect which is hemodynamically unrestrictive, indicating that there is 
no pressure difference from one side of the defect to the other.104 The systemic level 
pulmonary artery pressure and increased pulmonary artery flow causes muscular hypertrophy 
of the small pulmonary arteries resulting in excessive pulmonary vascular remodelling.  
 
Figure 5.2 – Survival in different PH-etiologies 
Survival analyses of the three etiologies of pulmonary hypertension discussed in this review. Patients 
with PAH secondary to Eisenmenger syndrome have the best outcome with a 3-years survival of 85%, 
whereas this is only 63% in patients with idiopathic PAH and even worse in PAH-secondary to systemic 
sclerosis in which 3-years survival is only 52%.96 Data suggest that these survival differences cannot be 
described to the severity of the pulmonary vascular remodelling, but is most likely ascribed to 
differences in the RV response to pressure overload. The magnitude of RV pressure overload is similar 
among the groups, or even lower in the PAH-patients with systemic sclerosis, but the adaptation of the 





























Right ventricular hypertrophy 
Right ventricular adaptation 
As discussed above, one of the mechanisms of adaptation to an increased pressure overload 
of the right ventricle is the induction of hypertrophy. Although it has been suggested in 
several previous review papers that the right ventricle in PAH-patients first adapt with 
concentric hypertrophy and eventually evolves into eccentric hypertrophy, this transition is 
difficult to prove due to the limitations of tissue collection. Indeed there is relatively little 
known about the kind of RV hypertrophy that is induced by increased pressure overload. 
The amount of RV hypertrophy has been compared between iPAH-patients, patients with 
PAH-secondary to systemic sclerosis and Eisenmenger patients by different imaging 
techniques. Interestingly, these analyses have revealed that the amount of hypertrophy 
between idiopathic PAH and PAH secondary to systemic sclerosis does not differ 
significantly.105,106 In contrast, in Eisenmenger patients RV hypertrophy is more pronounced,98 
despite similar pulmonary vascular remodelling and RV afterload in all three groups. This 
suggest that the adaptation of the right ventricle to increased RV afterload is best in 
Eisenmenger patients in comparison to iPAH and PAH-secondary to systemic sclerosis (Figure 
5.3). 
The heart of Eisenmenger patients (NB: post-tricuspid defects) is more comparable to a fetal 
heart than an adult heart.103 Like in the fetal circulation in which pulmonary and systemic 
arterial pressures are equal because of the fetal ductus arteriosus, the heart of Eisenmenger 
patients has similar RV and LV free wall thickness and a flattened interventricular septum. In 
addition, whereas patients with other forms of PAH undergo regression of RV wall thickness 
during infancy, this does not occur in patients with Eisenmenger syndrome. Therefore, it has 
been hypothesized that the RV cardiomyocytes of Eisenmenger patients are “primed” to 
endure the increased pressure overload. It is of utmost importance to unravel the molecular 
changes that are associated with the priming of the RV cardiomyocytes to endure prolonged 
RV pressure overload to enable the generation of therapeutic targets to induce a 
compensatory RV phenotype in other forms of PAH-induced right heart failure.  
 
Right ventricular recovery 
Right ventricular hypertrophy in patients with pulmonary hypertension is reversible. Studies 
before and after lung transplantation demonstrated that normalization of RV afterload results 
in normalization of RV mass. Whether intrinsic RV function is also restored remains to be 
established, though data from patients with chronic thromboembolic disease after effective 
pulmonary endarterectomy suggest the RV still may be impaired.129,130 Recent advancements 
with balloon pulmonary angioplasty in patients with chronic thrombo-embolic pulmonary 
hypertension allows to study the process of RV recovery following a decrease in RV afterload 
in the absence of interfering drugs in large number of patients.107  
 
Intrinsic cardiomyocyte dysfunction 
 
 
In addition to the size of the RV cardiomyocytes, intrinsic cardiomyocyte function is essential 
for the adaptation of the right ventricle to increased pressure overload. RV pressure-volume 
analyses can give an indication on the load-independent alterations of RV function in PAH-
patients. Because the original pressure-volume approach of obtaining multiple pressure 
volume loops by temporary vena cava occlusions are not without risks in PAH-patients, 
alternative approaches have been developed during past years. Translating from work 
performed on the LV, Brimioulle et al. described a single beat method to determine load-
independent RV systolic function,108 which has been implemented in several clinical 
studies.19,21,109-112 A Valsalva manoeuvre to decrease preload, and more recently, external 
inferior vena cava pressure, have recently been used to generate multiple pressure-volume 
loops and asses load-independent systolic function in PAH-patients97,105. It should be noted 
that the studies that we will discuss in the following paragraph, may differ on the techniques 
that were used to generate the information on load-independent RV systolic function.  
In patients with idiopathic PAH, an increase in RV contractility is observed in all patients 
independent of disease severity.19 This is also confirmed on tissue level, in which we have 
determined force generation of RV cardiomyocyte from PAH-patients (both idiopathic PAH 
and Eisenmenger) in comparison to donors. RV cardiomyocytes of PAH-patients generated 
over the whole spectrum of calcium concentrations, more force than RV cardiomyocytes of 
donor hearts also after correction for differences in RV cardiomyocyte size.21 Also a subgroup 
analyses was performed to compare idiopathic PAH and Eisenmenger patients, but no 
difference was observed, although it should be noted that the study was not powered for 
such an analyses.  
These measurements do not indicate whether the increase in RV contractility is sufficient to 
cope with the increase in RV pressure overload as is seen in PAH-patients. When RV 
contractility is corrected for the increase in RV afterload (RV-arterial coupling), we observed 
that the RV contractility increase is indeed insufficient to cope with the RV afterload in end-
stage PAH-patients.  
Interestingly, recent studies suggest that in patients with PAH secondary to systemic sclerosis 
the increase in RV contractility is absent (Figure 5.3). Overbeek et al. demonstrated that RV 
pump function was more affected in PAH-patients with systemic sclerosis in comparison to 
idiopathic PAH.113 In addition, also with pressure-volume analyses it was shown that RV 
contractility was reduced in PAH-patients with systemic sclerosis in comparison to idiopathic 
PAH, resulting in an abnormal RV-arterial coupling.97 More recently, preliminary data by Hsu 
and colleagues have extended this observation with RV cardiomyocyte measurements in 
which they confirmed the increased force generation of RV cardiomyocytes of idiopathic PAH-
patients, which was absent in RV cardiomyocytes of patients with PAH-secondary to systemic 
sclerosis (Hsu S, et al. J Heart Lung Transplant 2017, abstract).  
There are several possible explanations for this discrepancy between idiopathic PAH and PAH 
secondary to systemic sclerosis including impaired calcium handling105 or dysfunctional 
contractile machinery. Additionally, differences in beta-adrenergic receptor signalling may 
 
 
also play a role. Although it has been demonstrated that beta-adrenergic receptor signalling 
is also disturbed in idiopathic PAH patients,60 this could be more pronounced in PAH 
secondary to systemic sclerosis. Increased inflammation could lead to increased expression 
of prostaglandin E2, which can inhibit intracellular beta-adrenergic receptor signalling by 
preventing cAMP diffusion to the sarcoplasmic reticulum thereby blocking the beta-
adrenergic induced contractile response of cardiomyocytes.114 This hypothesis is supported 
by the recent finding of Hsu et al, that the contractile reserve upon exercise in patients with 
PAH secondary to systemic sclerosis is more impaired than in patients with idiopathic 
PAH.105,110 Future studies should further investigate the contribution of inflammation on the 
disturbed contractile reserve in patients with systemic sclerosis.  
  
RV fibrosis and RV inflammation 
RV fibrosis 
There are various techniques available to quantify right ventricular fibrosis in vivo as well as 
ex vivo. Most often used techniques in PAH-patients is delayed gadolinium enhancement and 
T1 mapping by magnetic resonance imaging (in vivo)115-119 or histomorphometric analyses in 
cardiac tissue (ex vivo).21,120,121  All studies have reported increased levels of RV fibrosis in PAH-
patients. However, with imaging techniques the observed RV fibrosis is often limited to the 
hinge-points of the right ventricle connected to the interventricular septum, whereas 
histomorphometric analyses also illustrates increased RV fibrosis in the RV free wall. This 
discrepancy may be explained by the observation that the RV fibrosis in PAH-patients is not 
replacement fibrosis but interstitial fibrosis. The latter being more difficult to detect by 
imaging techniques such as magnetic resonance imaging due to the limited resolution.  
The functional relevance of the observed increase in RV fibrosis remained elusive until 
recently. Although the differences between control and PAH RV fibrosis are modest,21 it is 
sufficient to explain the impaired RV diastolic stiffness observed in end-stage right heart 
failure.122 Besides the amount of RV fibrosis, also the type of RV fibrosis may be relevant. 
However, currently no data is available on the type of collagen deposition and cross-linking 
in the right ventricle of PAH-patients with different etiologies.  
The amount of RV fibrosis has been compared between idiopathic PAH patients and patients 
with PAH secondary to systemic sclerosis or Eisenmenger. Intriguingly, no difference in RV 
fibrosis has been observed in idiopathic PAH patients and patients with PAH-secondary to 
systemic sclerosis, both with in vivo analyses as well as with histomorphometric analyses on 
RV tissue.115,120 This observation was unexpected based on the fact that systemic sclerosis is 
an auto-immune disease characterized by increased collagen deposition in visceral organs. In 
line with the similar amount of RV fibrosis between idiopathic PAH-patients and patients with 
PAH-secondary to systemic sclerosis, also no difference in RV diastolic stiffness has been 
observed,97 indicating that the effect of RV pressure overload on RV diastolic function is similar 
between the two patient groups.  
 
 
A recent post-mortem morphometric analyses by Gomez-Arroyo et al. comparing cardiac 
tissue of patients with idiopathic PAH, Eisenmenger and control subjects, revealed increased 
RV fibrosis in both PAH-patient groups.121 However Eisenmenger patients appeared to have 
less RV fibrosis than idiopathic PAH-patients, suggesting that RV diastolic function is more 
preserved in Eisenmenger patients. This hypothesis is further supported by the observation 
that right atrial pressures are normal in Eisenmenger patients, whereas this is increased 
idiopathic PAH and PAH secondary to systemic sclerosis (Figure 3).  
From current literature, we can conclude that an adaptive RV phenotype, as is observed in 
Eisenmenger patients, coincides with less RV fibrosis and RV diastolic impairment. Future 
therapeutic studies should reveal whether targeting RV fibrosis could be a strategy to prevent 
the development of right heart failure.   
 
RV inflammation 
Little is known about the contribution of RV inflammation on RV adaptation in PAH. From in 
vitro studies in left heart failure, increased wall stress due to pressure overload results in the 
secretion of pro-inflammatory cytokines such as tumor necrosis factor alpha by 
cardiomyocytes.123,124 In addition, increased RV inflammatory cell infiltration has been 
described in an animal model of PAH.83 We could therefore speculate that impaired 
adaptation of the right ventricle to the increased load would lead to increased RV wall stress, 
thereby stimulating RV cardiomyocytes to secrete pro-inflammatory cytokines and attract 
inflammatory cells. Interestingly, more inflammatory cell infiltration is indeed observed in 
patients with PAH secondary to systemic sclerosis than in idiopathic PAH-patients, though it 
is unknown if this is a result of the systemic disease or response to pressure overload.120,125 
Novel developed tracers for positron emission tomography imaging may enable us to better 
study these hypotheses, for example inflammation can be visualized by a macrophage cell 
membrane tracer (18F-FMCH),126 fibrosis may by visualized by RGD based PET tracers,127 
neurohormonal activity may be visualized by a beta-adrenergic receptor tracer (11C-
CGP12177).128  Overall, future studies should reveal whether RV inflammation is a contributor 
to the transition towards right heart failure.  
 
CONCLUSION 
By comparing different PAH etiologies, we could identify 3 phenotypes of RV adaptation: 1. 
RV adaptation, as is observed in Eisenmenger patients, which is coincided with RV 
hypertrophy, RV contractility and low levels of RV fibrosis and RV diastolic stiffness; 2. RV 
failure, as is observed in PAH-patients secondary to systemic sclerosis, which is characterized 
by impaired contractile reserve, increased RV fibrosis and RV diastolic stiffness; 3. A mixed 
phenotype, as is observed in patients with idiopathic PAH.  
 
Further in depth comparison of RV hypertrophy development, neurohormonal regulation and 
RV function between patients with idiopathic PAH, PAH secondary to systemic sclerosis and 
 
 
Eisenmenger patients will gain our understanding of the different RV adaptation profiles. In 
addition, progress in new models such as cell culture models or nuclear imaging techniques 
is of utmost importance to extent our analyses from end-stage heart failure to longitudinal 
analyses of heart failure development. 
 
Figure 5.3 – Right ventricular adaptation 
 
Right ventricular adaptation in patients with idiopathic pulmonary arterial hypertension, patients with 
PAH secondary to systemic sclerosis and patients with PAH secondary to Eisenmenger syndrome. RV 
adaptation in patients with idiopathic PAH is characterized by increased RV hypertrophy, enhanced RV 
contractility, excessive RV fibrosis and RV diastolic stiffness.21 RV adaptation in patients with PAH 
secondary to systemic sclerosis is comparable to idiopathic PAH except that patients with systemic 
sclerosis suffer from impaired RV contractility.105 RV adaptation in patients with Eisenmenger syndrome 
is more beneficial indicated by the lower amount of RV fibrosis and RV diastolic stiffness in comparison 
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Background:  Management of Pulmonary Arterial Hypertension (PAH) patients is 
conventionally based on functional plus invasive measurements obtained during right heart 
catheterization (RHC). Whether risk-assessment during repeated measurements could also be 
performed using imaging parameters is unclear, as a direct comparison of strategies is lacking. 
 
Research question: How do the predictive value of non-invasive parameters compare with 
invasive hemodynamic measurements at 1 year after the diagnosis of iPAH? 
 
Study Design & Methods: 118 iPAH-patients who underwent RHC and cardiac magnetic 
resonance imaging (CMR) were included in this study (median time between baseline 
evaluation and first parameter measures: 1.0[0.8-1.2] years). 44 patients died or received a 
lung transplantation. Forward cox-regression analyses were used to determine the best 
predictive functional, hemodynamic and/or imaging model. Patients were classified as high-
risk if the event occurred <5 years after diagnosis (n=24), whereas patients without event were 
classified as low-risk.  
 
Results: A prognostic model that was based on age, sex and absolute values at follow-up of 
functional parameters (6-minute walk distance) performed well (Akaike information criterion 
(AIC): 279, concordance: 0.67).  Predictive models with only hemodynamic (right atrial 
pressure, mixed venous oxygen saturation; AIC: 322, concordance: 0.68) or imaging 
parameters (right ventricular ejection fraction; AIC: 331, concordance: 0.63) at 1 year of follow 
up performed similar.  The predictive value improved when functional data was combined 
with either hemodynamic data (AIC: 268, concordance: 0.69) or imaging data (AIC: 273, 
concordance 0.70). A model comprised of functional, hemodynamic and imaging data 
performed only marginally better (AIC: 266, concordance: 0.69).  Finally, changes between 
baseline and 1 year follow up were observed for multiple hemodynamic and CMR-parameters, 
only a change in CMR-parameters was of prognostic predictive value.  
 
 
Interpretation: Risk-assessment at 1-year of follow-up based on CMR is at least equal to risk-
assessment based on RHC.  In this study, only changes in CMR- but not hemodynamic 














Pulmonary arterial hypertension (PAH) is a progressive condition, characterized by extensive 
pulmonary vascular remodeling, resulting in an ongoing rise in right ventricular (RV) pressure 
overload.1 To secure RV systolic function and thus oxygen supply to all organs, the right 
ventricle adapts via several compensatory mechanisms. However, ultimately these are 
insufficient and progression to RV dysfunction and failure remains inevitable, with a grim 
prognosis as a result.2  
According to the guidelines, a right heart catheterization (RHC) is recommended to support 
the diagnosis of PAH. In addition, RHC should be considered to guide treatment decisions 
including adjustments in treatment regimen and/or referral to a transplantation center (IIa 
recommendation).3 However, whether hemodynamic assessment during follow-up is 
preferred above non-invasive monitoring is currently unclear.  
A risk-stratification algorithm has been published in the ERS/ESC guidelines and has been 
validated by several groups.4-6 In addition, recent studies of Weatherald et al.7 and Chin et al.8 
have demonstrated that after 4-months of follow-up, right atrial pressure (RAP), stroke volume 
index (RHC-SVi) and serum levels of N-terminal pro brain natriuretic peptide (NT-proBNP) are 
independently associated with death or lung-transplantation and are therefore important 
parameters to determine treatment response in PAH-patients.  
Notwithstanding the unquestionable predictive value of invasive hemodynamic assessment, 
several studies have shown that non-invasive imaging by cardiac magnetic resonance imaging 
(CMR) has also great predictive value at baseline.7, 9-13 The non-invasive character of CMR may 
enable easier routine follow-up of PAH-patients, as it is more patient-friendly and carries 
minimal patient risks. As in our institute functional, hemodynamic and imaging assessment is 
routinely combined during follow-up, we have a unique cohort to compare the predictive 
value of the different modalities of monitoring of idiopathic PAH-patients. Therefore, the aim 
of this study was to compare the predictive value of CMR parameters with invasive 





We retrospectively evaluated all idiopathic and hereditary PAH (iPAH)-patients seen between 
March 2000 and September 2018 at the Amsterdam University Medical Center, location VU 
University Medical Center, The Netherlands (a tertiary referral center for PAH). A diagnosis of 
idiopathic or hereditary PAH was made by a multidisciplinary pulmonary hypertension team 
after extensive clinical evaluation according to the ERS/ESC guidelines in the relevant time-
period.3  Since the repeated functional, hemodynamic and imaging measurements were 




Research Involving Human Subjects Act (confirmed by the Medical Ethics Review Committee 
of the VU University Medical Center, 2012.288).  
 
Functional assessment 
Functional assessment of the patients was performed by 6-minute walk distance (6MWD), 
New York Heart Association (NYHA) classification and NT-proBNP. 
 
Hemodynamic assessment by right heart catheterization 
RHC was performed using a balloon-tipped, flow directed 7.5F triple lumen Swan-Ganz 
catheter (Edwards Lifesciences LLC, Irvine, CA, USA). Cardiac output (CO) was measured by 
either the Fick method or thermodilution (23% direct Fick, 4% indirect Fick and 73% 
thermodilution). Pulmonary vascular resistance (PVR) was calculated as: PVR= (mPAP-
PAWP)/CO, where mPAP is mean pulmonary arterial pressure and PAWP is pulmonary arterial 
wedge pressure.  
 




In total 157 iPAH-patients were identified that had CMR and RHC assessment at baseline. In 39 
patients, no follow-up analyses including both CMR and RHC were available. Median follow-up time 
was 1 year with an interquartile range between 0.8-1.2 years. Of the 118 patients with follow-up 
measurements, 2 patients were excluded because from 1 patient no baseline data was available and 1 
patient was misclassified as iPAH. In total, 44 patients died or had a lung transplantation (24 patients 
had an event within 5 years after diagnosis, 20 patients had an event later than 5 years after diagnoses). 






Imaging by cardiac magnetic resonance imaging 
CMR was performed on a 1.5T Avanto or Sonata scanner equipped with a 6-element phased 
array coil (Siemens Medical Solutions, Erlangen, Germany). Image acquisition and post-
processing were performed as described previously.14, 15 RV ejection fraction (RVEF) was 
calculated according to the following formula: RVEF= (RVEDV-RVESV)/RVEDV *100%, where 
RVESV is RV end-systolic volume, and RVEDV is RV end-diastolic volume. In line with Mauritz 
et al., stroke volume was calculated by using left ventricular volumes (left ventricular end-
diastolic volume (LVEDV) minus left ventricular end-systolic volume (LVESV) ).16  
 
Statistical analysis 
Data are presented as mean ± standard deviation or median [interquartile range] depending 
on distribution. Categorical variables are presented as absolute numbers and relative 
frequencies (percentage). No further analyses were computed on the missing data, neither 
data imputation was executed. 
Average and median values of general characteristics of patients at baseline were calculated 
with R package tableone (https://CRAN.R-project.org/package=tableone). Individual baseline 
and follow-up graphs were constructed using R package ggpubr (https://CRAN.R-
project.org/package=ggpubr). Differences between baseline and follow-up were tested by 
paired t-test for continuous variables and McNemar’s test for categorical variables, with 
correction for multiple comparisons by Bonferroni.  
The predictive value of functional, hemodynamic and imaging parameters was tested by 
univariate and multivariate cox regression analyses using R package survival (https://CRAN.R-
project.org/package=survival). Forward cox-regression modeling was used to determine the 
best predictive functional, hemodynamic or imaging model using a p<0.1 as cut-off to be 
included to the final model. To compare the predictive value of the different models, the 
concordance (c-statistics) and Akaike information criteria (AIC) are provided. The Akaike 
information criterion provides a relative measure of the quality of the model and estimates 
the information lost by the number of parameters in the models and the strength of the 
predictive value. A low number means less information lost and could be interpreted as a 
better model. The concordance or C-statistics provides measure of goodness-of-fit in survival 
models. A higher concordance value means that the model gives a better prediction for 
survival. Pairwise comparisons were performed and corrected for multiple comparison with 
Bonferroni correction. All graphs were generated with ggplot2.   
All tests were two-sided and a p<0.05 was considered significant. Statistical analyses were 











Baseline characteristics  
In total 118 patients with As can be observed in Figure 1, baseline CMR and RHC data was 
available for 157 iPAH-patients (Figure 1). In 39 iPAH-patients, no complete follow-up with 
CMR and RHC was available and we therefore excluded these patients. In total, 118 patients 
with functional, hemodynamic and imaging assessment at baseline and follow-up were 
included in this study with a median time between the baseline measurement and the 
following complete CMR+RHC measurement of 1.0 year and interquartile range of 0.8-1.2 
years. 
Sixty-three percent of the patients classified as survivor, whereas in 37% an event (death or 
lung transplantation) had occurred. In 24 patients this event occurred <5 years after diagnosis. 
These patients were classified as high-risk patients, whereas patients classified as survivors 
were considered as low-risk patients (Figure 6.1).  
General characteristics of the patients are presented in Table 6.1. The study population was 
49±17 years old and consisted predominantly of females (69%). Most patients were in NYHA 
functional class II and III. In 52 out of 118 patients (44%) monotherapy was the initial treatment 
strategy of choice. Combination therapy or triple therapy was initiated in respectively 51% 
and 5% of the study population.  
Patients presented with a mPAP of 54±14 mmHg, mixed venous oxygen saturation (SvO2) of 
64±8 %, mRAP of 8±5 mmHg, NT-proBNP of 657[246-1999] ng/L and a RVEF of 36±12% The 
first follow-up was performed after a median time of 1.0 [0.8-1.2] years. 
 






A significant improvement in 6-minute walk distance (A) and NT-proBNP (B) is only observed in patients 
with a low risk (survivors). Non-survivor patients with short survival time (<5 years) are classified as high-
risk patients, whereas survivor patients with follow-up data > 5 years after diagnosis were classified as 
low-risk patients. All p-values are corrected for multiple comparison by Bonferroni. Abbreviations: 
6MWD, 6-minute walk distance; FU, follow-up.  
 
The predictive value of functional, hemodynamic and imaging parameters 
In order to determine the individual predictive value of functional, hemodynamic and imaging 
parameters in our cohort, univariate Cox-regression was performed. At follow-up, all variables 
except age were associated with the risk of death or lung transplantation (Table 6.2). 
A multivariate Cox-regression analysis was performed to compare the additional value of CMR 
parameters. First, we determined the best functional model, by using Cox-regression analyses 
with age, sex, 6MWD, NYHA functional class and NT-proBNP. A model only with age, sex and  
6MWD reached statistical significance with an AIC of 279 and a concordance index of 0.67 
(Table 6.3, Supplemental Figure 6.2).  
Subsequently, we determined the predictive value of hemodynamic prognostic model using 
forward cox-regression analyses with all hemodynamic parameters in addition to age and sex. 
Although the parameters individually all reached a significant predictive value, the forward 
cox-regression model resulted in a model containing age, sex, SvO2 and mRAP.  
 
In a similar analysis for the CMR-derived right ventricular parameters, the forward cox-
regression analyses resulted in a model containing age, sex and RVEF.  
The predictive value of the models with only hemodynamic or CMR parameters was 
comparable. (Table 6.3). The combination of hemodynamic or CMR parameters with 
functional measurements provided the best predictive value. Combining all three modalities 
did result in a trivial improvement in quality of the prognostication (Supplemental figure 6.1). 
These analyses suggest that during follow-up, functional assessment in combination with 
either hemodynamic or imaging provides the best prognostic information. 
 
Change in CMR parameters discriminate between high- and low-risk patients 
To determine whether a change between baseline measurements and measurements after 1 
year would provide further information on the clinical status of the patients, we assessed the 
discriminative value of the change in functional, hemodynamic and imaging parameters to 
identify low- and high-risk patients (Table 6.4). High-risk patients were defined as patients 
having an event within 5 years after diagnosis. Low-risk patients had no event during >5 years 
of follow-up. Treatment and comorbidities in the distinctive groups can be observed in the 









Table 6.1 – Patient characteristics at baseline 
 
 
Data presented as mean ± SD or median [IQR] when data is not normally distributed. Abbreviations: 
NYHA, New York Heart Association; PDE5, phosphodiesterase 5.  
 
Because of the arbitrary nature of the 5-year cut-off, analyses were repeated with a cut-off of 
an event within 3- and 7-years after diagnosis, as can be observed in the supplemental 
material (Table S6.3 and S6.4). Hemodynamic parameters showed improvements in all groups 
at follow-up independent of high or low-risk patients (Figure 6.3). In contrast, 6MWD, NT-
proBNP (Figure 6.2) and RV function (Figure 6.4, Supplemental Figure I) only improved in low-
risk patients. To further corroborate this finding, we determined the prognostic value of a 
change in functional, hemodynamic and imaging parameters. Only a change of RVEF was 




(HR: 0.96, 95%CI: 0.92-0.99, p=0.005). This suggests that although a patient improves 
hemodynamically, this does not necessarily translate into improved prognosis.  
 




For sex; males are used as reference. Abbreviations: NT-proBNP, N-terminal pro brain natriuretic 
peptide; RHC, right heart catheterization; CMR Cardiac Magnetic Resonance. 
 
Table 6.3 – Multivariate cox-regression analyses of function, hemodynamic and imaging 
parameters 
 




Parameters Hazards Ratio 95% CI P-value AIC Concordance
Model 1: Functional Age 1.00 0.98-1.02 0.681 279 0.67
Sex 0.44 0.22-0.89 0.023
6MWD 1.00 0.99-1.00 0.003
Model 2: Hemodynamic Age 1.02 1.00-1.04 0.062 322 0.66
Sex 0.46 0.24-0.89 0.021
RHC-RAP 1.08 1.01-1.15 0.024
RHC-SvO2 0.94 0.90-0.98 0.005
Model 3: Imaging Age 1.03 1.01-1.05 0.009 331 0.63
Sex 0.52 0.27-0.99 0.045




Part II – Functional, hemodynamic and imaging models combined 
 
 
Abbreviations: 6MWD, six minute walk distance; NT-proBNP, N-terminal pro brain natriuretic peptide; 
NYHA, New York Heart Association; RHC, right heart catheterization; SVi, stroke volume index; RAP, 
right atrial pressure; CI, cardiac index; PVRi, pulmonary vascular resistance indexed; SVO2, mixed 
venous oxygen saturation; HR, heart rate; RVEF, right ventricular ejection fraction; RVESVi, right 
ventricular end-systolic volume indexed; RVEDVi, right ventricular end-diastolic volume indexed; AIC, 




In the present study, we compared the predictive value of functional, hemodynamic and 
imaging parameters one year after the diagnosis of iPAH. We were able to demonstrate that:  
1) Both invasive RHC and CMR parameters have prognostic value at follow-up. 
2) The predictive value of follow-up with RHC (RHC-SvO2 and mRAP) and CMR (RVEF) 
alone was similar   
3) The predictive value of a model combining functional parameters with hemodynamic 
or imaging parameters provided the best predictive model. Combining all three 
modalities did not provide further prognostic information. The additional value of 
hemodynamics or imaging parameters to functional parameters was similar. 
4) With repeated measurements after 1-year follow-up, hemodynamic parameters 
improved even in non-survivors, whereas RV imaging and functional parameters only 
improved in survivors. Only a change in RVEF was shown to be of predictive value.  
Taking these findings together, we can conclude that follow-up by CMR is at least equal to 
invasive hemodynamic measurements to discriminate between high- and low-risk PAH-
patients, and that combining functional with either hemodynamic or imaging measurements 
is of additional value during follow-up of PAH-patients.  
Model 1+2 : Functional + Hemodynamic Age 1.01 0.98-1.01 0.539 268 0.69
Sex 0.43 0.21-0.89 0.022
6MWD 1.00 0.99-1.00 0.220
RHC-RAP 1.05 0.98-1.13 0.180
RHC-SvO2 0.95 0.90-1.00 0.064
Model 1+3: Functional + Imaging Age 1.01 0.99-1.04 0.298 273 0.70
Sex 0.51 0.25-1.05 0.069
6MWD 1.00 0.99-1.00 0.045
CMR-RVEF 0.96 0.94-0.99 0.004
Model 2+3: Hemodynamic + Imaging Age 1.03 1.01-1.05 0.012 320 0.71
Sex 0.49 0.26-0.95 0.036
RHC-RAP 1.05 0.98-1.12 0.180
RHC-SvO2 0.96 0.92-1.01 0.102
CMR-RVEF 0.97 0.94-1.00 0.040
Model 1+2+3: Functional + Hemodynamic
+ Imaging
Age 1.02 0.99-1.04 0.227 266 0.69
Sex 0.47 0.23-0.98 0.044
6MWD 1.00 0.99-1.00 0.220
RHC-RAP 1.02 0.95-1.10 0.577
RHC-SvO2 0.98 0.92-1.04 0.451





Predictive value of non-invasive follow-up using CMR 
RHC is recommended in the ERS/ESC guidelines at time of diagnosis. In addition, there is a 
IIa recommendation to perform a RHC to assess of treatment response and in case of clinical 
deterioration.3 However, as is known from multiple registry studies, not all PAH-institutes 
perform routine hemodynamic assessment at follow-up. It can be argued that an invasive 
follow-up strategy is not superior to a non-invasive strategy, as a direct comparison is currently 
lacking. In this unique study we were able to compare 3 follow-up strategies: 1. Functional: 
with 6MWD, NT-proBNP NYHA functional class; 2. Hemodynamic: with RHC-obtained data, 
and 3. Imaging: with CMR-derived data. The best predictive model was obtained by 
combining functional assessment with imaging and hemodynamic analyses. However,  the 
differences between the models containing functional assessment with imaging or 
hemodynamics were minimal. This indicates that routine follow-up of iPAH-patients may be 
performed non-invasively using CMR.  
Recent advances with artificial intelligence in cardiovascular imaging may open new 
opportunities to combine multiple clinical modalities and CMR in the future.17 Future 
prospective cohort studies should reveal whether such an approach is beneficial and should 
be incorporated in the treatment algorithm of PAH.  
 
Table 6.4 – Patients hemodynamics, functional and right ventricular characteristics at baseline and 
1 year follow-up stratified on survival time  
 
  
Abbreviations: 6MWD, six minute walk distance; NT-proBNP, N-terminal pro brain natriuretic peptide; 
NYHA, New York Heart Association; RHC, right heart catheterization; SVi, stroke volume index; RAP, 
right atrial pressure; CI, cardiac index; PVRi, pulmonary vascular resistance indexed; SVO2, mixed 






Changes in invasive and non-invasive assessments after 1-year of follow-up 
Non-invasive imaging was performed by CMR, because previous studies have shown that 
CMR is more sensitive to detect changes in RV function over time than echocardiography.18 
After 1-year of follow-up, no change in RAP and RVEDVi was observed, whereas only patients 
with a low-risk of mortality (and not in high-risk) showed significant improvements in 6MWD, 
NTproBNP, CMR-SVi, RVEF and RVESVi. In contrast, improvement in hemodynamic 
parameters were observed in low-and high-risk patients (non-survivors <5 years). This 
indicates that patients can still be at high-risk for mortality although their hemodynamic 
parameters improved.  
 
Right ventricle as a treatment target 
The results of this study highlight again the importance of RV adaptation on prognosis of 
iPAH-patients. All identified predictive markers are closely related to reduced RV function. 
Unfortunately, to date no specific RV therapies exist.2 Current pharmaceutic strategies are not 
sufficient to normalize RV function.15 This is confirmed in our study where no improvements in 
RV volume or RAP could be observed after 1-year of treatment. Recent studies have 
suggested that when PVR is reduced by >40%, reverse remodeling of the right ventricle may 
occur.19, 20 Future treatment strategies with (upfront) double or triple therapy21, 22 may prove to 
induce early reverse remodeling of the right ventricle and ultimately may improve prognosis 
of this serious condition. Another possible way to improve prognosis of PAH-patients is 
identification of novel therapeutic compounds directed to the right ventricle. However, it is 
difficult to identify proper treatment targets when tissue is only available in end-stage right 
heart failure or from animal models with important differences in RV physiology when 
compared to humans.23   
 
Study limitations 
The sample size of this study is relatively small in comparison to earlier studies due to the 
strict selection criteria. This limited the possibilities to perform multivariate regression 
analyses including general prognostic markers of PAH. In addition, the relatively small sample 
size might have led to an overfit of the developed models and are not validated in additional 
populations.   
More importantly, this is the first study in which paired analyses of function, hemodynamic 
and imaging are performed in a sample size of 118 iPAH-patients with a meaningful follow-
up of more than 5 years.  
Because prognostic importance was determined after 1-year of follow-up, there may have 
been a selection bias by not selecting patients that died or received a lung transplantation in 
the first year after diagnosis. In addition, due to the retrospective nature of this study, we had 






Figure 6.3 – Treatment effect on hemodynamic parameters in patients with a low- and high-risk 
profile 
 
Improvements in hemodynamic parameters are observed in both patients with low as well as in patients 
with high risk of mortality (Table 4). Individual data of stroke volume index (A) and mixed venous oxygen 
saturation (B) are demonstrated at baseline and after 1 year of follow-up. All p-values are corrected for 
multiple comparison by Bonferroni. Abbreviations: RHC, right heart catheterization; SVi, stroke volume 
index; SVO2, mixed venous oxygen saturation 
 
This study was performed in a single center. Although the overall hemodynamic and general 
characteristics of our iPAH population was comparable with previous published studies by 
Weatherald et al, our 5 years survival was higher. This may be explained by the difference in 
mean age between both studies (average age our study: 49 years, average age Weatherald 
et al.: 64 years). Age has been shown to be a key prognostic indicator in PAH before.5 The 
age difference between the studies can further be explained by the high prevalence of 
hereditary PAH included in this study (20%), who are on average diagnosed at an earlier age 
than iPAH-patients.24 
The definition of high vs. low risk at 5 years of follow-up is arbitrary. Similar results were 
obtained when repeating the analyses with a cut-off of 3 and 7 years (Tables S1, S2), which 
demonstrates the robustness of our analysis.  
 
Interpretation 
Risk-assessment based on CMR measurements is at least equal to risk-assessment based on 









Figure 6.4 – Treatment effect of CMR parameters in patients with a low- and high-risk profile 
 
Significant improvements in RV function and morphology were only observed in patients with a low 
risk-profile. Individual data of A. Stroke volume index measured by CMR and B. RV ejection fraction 
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THE VALUE OF HEMODYNAMIC MEASUREMENTS OR 
CARDIAC MAGNETIC RESONANCE IMAGING IN THE 

































 Survivor  Non-Survivor  
  n=74 ≥5 year (n=20) <5 year (n=24) P-value 
Monotherapy 26 (35%) 13 (65%) 13 (54%) 0.01 
Duotherapy 45 (61%) 6 (30%) 8 (33%)  
Triple therapy 2 (3%) 0 (0%) 3 (13%)  
Calcium-
antagonist 




58 (78%) 13 (65%) 13 (54%) 0.04 
PDE-5 inhibitor 52 (70%) 5 (25%) 19 (79%) <0.001 
Prostacyclin 
analogue 
6 (8%) 7 (35%) 5 (21%) <0.01 
 
 
 Survivor Non-Survivor  





Coronary disease 3 (4%) 0 (0%) 3 (12.5%) 0.157 
Hypertension 12 (16%) 1 (5%) 5 (20.8%) 0.380 
Diabetes Mellitus 3 (4%) 2 (10%) 3 (12.5%) 0.197 
Thyroid disease 7 (9%) 0 (0%) 1 (4.2%) 0.440 
Pulmonary disease 























Table S3 – Patients hemodynamics and imaging characteristics at baseline and 1-year follow-up 
stratified on event time of 3 years 
 
 
Table S3 – Patients hemodynamics and imaging characteristics at baseline and 1-year follow-up 






Figure S1 – Akaike information criterion and concordance index of the predictive models  
 
 
The Akaike information criterion provides a relative measure of the quality of the model and estimates 
the information lost by the number of parameters in the models and the strength of the predictive 
value. A low number means less information lost and could be interpreted as a better model. The 
concordance or C-statistics provides measure of goodness-of-fit in survival models. A higher 
concordance value means that the model gives a better prediction for survival. All models constructed 
by forward cox regression analyses are presented: Model 1 – Functional: Age + Sex + 6MWD; Model 
2 – Hemodynamic: Age + Sex + RHC-mRAP + RHC-SvO2; Model 3 – Imaging: Age + Sex + RVEF; 
Model 1+2: Age + Sex + 6MWD + RHC-mRAP + SvO2, Model 1+3: Age + Sex + 6MWD + CMR-RVEF; 
Model 2+3: Age + Sex + RHC- mRAP + RHC-SvO2 + RVEF; Model 1+2+3: Age + Sex + 6MWD + RHC-
mRAP + RHC-SvO2 + CMR-RVEF. The combination of functional with either hemodynamic and/or 
imaging parameters yielded highest predictive value.  
Abbreviations: NYHA, New York Heart Association class; 6MWD, 6-minute walk distance; RHC, right 
heart catheterization; SVi, stroke volume index; RAP, right atrial pressure; SVO2, mixed venous oxygen 
saturation; CI, cardiac index; CMR, cardiac magnetic resonance imaging, RVEDVi, RV end-diastolic 
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Introduction: Patients with idiopathic pulmonary arterial hypertension (IPAH) and a reduced 
diffusion capacity of the lung for carbon monoxide (DLCO) have a worse survival compared 
to IPAH patients with a preserved DLCO. Whether this poor survival can be explained by 
unresponsiveness to pulmonary hypertension (PH)-specific vasodilatory therapy is unknown. 
Therefore, the aim of this study was to evaluate the hemodynamic and cardiac response to 
PH-specific vasodilatory therapy in patients with IPAH and a reduced DLCO.  
 
Methods: Retrospectively, we studied treatment naïve hereditary and IPAH patients 
diagnosed between January 1990 and May 2015 at the VU University Medical Center. After 
exclusion of participants without available baseline DLCO measurement or right heart 
catheterization data and participants carrying a BMPR2 mutation, 166 participants could be 
included in this study. Subsequently, hemodynamics, cardiac function, exercise capacity, and 
oxygenation at baseline and after PH-specific vasodilatory therapy were compared between 
IPAH patients with a preserved DLCO (DLCO >62%), IPAH patients with a moderately 
reduced DLCO (DLCO 43–62%), and IPAH patients with a severely reduced DLCO (DLCO 
<43%).  
 
Results: Baseline hemodynamics and right ventricular function were not different between 
groups. Baseline oxygenation was worse in patients with IPAH and a severely reduced DLCO. 
Hemodynamics and cardiac function improved in all groups after PH-specific vasodilatory 
therapy without worsening of oxygenation at rest or during exercise.  
 
Conclusion: Patients with IPAH and a severely reduced DLCO show a similar response to PH-
specific vasodilatory therapy in terms of hemodynamics, cardiac function, and exercise 





















Patients with pulmonary hypertension tend to have a mildly reduced pulmonary diffusion 
capacity for carbon monoxide (DLCO) compared to healthy subjects (1). A severely reduced 
DLCO is most often seen in pulmonary hypertension related to connective tissue disease, 
lung parenchymal disease or in pulmonary veno-occlusive disease, but also in a subset of 
patients with idiopathic pulmonary arterial hypertension (IPAH) without signs of these 
underlying conditions (2-5). Recent studies revealed that IPAH patients with a low DLCO have 
a worse survival (6). Although it is yet unknown what causes this difference in survival, it has 
been argued that compared to other IPAH patients, IPAH patients with a severely reduced 
DLCO may have a distinct type of pulmonary vasculopathy that is less responsive to PAH-
specific therapy (7, 8). 
Therefore, the aim of this study was to compare the response to pulmonary arterial 
hypertension specific vasodilatory therapy in terms of hemodynamics, cardiac function, 






We studied retrospectively treatment naïve hereditary- and IPAH patients who were 
diagnosed between January 1990 and May 2015 at the VU University Medical Center. Part of 
this cohort was described in the study of Trip et al. (5). A diagnosis of hereditary- and IPAH 
was established by a multidisciplinary PH team, after rigorous clinical evaluation according to 
the ERS/ESC guideline (9).  
 
Subjects without available baseline DLCO measurement, with severe emphysema or 
pulmonary fibrosis on HRCT (5) were excluded from this study. Furthermore, to avoid clouding 
of the results, patients carrying a BMPR2 mutation were excluded from this study as recent 
studies showed the reduced life-expectancy but preserved DLCO status in these subjects (4, 
10). In total 166 patients were included in this study (Figure 7.1).  
 
The cohort was divided into three groups using tertiles, leading to one group with a severely 
reduced DLCO (<43%), one group with a moderately reduced DLCO (43%-62%) and one 
group with a preserved DLCO (>62%) . 
 
Right heart catheterization 
Hemodynamics and RV pressure curve recordings were assessed with a balloon-tipped, flow 




Cardiac output measurements were performed using thermodilution or the direct Fick 
method.  
 
Figure 7.1 – Flow chart 
PAH = pulmonary arterial hypertension; RHC = right heart catheterization 
 
 
Cardiac function and volumes 
RV function and volumes were assessed using cardiac magnetic resonance imaging  (CMRI). 
All scans were performed on a Siemens 1.5T Sonata or Avanto scanner (Siemens Medical 
Solutions, Erlangen, Germany). Image acquisition and post-processing was done as described 
previously (11). Left and RV volumes were indexed to body surface area (BSA). Stroke volume 
(SV) and ejection fraction (EF) were calculated according to the following formulas, in which 
EDV= end-diastolic volume and ESV = end-systolic volume: SV = EDV-ESV and EF = (EDV-
ESV)/EDV.  
 
Six-minute walking test (6 MWT): 
6MWTs were performed according to the ATS guidelines (12, 13). The distance walked (in 
meters) and the arterial oxygen saturation at rest and during exercise were measured at 







Treatment response:  
Treatment responses were assessed by the baseline-to-follow-up responses in 
hemodynamics, cardiac function and 6MWD. Time between baseline and follow-up was 1.9 
± 1.6 years in the DLCO<43% group, 1.6 ± 1.2 years in the DLCO 43-62% group and 2.1 ± 
2.2 years in the DLCO>62% group (p=0.860). 
 
Statistical analysis: 
Data are presented as mean ± standard deviation (SD) unless stated otherwise. Comparisons 
of baseline hemodynamics, cardiac function and the change in hemodynamic and cardiac 
function after PAH-specific therapies between the DLCO<43%, DLCO 43-62% and the 
DLCO>62% group were performed using one-way ANOVA with Bonferroni post-hoc 
corrections and Kruskas-Wallis tests with Dunn’s multiple comparisons post-hoc test as 
appropriate.  
Kaplan-Meier analyses were performed to test for survival differences between the 
DLCO<43%, DLCO 43-62% and the DLCO>62%  groups in the entire cohort and the cohort 
in which a MRI at follow-up was present. Kaplan-meier analysis was also performed to test for 
survival differences between the subjects with and without a CMRI at follow-up in the 
DLCO<43% group. Subsequently, multivariable cox regression analyses were performed to 
correct the association between DLCO and survival for age differences. 
Statistical analyses were performed using SPSS for Windows version 20 (IBM Corp., Armonk, 
NY, USA) and GraphPad Prism for Windows version 6 (GraphPad Software, Inc., San Diego, 
CA, USA). P-values <0.05 were considered statistically significant.  
 
RESULTS 
Characteristics of the DLCO<43%, DLCO 43-62% and DLCO>62% patients are summarized 
in Table 7.1. A detailed characterization of the majority of patients was already given in our 
previous study (5). 
 
Baseline measurements 
SvO2, LVEDVI and LVESVI were significantly lower in the DLCO<42% group compared to the 
DLCO>62% group. Except from these, baseline hemodynamics and cardiac function were not 
different between groups.  
Exercise capacity, assessed by the 6MWT, was significantly lower in the DLCO<42% group 
compared to the moderately reduced and preserved DLCO group, as well as the arterial 
oxygen tension and saturation at rest. Furthermore, the DLCO<42% group showed a larger 







As can be appreciated from Table 2, the DLCO<42% group received more double-therapy, 
more prostacyclin monotherapy and less endothelin receptor antagonist or 
phosphodiesterase type 5 inhibitor mono therapy. Interestingly, a significantly higher 
percentage of patients switched from monotherapy to combination therapy in the severely 
reduced DLCO group.  (Table 7.3) 
 
All groups showed a decrease in mPAP and pulmonary vascular resistance (PVR), an increase 
in cardiac index (CI) and no change in pulmonary arterial wedge pressure (PAWP) and heart 
rate (HR) from baseline to follow-up (Figure 7.2). 
 
Cardiac responses are depicted in Figure 7.3. Both groups showed no change in left 
ventricular end-systolic volume index (LVESVI).  Delta left ventricular end-diastolic volume 
index (LVEDVI) and delta left ventricular ejection fraction (LVEF)  did not differ between the 
three groups. Delta RVEDVI, RVESVI and RVEF were similar between severely reduced DLCO 
group, the moderately reduced group and the group with a preserved DLCO.  
 
6MWD increased in all three groups after PH specific vasodilatory therapy. Arterial oxygen 
saturation did not change from baseline to follow-up, while the moderately reduced DLCO 
group had a lower arterial oxygen saturation after exercise compared to the severely reduced 
DLCO and preserved DLCO group (Figure 7.4). 
 
Survival analyses 
LVEDVI and LVESVI proved to be confounders to the survival analysis. LVEDVI and age-
corrected survival was worse for patients with a DLCO<43% (Figure 7.5A). These survival 
differences between DLCO<43% and DLCO 43-62% and DLCO>62% were also present in 
the selected cohort with a CMRI available at follow-up (figure 7.5B). No difference in survival 







Table 7.1 – Baseline characteristics 
 
6MWD = six minute walking distance; SaO2 = arterial oxygen saturation; HR = heart rate; mPAP = 
mean pulmonary arterial pressure; mRAP = mean right atrial pressure; PAWP = pulmonary arterial 
wedge pressure; PVR = pulmonary vascular resistance; CI = cardiac index; SvO2 = mixed venous 
oxygen saturation; LVEDVI = left ventricular end-diastolic volume index; LVESVI = left ventricular end-
systolic volume index; LVEF = left ventricular ejection fraction; RVEDVI = right ventricular end-diastolic 
volume index; RVESVI = right ventricular end-systolic volume index; RVEF = right ventricular ejection 
fraction. *DLCO<43% significantly different compared to DLCO 43-62%, †DLCO<43% significantly 














Table 7.2 – PAH-specific medication during follow-up 
 
 
ERA = endothelin receptor antagonist; PGI2 = prostacyclin; PDE5i = phosphodiesterase type 5 
inhibitor. 
 
Table 7.3 – Treatment changes during follow-up (changes after an unsatisfactory response to 







In the present study we evaluated the effects of pulmonary hypertension specific vasodilatory 
therapy in IPAH patients with a severely reduced DLCO. It is known that IPAH patients with a 
low DLCO have a worse survival compared to IPAH patients with a preserved DLCO (6). In 
addition, it has been shown that IPAH patients with a low DLCO have more coronary artery 
disease, a higher tobacco exposure, a higher body mass index, are older, have worse 
pulmonary function tests and show more mild abnormalities on HRCTs compared to IPAH 
patients with a preserved DLCO (5). Although it seems that the IPAH patients with a low DLCO 
share some risk factors with group 2 and group 3 PH, normal PAWP pressures, spirometry and 
HRCT excluded left heart conditions and lung disease as a cause of PH. In addition, HRCTs of 
the IPAH patients with a low DLCO showed no signs of PVOD (14, 15). The question rises 
whether the low DLCO group has a different pulmonary vasculopathy compared to IPAH 
patients with a preserved DLCO (7, 8). The answer to this question remains elusive and 
requires further investigation. As a first step, we analyzed the treatment response in this 









Figure 7.2 – Hemodynamic treatment response 
 
Hemodynamic treatment response. mPAP = mean pulmonary artery pressure; PAWP = pulmonary 
arterial wedge pressure; mRAP = mean right atrial pressure; PVR = pulmonary vascular resistance; CI = 
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Figure 7.3 – Cardiac response to treatment 
 
 
LVEDV = left ventricular end-diastolic volume index; LVESVI = left ventricular end-systolic volume index; 
LVEF = left ventricular ejection fraction; RVEDVI = right ventricular end-diastolic volume index; RVESVI 
= right ventricular end-systolic volume index; RVEF = right ventricular ejection fraction. Data is 
presented as mean ± SEM. 
 
 
Figure 7.4 – Treatment response in oxygenation and 6MWD 
 
6MWD = 6 minute walking distance; SaO2 rest = arterial oxygen saturation in rest; SaO2 rest-ex = 
change in arterial oxygen saturation during exercise. * = p<0.05. Data is presented as mean ± SEM. 
 
 
Remarkably, we observed a significant improvement in hemodynamics, right ventricular 
function and exercise capacity upon pulmonary hypertension specific vasodilatory therapy 
without an impact on oxygen saturation in this cohort as in comparison to the IPAH patients 
with an moderately reduced or preserved DLCO.  
Less follow-up data was available in the DLCO<43% group compared to the DLCO 43-62% 
and DLCO>62% group which could have led to a selection bias and subsequent 
overestimation of the treatment effect in the DLCO<43% group. However, no survival 
difference existed in the DLCO<43% group between the subjects with and without available 
follow-up data. This to some extent suggests that the subjects in the DLCO<43% group with 
follow-up data are representative for the total DLCO<43% group. Furthermore, survival 

























































































































































































differences between the DLCO<43% and the moderately reduced and preserved DLCO 
groups continued to exist when only the subjects with follow-up data were entered in the 
survival analysis further arguing against the presence of an important selection bias. At follow-
up, the DLCO<43% group received more combination therapy compared to the DLCO≥43% 
groups. This may have confounded our results. 
 
Figure 7.5 – Survival analyses 
 











HR: DLCO<43 % vs. DLCO 43-62%: 0 .32  (95% CI:  0 .1 4-0 .76)*
HR: DLCO<43% vs. DLCO>62 %: 0 .23  (95% CI: 0 .09-0 .58)*











HR: DLCO<43% vs. DLCO 43 -62 %: 0 .23  (9 5% CI: 0 .0 7-0 .74 )
HR: DLCO<4 3% vs. DLCO>62%: 0 .13  (95% CI: 0 .0 4-0 .45 )
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A: Difference in survival between the DLCO<42%, DLCO 43-62% and DLCO≥63% groups in the total 
cohort (n=166). The DLCO<42% group showed a worse survival than the moderately reduced DLCO 
and preserved DLCO groups. B: Difference in survival between the severely reduced DLCO group, the 
moderately reduced DLCO and preserved DLCO group in the cohort in which a CMRI at follow-up was 
available (n=68). Also in this selected cohort the DLCO<42% group showed a worse survival compared 
to other two groups. C: Difference in survival between the group with and without a CMRI at follow up 
in the DLCO<42% group (n=42). No difference in survival was found between the group with and 
without a CMRI at follow-up in the DLCO<42% group. * adjusted for age and left ventricular end 
diastolic volume index. 
 
Based on the pulmonary vascular response on treatment there is no reason to withhold 
pulmonary arterial hypertension specific treatment from patients with IPAH and a severely 
reduced DLCO. The similarities in hemodynamic and cardiac treatment responses between 
IPAH patients with a severely reduced DLCO and IPAH patients with a preserved DLCO 
suggests that the poor survival in the low DLCO group is not explained by unresponsiveness 
of the pulmonary vasculature to current pulmonary arterial hypertension specific medications. 
Survival differences may be partially explained by the fact that the DLCO<42% group was 
older (16). Cox proportional hazard analyses showed that age was a confounder for the 
differences in survival between groups, however, survival differences remained after adjusting 
for age. As such, the question remains why survival in this subgroup of patients with IPAH and 
a severely reduced DLCO is so poor (6). 
 
CONCLUSIONS 
Patients with IPAH and a severely reduced DLCO show a similar response to PH specific 
vasodilatory therapy as patients with IPAH and a moderately or preserved DLCO in terms of 
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Pulmonary hypertension (PH) is a hemodynamic condition leading to a progressive increase 
in pulmonary vascular resistance (PVR) and mean pulmonary artery pressure (mPAP). 
Irrespective of its cause, the main cause of death in PH patients is right ventricular failure. 
Noninvasive imaging techniques play an essential role in the diagnostic process, differential 
diagnosis and in monitoring disease progression. This chapter will give an overview of the 
most important noninvasive imaging tools for assessing pulmonary pressures, RV function and 





































Pulmonary hypertension is rapidly progressive and lethal disease and is defined as a 
hemodynamic condition with a mean pulmonary arterial pressure (mPAP) > 25 mmHg at rest, 
measured invasively by right heart catheterization (RHC).(1) Although primarily a lung disease, 
prognosis of PH patients is closely related to right ventricular (RV) function.(2–6)  Initially, the 
RV adapts to it increased afterload by several compensatory mechanisms but in the end these 
are not sufficient to prevent progression to RV dysfunction and failure.  
 
Table 8.1 – Clinical classification of pulmonary hypertension 
 
1. Pulmonary Arterial Hypertension 
1.1 Idiopathic PAH 
1.2 Heritable PAH 
1.3 Drugs and toxins induced 
1.4 Associated PAH (connective tissue disease, HIV infection, portal 
hypertension, congenital heart disease, schistosomiasis, chronic haemolytic 
anaemia) 
       1’.    Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis 
1”.   Persistent pulmonary hypertension of the newborn (PPHN) 
2. Pulmonary Hypertension due to left heart disease 
2.1 Systolic dysfunction 
2.2 Diastolic dysfunction 
2.3 Valvular disease 
2.4 Congenital/acquired left heart inflow /outflow tract obstruction and 
congenital cardiomyopathies 
3. Pulmonary hypertension due to lung diseases and/or hypoxia 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude 
3.7 Developmental abnormalities 
4. Chronic thromboembolic pulmonary hypertension 
5. PH with unclear and/or multifactorial mechanisms 
5.1 Haematological disorders 
5.2 Systemic disorders 
5.3 Metabolic disorders 
5.4 Others 
 
Despite the fact that the five PH entities as described in the updated clinical classification of 
Nice 2013 (Table 8.1) are characterized by an increased pulmonary vascular resistance (PVR) 
and mPAP, underlying mechanisms, prognosis and treatment strategies vary significantly. (1) 
A critical distinction is the division in pre- and post-capillary pulmonary hypertension, as post-




(PAH) specific treatment. Therefore, it is of utmost importance to determine a right diagnosis, 
assessed by a complete evaluation of both hemodynamics and RV function.  
Multiple noninvasive imaging techniques are applicable and essential in addition to RHC 
measurements to assess the correct diagnosis . Furthermore, given the increased knowledge 
of disease progression and the importance of timely referral for lung transplantation, the role 
of noninvasive imaging techniques is indispensable. In this chapter, we provide an overview 
of imaging techniques in the diagnostic process as well as the monitoring of PH patients over 
time, as summarized in Figure 8.1 .   
 
Figure 8.1 – Screening, diagnosing and monitoring pulmonary hypertension 
 
HRCT: high resolution computed tomography, V/Q scan: ventilation/perfusion scanning, cMRI: cardiac 
magnetic resonance imaging. 
 
The diagnostic process 
Most PH patients are diagnosed when the disease is already in an advanced stage, due to the 
non-specific and subtle onset of symptoms at presentation (exercise-induced dyspnea, 
syncope, unexplained fatigue).(7–9) Early detection and thereby early initiation of treatment 
can improve clinical outcome. Often, noninvasive imaging techniques as computed 
tomography (CT) and cardiac echocardiography are performed during the diagnostic work-
up of patients presenting with shortness of breath. Both techniques provide the opportunity 





Routinely performed CT’s from patients presenting with shortness of breath may provide 
important clues about the presence of PH. The most extensive studied parameter to predict 
PH on CT pulmonary angiography (CTPA) is a diameter ratio > 1 of the pulmonary artery (PA) 
to ascending aorta (AA), measured at the level of the bifurcation of the pulmonary trunk. (10–
13) In 2014, a meta-analysis showed a relatively high sensitivity of 74% and a specificity of 
81%. (14)  In 2014, Spruijt et al. showed an increased predictive value and sensitivity of CTPA 
when adding ventricular measurements to the PA/AA ratio. (15) Other important parameters 
are the PA diameter versus bronchus diameter and right ventricular hypertrophy. Hence, 
isolated CTPA measurements are not suitable to rule out or confirm PAH, and as a next 
diagnostic step echocardiography is recommended.  
 
Echocardiography 
Echocardiography is a noninvasive, inexpensive and widely available technique and therefore 
attractive as a screening tool to estimate pulmonary pressure and to assess RV function. Yock 
et al. were the first to find a strong correlation between echo Doppler (DE)-derived estimated 
pulmonary pressures and RHC derived RV pressures, using the simplified Bernouilli to 
calculate the pressure gradient between the right ventricle and right atrium. (16) More recent 
studies showed a tendency of both under- and overestimation using this method, particularly 
at higher pressures. (17–19) Thus, despite the initial impressive associations, DE derived 
pressures cannot be used as a substitute for invasive pressure measurements during a RHC. 
Nevertheless, this method remains a reliable and adequate screening tool for PH.  An apical 
4-chamber view may give further indications for the diagnosis PH, by showing RV hypertrophy, 
dilatation or RA dilation. 
 
Assessing the correct diagnosis  
When PH is likely based on the results of echocardiography or CT scan, or confirmed by means 
of RHC, multiple underlying causes should be considered. Noninvasive imaging modalities 
play an important role in assessing the correct diagnosis. In the following paragraph, the 
added value of imaging techniques in the diagnostic process will be discussed in the order of 
the current ERS diagnostic guidelines, depicted in figure 8.1.  
 
1. Excluding the most common causes of PH: PH due to left heart disease and PH due 
to hypoxia/lung diseases.  
PH due to left heart disease (PH-LHD), classified as group 2 PH, is the most common cause of 
PH and is defined as a mPAP >25 mmHg at rest, accompanied with a pulmonary arterial 
wedge pressure (PAWP) >15 mmHg. (20) The presence of PH in combination with 
predominantly HF with preserved or reduced EF, results in more severe symptoms, worse 
exercise tolerance and is associated with high morbidity and mortality in comparison to heart 




process, given the potential detrimental effects of pre-capillary drugs in patients suffering PH-
LHD.  
Echocardiography plays a crucial role in diagnosing PH-LHD, in particular by making a 
distinction between diastolic and systolic heart failure or by showing a combination of both 
conditions. (25,26) Although the diagnosis of systolic heart failure is straightforward, 
diagnosing diastolic heart failure remains a challenge.  One of the most sensitive 
echocardiographic parameters to diagnose diastolic heart failure might be left atrial 
dilatation.(27,28) High resolution chest computed tomography (HRCT) plays a minor role in 
the diagnostic process of PH-LHD, although mosaic perfusion patterns and ground-glass 
opacities might be indicative for this type of disease.  
The prevalence of PH due to hypoxia/lung diseases varies from 5-36% in chronic obstructive 
pulmonary disease (COPD) to around 12% in idiopathic pulmonary fibrosis patients (IPF) and 
an estimated 40% in patients with combined pulmonary fibrosis and emphysema (CPFE).(29–
33) Although the sensation of dyspnea and the decreased exercise tolerance in this patient 
group is usually not primarily due to circulatory limitations, PH is a strong predictor of mortality 
and therefore important to acknowledge. (34) 
Estimating pulmonary pressures may be challenging in group 3 PH patients. Several factors 
affected by pulmonary diseases, such as hyperinflation of the lungs and alterations in heart 
position, may influence the accuracy to assess the velocity of the TR jet. In previous studies 
pulmonary pressures could be estimated in 44-87%, depending of disease severity. (35–38) 
Moreover, as sensitivity and specificity are lower compared to other PH groups and poor 
positive predictive value is poor (87%), reliance on echocardiography can lead to 
overestimation of the prevalence of PH. (37,39,40) Using RV characteristics, PH can reliably 
be excluded by the absence of RV abnormalities (RV hypertrophy, dilation or systolic 
dysfunction). (39) 
Notably, as COPD and other lung diseases have a high prevalence, the presence of PH may 
be coincidental. To differentiate between group 1 and group 3, noninvasive imaging may play 
an important role in combination with pulmonary function test and exercise testing. HRCT 
plays a crucial role in the assessment of an underlying lung disease as a possible cause of PH 
(group 3).  
 
2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH) 
If PH-LHD and PH due to hypoxia/lung disease are excluded as the underlying cause of PH, 
the following diagnostic step is to study the probability of CTEPH.  
The first description of CTEPH dates back to the 1920s, when Barnes et al. recognized 
nonresolving thromboemboli as a possible cause of RV failure. (41) Nearly a century later, 
even though knowledge has increased drastically, pathogenesis is still not fully understood. 
The main contributors of disease  development and progression are persistent vascular 
obstruction, small vessel arteriopathy and vasoconstriction. (42) Even though it is suggested 




of CTEPH patients (25-63%) does not have a prehistory of APE or deep venous thrombi, 
making it challenging to assess true incidence and prevalence. (43–45) 
For 60-80% of patients, a potentially curative treatment is available: pulmonary 
endarterectomy (PEA). This surgical procedure involves the eradication of obstructive tissue 
from the pulmonary arteries during circulatory arrest. However invasive and considerable 
mortality rates, long-term outcomes after PEA regarding functional status, quality of life and 
hemodynamics are very positive. (46–48) Therefore it is of utmost importance to diagnose 
CTEPH early, and furthermore to recognize patients eligible for PEA.  
 
Diagnosis is based on two criteria: 1) PH ascertained by RHC, 2) at least one larger defect as 
shown by planar radionuclide ventilation-perfusion scanning (V/Q) after at least three months 
of adequate anticoagulation therapy.(20,49,50) In recent years, computed tomography 
angiography (CTA) largely replaced V/Q scanning. However earlier studies suggest a superior 
sensitivity of V/Q scanning, novel publications show a comparable or non-inferior accuracy of 
CTA in diagnosing CTEPH. (51–53) A recent study of Rajaram et al. showed a similar sensitivity 
(94%) using 3D contrast-enhanced lung perfusion MRI, with the advantage of a better 
assessment of regional perfusion abnormalities without using ionizing radiation. (54) 
 
If V/Q is suggestive for CTEPH, further diagnostic steps are required to assess if patients are 
suitable for PEA. CTA and pulmonary angiography play an important role in this process. 
Whereas CTA might be superior in the assessment of more central lesions, pulmonary 
angiography has superior qualities in imaging more peripheral lesions. Vascular abnormalities 
which can be observed in CTEPH consist of completely obstructed vessels due to organized 
thrombi (sudden loss of contrast filled vessels) and partly obstructed vessels (narrowed 
vasculature, bands, webs). (55) A typical example of CTEPH imaging is depicted in Figure 8.2.   
 
Parenchymal signs visible on CTA may include a mosaic perfusion pattern, bronchial 
anomalies and  focal ground-glass opacities. Moreover, bronchial circulation can a thirty fold 
increase in CTEPH patients, leading to bronchial hypervascularisation which is visible as 
dilatation and tortuosity at CTA. (56–58) Recent developments of dual-energy CT (DECT) 
suggest future possibilities for better detection of peripheral thromboembolic disease. (59,60) 
The use of MRI in diagnosing CTEPH is upcoming, particularly because of the large benefits 
considering combined perfusion measurements, MR-angiography and the possibility to 




Figure 8.2 – CTEPH  
Images of a 59-year-old chronic thromboembolic pulmonary hypertension (CTEPH) patient. (A) 
ventilation-perfusion scanning (V/Q), (B) pulmonary angiography, (C) CT angiography and (D) cardiac 
MRI. Arrows indicate perfusion defects (A and B) and calcified intraluminal thrombi organisation (C). 
cMRI shows typical features of a pressure-overloaded right ventricle; RV hypertrophy, dilatation and 
intraventricular septal flattening (D-shape of the left ventricle).  
 
The less common causes; Pulmonary Arterial Hypertension (PAH) or PH with unclear and/or 
multifactorial mechanisms   
Pulmonary arterial hypertension is primarily a disease of the pulmonary vasculature, 
characterized by progressive vascular remodeling and narrowing of the precapillary 
pulmonary arteries. It may be idiopathic (IPAH) or associated with an underlying condition, 
like congenital heart disease, a genetic mutation (mostly the bone morphogenetic protein 
receptor 2 mutations (BMPR2)) connective tissue disease or HIV/Aids. Despite the different 
origins, the different groups share a similar clinical presentation and pathological changes of 
the lung microvasculature.(20)  As PAH is a rare disease, population-based estimates of 
incidence and prevalence are not available. However, large registries from France, the United 




population per year. (9,62–66) Diagnosis is primarily based on absence of other causes of pre-
capillary disease, mostly PH due to lung diseases and chronic thromboembolic PH.   
Besides clinical history, physical and laboratory analysis and prehistory, noninvasive imaging 
techniques may give important clues to differentiate within group 1 PAH.  
PAH is a common complication in patients born with a congenital heart defect, as a response 
to a chronic volume overload of the pulmonary circulation, as caused by a left-to-right shunt. 
Important diagnostic tools to diagnose systemic-to-pulmonary shunts, Eisenmenger’s 
syndrome or small defects are cardiac MRI and transthoracic and/or transesophageal 
echocardiography. Furthermore, a recent study found that PA calcifications and mural thrombi 
as found at CT strongly indicate PAH-CHD, as well as centrilobular ground glass opacities. 
(67)  
An abdominal ultrasound may be very helpful where there is a clinical suspicion of portal 
hypertension. To improve diagnostic accuracy, a colour-Doppler examinations may be added.  
Pulmonary veno-occlusive disease (PVOD) is a very rare cause of pulmonary hypertension and 
is often misdiagnosed as idiopathic PAH (IPAH). A definite diagnosis can only be assessed via 
a surgical biopsy, but as this is contraindicated in PH patients, a noninvasive diagnostic 
approach is needed. Hallmarks at HRCT are typical bilateral thickening of the interlobular 
septae, ground-glass opacities and interstitial edema.(68–70) 
Group 5, PH with unclear and/or multifactorial mechanisms is a very heterogeneous group 
with different pathogenesis and etiologies, varying from systemic disorders to hematological 
diseases. Diagnosis is primarily based on physical analysis and laboratory testing.  
 
Disease severity & monitoring 
Currently available therapies target the pulmonary vasculature, predominantly by 
vasodilation. Despite a wide range of therapeutic options, only partial reductions in PVR are 
achieved. These are not sufficient to achieve normal PVR values in the majority of patients, 
and therefore insufficient to prevent progression to right heart failure in PAH patients. (71) 
Furthermore, there is a very heterogeneous response to an increased afterload, independent 
of the amount of pressure itself, as is illustrated in Figure 8.3. As RV function is closely related 
to prognosis, measures for systolic (RV ejection fraction (RVEF), tricuspid annular systolic 
excursion (TAPSE) and RV fractional area change (FAC)) and diastolic function (RV end diastolic 
volume (EDV) and isovolumic relaxation (IVRT) are the most important focus of monitoring PH-
patients. The practicality as a monitoring tool for CT is limited due to its relatively high 
radiation use and lack of clinical applicable parameters which have proven to be reflective of 
changes in pressures or function.  Meanwhile, a broad range of cardiac MRI and 








Figure 8.3 – Cardiac adaptation is independent of pressure overload 
 
Cardiac adaptation is independent of pressure-overload. Four-chamber cardiac MRI obtained for two 
patients with a different cardiac response to a similar pressure overload. A) The adapted right ventricle 
(RV) of patient A shows a hypertrophied RV accompanied by a small right atrium (RA). B) The failing RV 
of patient B shows RV dilatation together with a dilated RA, despite an even lower pressure overload 
(mean pulmonary artery pressure of 45 mmHg (patient B) compared to 55 mmHg (patient A).  
 
Echocardiography 
Echocardiography is a widely used monitoring tool in PAH, supported by an excellent cost-
effectiveness, widespread availability and safety. Despite difficulties assessing the complex 
anatomy of the highly trabeculated RV using two-dimensional imaging, transthoracic 
echocardiography and Doppler imaging can provide important information on chamber sizes 
and LV and RV function. (26,75) A major drawback in the evidence of using echocardiography 
in the follow-up of PH-patients is the lack of longitudinal studies assessing echocardiographic 
parameters over time.  
A comprehensive summary of echocardiographic  values of the right heart is offered by the 
American Society of Echocardiography guidelines.(26)  The two most important parameters 
of RV systolic function are TAPSE and RV fractional area change (RV FAC). TAPSE is a measure 
assessing longitudinal shortening. In contrast to the LV, which contracts almost uniformly in 
both the transverse and longitudinal plane, the RV contracts predominantly along the 
longitudinal plane. (76) Baseline measurements of TAPSE have proven to be of great 
prognostic importance.(72) In end-stage disease, longitudinal shortening reaches a lower 
limit, where-after RV function deteriorates due to a loss of circumferential shortening. (77) The 
second parameter, RV FAC, combines longitudinal and transverse RV shortening. It has been 
shown that this parameter best reflects MRI-derived RVEF. (78,79) However, assessing RV-








Figure 8.4 – Pulmonary hypertension over time 
 
Scans of an idiopathic pulmonary arterial hypertension patient at a) baseline and b) after 3 years of 
follow-up. A) a compensated right heart is shown, consisting of a hypertrophied right ventricle (RV), 
relatively small right atrium (RA) and no pericardial effusion. B) a failing dilated RV is shown, together 
with a dilated RA and pericardial effusion.  
 
Recent advances in echocardiography have led to the emerge of promising new 2D-
techniques. RV strain is a measurement of myocardial deformation. The myocardium deforms 
via longitudinal and circumferential shortening as a result of sarcomere shortening. Using RV 
strain, global and regional assessment of RV function can be assessed. A worsening RV systolic 
strain is associated with increased pulmonary pressures and decreased functional class.(80,81) 
Furthermore, it has been shown that RV systolic strain predicts morbidity and mortality and is 
able to improve after PH therapy.(82)  However, as no normative values are available yet, 
more research and experience is needed before applicable in clinical practice. 
 
Figure 8.5 – The importance of right ventricular function 
 
A) RV end-diastolic and B) RV end-systolic volume increased progressively in patients whose disease 
was progressing, but remained unchanged in stable patients (interaction p-value for both <0.01). C) RV 




Baseline. *p<0.05 between groups; ** p<0.01 between groups; ***: p<0.001 between groups. 
Reproduced and modified from [81] with permission of the publisher.  
 
MRI 
Cardiac MRI (cMRI) provides high-resolution, 3D-, accurate quantitative information of 
ventricular volumes, mass, flows, structure and function without the use of ionizing radiation 
and toxic contrast agents. Furthermore, cMRI is the golden standard to assess cardiac 
volumes. Despite the higher costs, limited accessibility and a more time-consuming analysis, 
cMRI is regarded as the ideal monitoring tool of patients with PAH. Figure 8.4 illustrates cMRIs 
of a PH patient over time. 
Stroke volume, RV volumes, RVEF and LV end-diastolic volume have shown to be strongly 
predictive of survival both at baseline and during follow-up. (6,71) Interestingly, the presence 
of a dilating RV and atrophying LV may be observed before clinical symptoms manifest, 
providing the opportunity to intervene in an early stage of RV failure, as depicted in Figure 
8.5. (83) One of the key measurements of systolic RV function is RVEF, calculated by dividing 
stroke volume by end diastolic volume. Underscoring the importance of this measure, van de 
Veerdonk et al. showed that changes in RVEF and not in PVR predict outcome. (71)   
More detailed information about the RV myocardium can be obtained using MRI tagging to 
assess myocardial deformation and delayed contrast enhancement imaging with gadolinium 
or by T1-mapping to assess regional fibrosis.(84–86) Delayed contrast enhancement was 
found at the interventricular insertion points, suggesting focal fibrosis.(15,87,88) No studies 
have been published so far to study the significance and usefulness of these measurements 
in the follow-up of PH patients.  
 
Besides the cardiac developments in MRI, recent studies focus on the role of MRI in estimating 
pulmonary pressures. A reliable noninvasive measure for pulmonary hemodynamics is an 
interesting and popular research topic, as it could make the invasive RHC unnecessary. 
Promising results in studies of Reiter et al. and Kreitner et al. indicate that the use of MRI 
derived velocity parameters enable an accurate noninvasive assessment of pulmonary 
hemodynamics. (89–91) However, further research in multiple subgroups of PH-patients are 
needed before applicable in clinical practice. 
 
CONCLUSION 
Noninvasive imaging techniques have a clear and vital role in both diagnosis and follow-up 
of PH patients. The initial tools to recognize PH are echocardiography and CT, however RHC 
is still inevitable for a definitive diagnosis. Subsequently, various noninvasive imaging 
techniques can be performed, depending on clinical suspicion and prehistory. The most 
common forms of PH, group 2 and 3, can be excluded using respectively echocardiography 
and HRCT.  A V/Q scan followed by an CTA or pulmonary angiography gives additional 
information about the presence of chronic pulmonary emboli, as seen in CTEPH. As a 




echocardiography. Future imaging techniques will focus on more insight into the RV 
myocardium, but it is still questionable whether these techniques will eventually be applicable 
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Pulmonary arterial hypertension (PAH)  is a disease in which the lumen of small pulmonary 
arteries is narrowed because of vasoconstriction, hyperproliferation, inflammation and 
remodeling of smooth muscle cells and endothelial cells. This leads to an increase in 
resistance of the pulmonary vascular bed and an therefore an increase in pulmonary artery 
pressures. As a result the load on the right ventricle (RV) drastically increases, with a 
subsequent rise in RV wall stress. The RV will initially decrease this wall stress via increasing its 
wall thickness through hypertrophy and enhancing its contractility. Current PAH-medication 
decreases the pulmonary vascular resistance (PVR) and therefore reduce the RV afterload, but 
seldom normalizes it. As a result, the transition of RV adaptation towards RV failure, 
characterized by RV dilatation and decreased cardiac output, will be inevitable. To date, lung 
transplantation is the only cure for PAH-patients. To provide timely referral to a transplantation 
center, it is of utmost importance to identify ‘adapted’ PAH-patients who are prone to develop 
RV failure. To do so, key players in the transition from RV adaptation towards RV failure have 
to be identified. In this thesis, we aimed to further identify factors playing a role in RV 
adaptation and RV failure by comparing different phenotypes of PAH patients. Secondly, we 
evaluated the use of RV imaging during follow-up in PAH. 
 
Part 1 – Right ventricular adaptation in Pulmonary Arterial Hypertension 
In recent years, it has become clear that multiple factors influence RV adaptation during a 
state of chronic pressure overload. These factors are not only important to recognize because 
of timely treatment escalation, but also because of the emerging possibilities of the RV as 
treatment target.  
 
A mutation in the Bone Morphogenetic Protein Receptor type 2 (BMPR2) gene is the most 
common mutation known to cause PAH. A loss-of-function of the BMPR2 mutation in the 
pulmonary vasculature leads to vasoconstriction and a pro-proliferative state of the 
endothelial cells and smooth muscle cells. (1) Previously, it has been shown that PAH-patients 
with a BMPR2 mutation had worse hemodynamics and a lower cardiac index than patients 
without a BMPR2 mutation.(2,3) In chapter 2, we investigated the effects of the BMPR2 
mutation on the RV by combining in vivo measurements with molecular and histological 
analysis of human cardiac tissue. We found that RV function is more severely affected in PAH-
patients with a BMPR2 mutation than without, despite a similar afterload. However, these 
differences could not be explained by a differential transforming growth factor-ß (TGF-ß), 
BMPR2 signaling or cardiac morphology.  
 
The prognostic value of a sympathetic overdrive in PH is well-established. (5,6) In left heart 
failure the beneficial effects of stimulating its counterpart, the parasympathetic nervous 




parasympathetic nervous system is reduced in PAH, and associated with RV dysfunction. 
Furthermore, by enhancing parasympathetic activity through acetylcholinesterase inhibition 
by the oral drug pyridostigmine, we were able to improve survival, RV function and pulmonary 
vascular remodeling in a sugen/hypoxia rat model of PH.  
 
Despite the fact that PAH predominantly affects females, male patients are known to have a 
worse survival. Our group has previously shown that this survival difference is explained by a 
differential RV treatment response in male and female patients. Despite a decrease in PVR in 
both groups, the right ventricular ejection fraction (RVEF) only increased in female patients 
and not in male patients. (4) This implicates a role for sex hormones in the pathophysiology 
of PAH. 
 
Therefore, in chapter 4, we tested whether sex hormone expression levels are associated with 
RV adaptation. In our translational study we combined cross-sectional analyses of sex 
hormones with histopathological analyses of RV tissue and longitudinal analyses of RV 
adaptation in male and female PAH-patients. We were able to show that in female and not in 
male PAH patients androstenedione and testosterone levels were decreased, while DHEA-S 
levels were reduced in both male- and female patients. At end-stage, the female heart 
showed to be more severely affected in terms of capillary rarefaction, increased hypertrophy 
and apoptosis. This suggests, that the female RV is longer able to maintain an increased 
pressure-overload. Our longitudinal data strengthen this hypothesis, by revealing that females  
females of reproductive age may persevere pressure-overload for a longer time period 
resulting in a worse RV phenotype at end-stage disease. 
 
To further understand the processes underlying the transition from RV adaptation to RV 
failure, we summarized distinct RV phenotypes in chapter 5. Because even though RV 
afterload does not differ between PH secondary to Eisenmenger syndrome, PAH secondary 
to systemic sclerosis and idiopathic PAH, the prognosis is distinctly different. We showed that 
in an adaptive RV phenotype (as in Eisenmenger patients), is characterized by RV hypertrophy, 
an increased RV contractility, low RV fibrosis and a low diastolic stiffness. A RV failure 
phenotype (as in PAH-systemic sclerosis patients), coincides with RV diastolic stiffness, the 
presence of RV fibrosis and diastolic stiffness.  
 
Part 2 – Novel insights in (assessing) treatment response in pulmonary arterial hypertension 
There are several question that remain to be answered regarding monitoring and follow-up 
of PAH-patients. Regarding the prognostic importance of RV function and volumes, it could 
be argued that CMR should be the modality of choice to guide treatment decisions. However, 
in the current guidelines, a right heart catheterization (RHC) is recommended.  
As a first step, in chapter 6, we compared non-invasive and invasive risk assessment in PAH-




follow-up is at least equal to risk assessment based on invasive hemodynamic and functional 
measurements. These results confirm the clinical value of non-invasive imaging during routine 
follow-up in PAH.  
 
Patients with idiopathic PAH and a reduced diffusion capacity of the lung for carbon monoxide 
(DLCO) have a worse survival compared to IPAH patients with a preserved DLCO.(10) Whether 
this survival difference can be explained by a differential response to PAH-specific medication 
is unknown. Therefore, in chapter 7, we investigated the hemodynamic and cardiac response 
to PAH-specific medication in IPAH patients with and without a severely reduced DLCO. We 
concluded that IPAH patients with a severely reduced DLCO show a similar response to PAH-
specific medication in terms of hemodynamics, cardiac function and exercise capacity as IPAH 
patients with a preserved DLCO.  
 
Noninvasive imaging techniques play an essential role in diagnosing PAH and monitoring 
disease progression. Therefore, in chapter 8, we provide an overview of the imaging 
techniques involved in the diagnostic process and follow-up of PAH patients.   
 





The pressure-overloaded right ventricle in pulmonary hypertension 
Collecting and connecting the dots. 
In the first part of this thesis, we investigated three factors affecting the transition of right 
ventricular (RV) adaptation towards RV failure. In chapter 2, 3 and 4, we respectively 
investigated the effects of the Bone Morphogenetic Protein Receptor type 2, the reduced 
parasympathetic activity and role of sex on RV adaptation in pulmonary arterial hypertension 
(PAH). Obviously, numerous other factors are hypothesized and studied to play a role in this 




adaptation and RV failure might lead to the future development of therapies preserving RV 
function and halting the progression towards RV failure. However, to eventually develop these 
new therapies, a better understanding of the chain of events in the transition from RV 
adaptation towards RV failure is needed. Which process plays a role at what time point? And 
moreover, are the observed changes in these processes causes, consequences or bystanders 
in the transition towards RV failure?  
 
As a first step studies large longitudinal cohort studies in PH-patients (of all categorized 
groups) are warranted. Ideally, these patients would be studied from the date of diagnosis 
until the occurrence of an event (death or lung transplantation). During the course of disease, 
patients should undergo a right heart catherization (RHC), cardiac magnetic resonance 
imaging (CMR) and venipuncture to obtain biomarkers on regular timepoints with a short time 
interval (maximum interval: one year). Alongside the standard hemodynamics and pressures 
collected during RHC, pressure curves should be registered. This way, load-independent 
measures of RV contractility and RV diastolic stiffness can be determined according to the 
single-beat method of Sunagawa.(16–18) With the results of these studies, we do not only 
gain valuable further insights of the transition of RV adaption towards RV failure in the different 
subgroups, but also can compare the similarities and differences in RV adaptation between 
the subgroups.  
 
Unfortunately, it is complex to study human RV tissue during the process of RV adaptation 
towards RV failure. RV tissue of PAH-patients is usually gathered after a combined heart-lung 
transplant or death and is therefore only representative of RV failure and not RV adaptation. 
However, there might be a new kid on the block. Our group developed a patient-specific 
three dimensional cell model from patient derived induced pluripotent stem cells (iPSCs).(19) 
It would be very interesting to identify the processes occurring in RV-cells during different 
levels of pressure-overload. As these cells are patient-derived and thus patient-specific, it 
would be intriguing to compare chronic pressure-overloaded RV-cells of PAH-patients with 
and without BMPR2 mutations. Furthermore, it would be possible to further compare male 
and female cardiomyocytes, in line with chapter 4. However, whether the results of this 
complex and time-consuming method can be extrapolated to the pressure-overloaded RV of 
PAH-patients is yet to be established.  
 
Another interesting technique to obtain further insights in the chain of events in PAH is 
positron emission tomography (PET-CT). PET-CT makes it possible to detect 
pathophysiological processes and establish the degree of activity of these processes, using 
tracers. In example, Ashek et al. recently showed that dynamic 18FLT PET imaging can be used 
to report hyperproliferation in the pulmonary vasculature in PAH-patients.(20) Such a tool 
would allow tailored use of medicine to individual PAH-patients regarding the pulmonary 




transition from RV adaptation towards RV failure. In 2011,Wong et al. were able to 
demonstrate that oxygen efficiency is reduced in more advanced RV failure, thereby 
indicating that mitochondrial dysfunction might play a role in the failing RV. (21,22) Other 
studies, showed that the uptake of free fatty acids is decreased, whereas the uptake of glucose 
is increased. (23,24)  
 
A promising future application of PET-CT in the field of PH is the use of tracers to image the 
neurohormonal disbalance in the RV by the use of [11C]-CGP12177 and [11C]-HED as 
markers. Despite the encouraging results of pre-clinical studies restoring the autonomic 
disbalance, survival and RV function did not improve in clinical studies. (25–28) Using [11C]-
HED as a marker of pre-synaptic adrenergic activity, Rijnierse et al. were able to demonstrate 
that ß-blockage did not affect local RV sympathetic nerve activity, RV wall tension and RV 
function.(29) Before new treatment studies targeting the neurohormonal disbalance take 
place, it is of utmost importance to identify which patients would benefit from restoring the 
sympathetic/parasympathetic balance. For a start, it would be of interest to compare [11C]-
CGP12177 and [11C]-HED uptake between PAH-patients with RV adaptation and PAH-
patients with RV failure.   
 
Unraveling the remaining questions regarding the Bone Morphogenetic Protein Receptor 
type 2 Mutation in Pulmonary Arterial Hypertension 
 
The effects of the BMPR2-mutation on RV adaptation 
In Chapter 2 we investigated the effects of the BMPR2 mutation on the RV of PAH-patients. 
In this study we found that despite a similar afterload, RV function is more severely decreased 
in PAH-patients carrying a BMPR2 mutation compared to PAH-patients without a BMPR2 
mutation. We found no alterations RV adaptation and in in TGF-ß and BMP-induced SMAD 
phosphorylation in the cardiomyocytes of PAH-patients with or without BMPR2 mutation. Pre-
clinical studies using a transgenic rodent model of PAH with mutant BMPR2 showed that RV 
lipotoxicity and fatty acid oxidation impairment might play an important role. (30,31) To 
eliminate the bias of end-stage human cardiac tissue, the previously mentioned RV three 
dimensional cell model can be used. It would be interesting to study RV lipotoxicity and fatty 
acid oxidation on this RV-specific cell model.  
 
The BMPR/TGF-ß balance as a potential treatment target 
The BMPR2 pathway is not only downregulated in PAH-patients carrying the BMPR2 mutation, 
but also in PAH-patients without the BMPR2 mutation. (32) This fact makes the BMPR2/TGF-
ß balance an attractive treatment target. Using an high-throughput screen of nearly 4000 US 
Food and Drug Administration (FDA)-approved drugs, FK506 (Tacrolimus) was identified as a 
potent BMPR2 activator. (33) FK506 proved to be safe and well tolerated in PAH-patients, 




stage PAH. (34,35) However, the efficacy of FK506 is yet to be established (NCT01647945). 
Other potential strategies to correct the impaired BMPR2 signaling are the use of chloroquine 
and BMP9. (36–38) In vitro studies showed that chloroquine increases BMPR2 receptor density 
at the cell surface by slowing down lysosomal degradation of BMPR2 (chloroquine) and 
restoring full-length protein (ataluren).(39–41)  Future studies should reveal the potential 
effects of these drugs on pulmonary vascular remodeling and RV adaptation in PAH.  
 
Incomplete penetrance of the BMPR2-mutation 
Only 14% of the male and 42% of the female BMPR2 mutation carriers will eventually develop 
PAH. (42) This incomplete penetrance leads to uncertainty and frustration in BMPR2 mutation 
carriers and their families. In addition, the incomplete penetrance leads to a reasonable doubt 
regarding genetic counseling in suspected families. White et al. described investigating the 
incomplete penetrance as ‘looking for a needle in the haystack’.(43) Nowadays, it is 
hypothesized that a ‘second-hit’ is needed to decrease the BMPR2 signaling beneath a certain 
threshold to develop PH.(1) Inflammation, additional gene mutations and sex hormones are 
named as potential second hits. (44–48) However, large epidemiological studies assessing the 
incomplete penetrance are lacking. Ideally, a large cohort study should be conducted 
including all patients diagnosed with the BMPR2 mutation without PAH to determine potential 
risk factors to develop PAH in BMPR2 mutation carriers.  
Naturally, it is also of utmost important to recognize the development of PAH in BMPR2 
mutation carriers at an early stage. It is known that BMPR2-mutation carriers developing PAH 
have an abnormal response of pulmonary artery pressures during exercise.(49,50) Future 
studies should reveal hemodynamic, RV or biomarkers able to recognize PAH in BMPR2 
carriers at an early stage. In our center, the AmsterdamUMC location VU Medical Center, the 
DOLPHIN-GENESIS study currently includes unaffected BMPR2-mutation carriers with the aim 
to provide better understanding of the development of pulmonary vascular disease in these 
patients, using PET-CT, liquid biopsy, cardiopulmonary exercise testing, stress 
echocardiography, RHC and CMR.  
 
The use of non-invasive imaging in the follow-up of pulmonary arterial hypertension 
In the current guidelines, a RHC is recommended to guide treatment decisions during the 
follow-up of PAH patients.(51) In Chapter 6, we found that non-invasive risk assessment at 1 
year of follow-up is at least equal to a risk assessment based on invasive hemodynamic 
measurements. Furthermore, Huis in ‘t Veld et al. showed that a standardized treatment 
strategy with RV ejection fraction (RVEF) measured by CMR as treatment goal. If RVEF 
deteriorated, PAH-specific therapy was escalated. This way, RVEF could be improved and 
patients remained clinically stable.(52) Moreover, an earlier study of van de Veerdonk et al. 
showed that changes in RV volumes and RV function are important indicators predicting 
clinical deterioration.(53) Taking these studies together provides rationale to use CMR in 




CMR-based treatment strategy, after which a randomized controlled clinical trial should be 
conducted comparing the CMR-based treatment strategy versus the current hemodynamics 
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Pulmonale arteriële hypertensie is een ziekte die wordt gekenmerkt door progressieve 
vernauwing van de kleine longvaten. Door deze vernauwing is er sprake van een hogere 
weerstand van het longvaatbed, wat dientengevolge weer leidt tot een verhoogde druk 
(hypertensie) aldaar. De vernauwing van de kleine longvaten wordt veroorzaakt door een 
combinatie van abnormale proliferatie (vermenigvuldiging), hypertrofie (toename in grootte) 
en vasoconstrictie (het samenknijpen van de longvaten). De cellen die dit met name 
veroorzaken zijn de cellen die direct in contact staan met de bloedstroom (endotheelcellen) 
en de gladde spiercellen die zich één laag daaronder bevinden.  
 
De rechterhartkamer heeft als functie het zuurstofarme bloed dat vanuit het lichaam 
terugstroomt door te pompen naar de longen, zodat daar opnieuw zuurstof kan worden 
opgenomen. Door de verhoogde druk in het longvaatbed ontstaat er een toegenomen 
werkdruk voor de rechterhartkamer. Hierdoor wordt er minder bloed per tijdseenheid door 
de longen gepompt, waardoor er een verminderde toevoer van bloed en dus zuurstof aan de 
weefsels van het lichaam ontstaat. Patiënten met pulmonale arteriële hypertensie ervaren 
hierdoor klachten van vermoeidheid, flauwvallen en kortademigheid (bij inspanning). 
 
De rechterhartkamer zal bij blootstelling aan de hoge drukken diverse 
aanpassingsmechanismen gebruiken. In eerste instantie zal er wandverdikking plaatsvinden 
(hypertrofie), waardoor er meer knijpkracht zal ontstaan. Na verloop van tijd zal dit 
compensatiemechanisme tekort schieten en vindt er verwijding (dilatatie) plaats van de 
rechterhartkamer. Deze verwijding is een voorloper van het uiteindelijke falen van het 
rechterventrikel, met overlijden tot gevolg. De prognose van patiënten met pulmonale 
arteriële hypertensie wordt dan ook grotendeels bepaald door de functie van de 
rechterhartkamer, terwijl het eigenlijk een ziekte is die zich primair in de longen bevindt. 
Daarom is het van belang meer inzicht te verkrijgen in de aanpassing van de rechterhartkamer 
bij pulmonale arteriële hypertensie patiënten. 
 
 
Deel 1; Aanpassingen van de rechterhartkamer in pulmonale arteriële hypertensie 
Het belang van de rechterhartkamer in pulmonale arteriële hypertensie is al veel beschreven. 
Hierbij is naar voren gekomen dat het voor de prognose van de patiënt minder belangrijk in 
welke mate de druk in het longvaatbed verhoogd is, maar wel hoe de rechterkamer hierop 
reageert. Zo heeft een deel van de patiënten een licht verhoogde druk in het longvaatbed 
maar een hevig aangedane rechterhartkamer, en heeft een ander deel een sterk verhoogde 
druk in het longvaatbed maar nog een goed functionerende rechterhartkamer. Het doel van 
deel 1 van dit proefschrift is dan ook om meer inzicht te verkrijgen in het 





In hoofdstuk 2 kijken we naar de effecten van de BMPR2-mutatie op de functie van de 
rechterhartkamer. De BMPR2-mutatie is de meest voorkomende genetische mutatie in 
pulmonale hypertensie patiënten. In aangedane families heeft circa 80% een mutatie in het 
BMPR2-gen, en in de algemene populatie pulmonale arteriële hypertensie patiënten heeft 
11-40% de BMPR2- mutatie. Patiënten met een BMPR2-mutatie krijgen op jongere leeftijd de 
ziekte, en vaak in ernstigere mate. Tevens hebben zij een slechtere prognose dan patiënten 
zonder BMPR2-mutatie. In dit hoofdstuk vergelijken we de functie van de rechterhartkamer in 
patiënten met en zonder mutatie. We laten zien dat patiënten met BMPR2-mutatie, ondanks 
dat zij dezelfde verhoogde drukken als patiënten zonder BMPR2-mutatie hebben, toch een 
slechtere rechterhartfunctie hebben. Om uit te zoeken wat hieraan ten grondslag ligt is er op 
microscopisch en moleculair niveau gekeken naar hartspiercellen van overleden of 
getransplanteerde pulmonale arteriële hypertensie patiënten. 
 
Hoofdstuk 3 richt zich op de rol van het autonoom (onwillekeurig) zenuwstelsel in pulmonale 
arteriële hypertensie. Het autonoom zenuwstelsel bestaat uit twee delen; 1) het sympathisch 
zenuwstelsel, dat het lichaam zodanig beïnvloedt dat er activiteiten kunnen worden verricht 
(het zogenaamde ‘gaspedaal’ of ‘fight or flight’ mechanisme), en 2) het parasympathisch 
zenuwstelsel, dat het lichaam zodanig beïnvloedt dat er rust en herstel kan plaatsvinden 
(‘rempedaal’). Bij pulmonale arteriële hypertensie patiënten is er sprake van overactiviteit van 
het sympathisch zenuwstelsel. In het begin van de ziekte is dit voordelig, want deze reactie 
zorgt er in het begin voor dat het hart tegen de verhoogde drukken in kan pompen. Op de 
lange termijn zorgt deze overactiviteit echter voor een slechtere overleving. In dit hoofdstuk 
laten we zien dat de verminderde activiteit van het parasympathisch zenuwstelsel een negatief 
effect heeft op de rechterhartkamer. Dit werd bevestigd met onderzoek van harten van 
overleden of getransplanteerde pulmonale arteriële hypertensie patiënten. Tevens laten we 
zien dat het medicamenteus stimuleren van het parasympathisch zenuwstel een positief effect 
heeft op de rechterkamerfunctie bij een diermodel (ratten) met pulmonale hypertensie.  
 
Pulmonale arteriële hypertensie is een ziekte die tweemaal zo vaak voorkomt bij vrouwen ten 
opzichte van mannen. De overleving van mannen is echter significant slechter dan die van 
vrouwen. Uit onderzoek blijkt dat dit komt door een verminderd aanpassingsvermogen van 
de rechterhartkamer. In hoofdstuk 4 werd in een groot Nederlands cohort gekeken naar 
geslachtshormonen en rechterhartfunctie. Ook werd er gekeken naar hartspiercellen van 
mannelijke en vrouwelijke pulmonale arteriële hypertensie patiënten. We vonden een link 
tussen mannelijke geslachtshormonen (androgenen) en een slechtere rechterhartkamer bij 
mannelijke pulmonale arteriële hypertensie patiënten. Daarnaast liet onderzoek naar 
hartspiercellen van overleden of getransplanteerde pulmonale arteriële hypertensie patiënten 
een ernstiger beeld zien (meer celdood en meer verdwenen longvaten) bij vrouwelijke 




rechterhartkamer langer met een sterk verhoogde druk in het longvaatbed kan omgaan, maar 
bij overlijden of transplantatie dan wel een ernstiger aangedaan beeld laat zien.  
In hoofdstuk 5 vergeleken we middels een literatuuroverzicht verschillende 
aanpassingsmechanismen van de rechterhartkamer bij een verhoogde werkdruk. In dit 
overzicht proberen we inzicht te verkrijgen in het proces van een aangepaste 
rechterhartkamer naar een falende rechterhartkamer. Waarom faalt de rechterhartkamer bij 
de ene patiëntengroep snel, en bij de andere groep niet? Om antwoord op deze vraag te 
krijgen kijken we naar drie verschillende soorten pulmonale hypertensie, met allemaal 
dezelfde mate van een verhoogde druk in het longvaatbed, maar met zeer verschillende 
prognoses. We laten zien dat een goed aangepaste rechterhartkamer, zoals gezien wordt bij 
pulmonale hypertensie patiënten met het Eisenmenger syndroom, wordt gekenmerkt door 
een goede knijpkracht, hypertrofie, weinig verlittekening en goede vullings-mogelijkheden. 
Een slecht aangepaste hartkamer, zoals gezien wordt bij pulmonale hypertensie patiënten 
met sclerodermie, wordt gekenmerkt door weinig reserve in knijpkracht, verlittekening en een 
verhoogde stijfheid. 
 
Deel 2; Nieuwe inzichten in het (verkrijgen van het) effect van de behandeling en de 
monitoring hiervan in pulmonale arteriële hypertensie 
Hoewel het aanpassingsvermogen van de rechterhartkamer de prognose van pulmonale 
arteriële hypertensie patiënten bepaalt, zijn er op dit moment geen medicijnen beschikbaar 
die direct effect hebben op de rechterhartkamer. De huidige beschikbare medicatie richt zich 
op het verminderen van de druk in het longvaatbed door het verwijden van de longvaten. Tot 
nu toe is er geen medicijn gevonden dat de ziekte kan genezen.  
 
In deel 2 van dit proefschrift wordt gekeken naar de effecten van de huidige 
behandelmethodes op de rechterhartkamer. Tevens wordt er onderzocht hoe deze effecten 
van behandeling het beste kunnen worden gemonitord. 
 
Tot op heden is de gouden standaard voor zowel de diagnose als de verdere monitoring van 
pulmonale arteriële hypertensie een rechterhart-katheterisatie. Gedurende dit invasieve 
onderzoek wordt er middels een katheter via de hals of lies de druk gemeten in de 
rechterhartkamer en de longvaten. Daarnaast vindt er in gespecialiseerde centra een MRI van 
het hart plaats, om op deze manier zowel de functie als de verwijding van de rechterhartkamer 
te meten. In hoofdstuk 6 tonen wij aan dat alleen een MRI van het hart gedurende de follow-
up van pulmonale arteriële hypertensie patiënten evenveel prognostische informatie geeft als 
zowel een MRI én een rechterhart-katheterisatie samen.  
 
In hoofdstuk 7 richten wij ons op pulmonale arteriële hypertensie patiënten met een 
verminderde zuurstof opnamecapaciteit van de longen (DLCO). De zuurstof 




van het membraan waarover het zuurstoftransport plaatsvindt. Voorbeelden van ziekten die 
zorgen voor een verminderde zuurstof opnamecapaciteit zijn longfibrose en longemfyseem. 
Bij pulmonale arteriële hypertensie is de zuurstof opnamecapaciteit meestal normaal. In een 
groeiende groep patiënten wordt echter een sterk verlaagde zuurstof opnamecapaciteit 
gevonden. Deze groep patiënten heeft een slechtere overleving dan pulmonale arteriële 
hypertensie patiënten met een goede zuurstof opnamecapaciteit. Of dit deels wordt 
verklaard door een slechtere respons op de huidige pulmonale arteriële hypertensie 
medicatie was voorheen niet bekend. Wij vonden in deze studie dat deze patiënten zowel in 
hartfunctie als in longvaat-drukken hetzelfde reageerden op de vaatverwijders. Ook 
ondervonden deze patiënten geen nadelige effecten van de vaatverwijders qua 
zuurstofgehalte in het bloed, waardoor er geen reden is om patiënten met pulmonale arteriële 
hypertensie en een lage zuurstof opnamecapaciteit deze medicatie te onthouden.  
 
In hoofdstuk 8 wordt een overzicht gegeven van de huidige beeldvormende technieken die 
gebruikt worden bij de diagnose en monitoring van pulmonale hypertensie.   
 
Concluderend laat dit proefschrift zien dat er verschillende factoren een rol spelen in het 
aanpassingsvermogen van de rechterhartkamer op de verhoogde drukken ten gevolge van 
de vernauwing van de kleine longvaten. Verder onderzoek zal moeten uitwijzen of de 
mechanismen die hieraan ten grondslag liggen kunnen worden gebruikt als aangrijpingspunt 
voor nieuwe medicijnen die kunnen zorgen voor een betere overleving voor deze patiënten. 
Daarnaast hebben we laten zien dat in de toekomst een invasief onderzoek zoals een 
rechterhartkatheterisatie mogelijk minder frequent noodzakelijk is bij de monitoring van 
pulmonale arteriële hypertensie patiënten door het gebruik van een MRI van het hart. Verder 
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Na 8.5 jaar is het moment eindelijk daar; ik mag het dankwoord gaan schrijven! Iets waar ik 
lang naar uitgekeken heb; want wat is het een voorrecht om juist op deze meest gelezen 
pagina’s van dit (gedrukte) proefschrift iedereen te mogen bedanken die direct én indirect 
aan de totstandkoming van dit proefschrift heeft bijgedragen. De tijd dat ik aan dit 
proefschrift heb mogen werken was een onvergetelijke, leerzame en soms ook moeilijke tijd, 
die ik voor geen goud had willen missen.  
 
Als eerste een woord van dank aan de patiënten met deze relatief zo onbekende ziekte. De 
patiëntendagen, ‘Heb Hart voor Longen’ weekenden en het contact gedurende de MRI-
avonden hebben mij altijd enorm gemotiveerd en geïnspireerd. Jullie kracht en 
doorzettingsvermogen zijn een voorbeeld voor velen.  
 
Prof. dr. A. Vonk Noordegraaf, beste Anton. Zo’n tien jaar geleden, het moet midden 2011 
geweest zijn, mocht ik bij jou op sollicitatiegesprek komen voor een baantje als student-
assistent. Dat we een decennium later nu hier zouden staan, had ik op dat moment nog niet 
durven hopen. Onder jouw vleugels promoveren (en misschien ook wel een beetje volwassen 
worden) was een uiterst goede leerschool waar ik nog elke dag profijt van heb. Ik bewonder 
jouw passie, betrokkenheid en vechtlust voor patiënten, snelle denken, oneindige stroom 
ideeën, fysiologisch redeneren en kritische blik enorm. Niet zelden liep ik na onze 
onderzoeksbespreking jouw kamer uit in een staat van verwarring, lichte paniek en 
tegelijkertijd enthousiasme over de nieuwe ideeën. Uiteindelijk heeft het tot hele mooie 
resultaten geleid waar we trots op kunnen zijn! Dank voor het vertrouwen, het geduld en 
betrokkenheid!  
 
Dr. F.S. de Man, lieve Frances. Mijn dank voor jou is niet in een paar zinnen uit te drukken; 
daar zou weer een nieuw boekje voor nodig zijn (maar laten we dat maar niet doen..). Maar 
misschien is het eigenlijk ook wel heel simpel; zonder jou was dit boekje er niet. Heel af en 
toe komt er iemand op je levenspad die de wegen daarna verandert, en voor mij ben jij dat. 
Jij geloofde in mij lang voordat ik dat zelf deed en hebt mij altijd heel veel vertrouwen 
gegeven, en daar ben ik je ontzettend dankbaar voor. En wat hebben we samen veel bereikt! 
Met jouw visie, doorzettingsvermogen, perfectionisme en wil om altijd het hoogste te 
bereiken kun je bergen verzetten en ik denk dat we dat bijvoorbeeld met ons BMPR2-stuk 
ook wel een beetje gedaan hebben. Ik heb genoten van ons samenwerken; je directheid, je 
les dat extra moeite áltijd de moeite waard is, je kritische blik (zonder pokerface), het werken 
aan onze gezamenlijke passie voor goede figuren, maar vooral het aan één blik genoeg 
hebben (binnen en buiten werk). Maar buiten al deze inhoudelijke kwaliteiten ben je bovenal 
een van de liefste personen die ik ken. Je bent er ontzettend voor me geweest in moeilijke 
tijden, maakte elke werkdag samen een fijne dag en daarnaast hebben we samen ook veel 
bijzondere momenten gedeeld. De komst van Lizzy en Björn, de trip naar Orlando, de 
champagne in Parijs, de prosecco in de Mahler, etentjes met Louis en Chris en onze talloze 
rondjes.. Ik kijk uit naar onze nieuwe avonturen, met dit boekje dan rustig in de kast. Time to 





Prof. dr. H.J. Bogaard, beste HJ. Vanaf het allereerste begin ben ik ontzettend blij dat je zo 
betrokken bent geweest bij mijn PhD-traject. Jouw positiviteit, enthousiasme, vriendelijkheid, 
pragmatische instelling en snelle en volledige commentaren op manuscripten zijn op 
meerdere fronten van grote waarde geweest. Dank! 
 
De leden van de promotiecommissie. Prof. Dr. Chamuleau, Prof. dr. Velthuis, dr. van Balkom, 
dr. Bartelds en dr. Altenburg; veel dank voor het kritisch lezen van het manuscript en het 
plaats willen nemen in de promotiecommissie. Prof. dr. S. Kawut, thank you for participating 
in the reading committee.  
 
Emeritus prof. dr. Westerhof, beste Nico. Uw betrokkenheid bij mijn PhD-traject beschouw ik 
als een groot voorrecht. Het grootse enthousiasme over de fysiologie en de wetenschap zelf, 
en met name de wil om elk getal in de resultaten écht te begrijpen is ontzettend waardevol 
en leerzaam geweest. Veel dank!  
Dr. B. Westerhof, beste Berend. Wat was ik blij met jouw toevoeging aan het 
begeleidingsteam! Jouw vriendelijkheid, rust, laagdrempeligheid en originele invalshoek 
maakten de laatste loodjes in het VUmc nog aangenamer.   
 
Dr. M.L. Handoko, beste Louis. Soms op de voorgrond, maar nog vaker op de achtergrond, 
ben je nauw betrokken geweest bij elk artikel in dit boekje. Dankjewel voor je betrokkenheid, 
cardiologische blik op het geheel, je hulp en gezelligheid. 
 
Prof. dr. Goumans, beste MJ. Je bent een inspiratie voor hoe je als powervrouw toch altijd 
warm en betrokken kan blijven. Dank voor je tips, wijsheden en gezelligheid gedurende 
borrels!  
 
Dr. J.T. Marcus, beste Tim. Bijna elke MRI die voor de onderzoeken in dit boekje is gebruikt, 
is door jou gemaakt. Op de vele dinsdag- en woensdagavonden die we achter het 
bedieningspaneel gespendeerd hebben, heb ik veel van je mogen leren over de oneindige 
mogelijkheden van een cardiale MRI. Dank daarvoor.  
Dr. L.J. Meijboom, beste Lilian. Dank voor de nieuwe input, expertise en gezelligheid! 
 
CVON-PHAEDRA collega’s, bedankt voor de samenwerking en gezellige PHAEDRA-dagen 
en weekendjes! Vooral de pikdonkere fietstocht van het enige (open) kroegje op Terschelling 
terug naar het hotel zal ik niet snel vergeten.  
 
Frank, Martha en Iris; het dreamteam. Jullie zorg, passie en kennis van én voor PH-patiënten 
is ongeëvenaard. Martha en Iris, jullie maakten het werk op 3F altijd gezellig, om over de 
fantastische ‘Heb Hart voor Longen’ weekenden nog niet eens te spreken. Inmiddels hebben 
jullie je vleugels uitgeslagen naar de andere ziekenhuizen die Amsterdam rijk is, en ik wens 
jullie daar ontzettend veel succes! Frank, na meer dan duizend rechterhart katheterisaties ben 
je nog steeds net zo betrokken, oprecht geïnteresseerd, enthousiast en lief voor patiënten en 
PhD-studenten. Door jou heb ik zelfs een zekere sympathie voor AZ gekregen, en blijf ik ze 





Beste Ella, Ellen en Anny. Dank voor alle administratieve hulp! Bij jullie kun je altijd terecht 
met allerlei problemen, en of het nu ‘bloedspoed’ heeft of niet.. uiteindelijk wordt het altijd 
opgelost. Ella, dank ook voor de mooie tijd bij de ‘Inspiratie’!  
 
Beste Jasmijn, mijn wetenschappelijke stage begon bij jou; met een project over PET-scans 
in de bèta-blokkerstudie. Nadat je me in mijn rolstoel naar een twijfelachtige uithoek van de 
medische faculteit had gereden, kon daar het gevecht met MATLAB en alle foutmeldingen 
beginnen. Ondanks dit alles ben ik mede door jouw enthousiasme toch besmet geraakt met 
het onderzoeksvirus. Dank daarvoor! Binnenkort weer een White Russian?  
 
Stafleden en arts-assistenten van de afdeling Longziekten in het VUmc, dank voor de vele 
onderwijsmomenten en de gezelligheid. Daarnaast dank de mooie en leerzame tijd 
gedurende mijn semi-arts stage! Wat is het fijn om in zo’n veilige en inspirerende omgeving 
de eerste klinische stappen te zetten.  
 
Dr. A. Boonstra, beste Anco. Ik kijk met heel veel plezier terug op de onderwijsmomenten, 
grote visites en de PH-meetings waar jij bij betrokken was. Jouw persoonlijke betrokkenheid 
bij patiënten en liefde voor longfysiologie blijven erg aanstekelijk.  
 
Bart, dankjewel dat ik jouw plekje op 6D mocht innemen. Je hebt me in mijn eerste dagen als 
student-assistent met veel geduld geholpen met het leren herkennen van de verschillende 
drukcurves, waardoor het leven daarna een stuk makkelijker werd. Dank voor de mooie 
borrels, gezelligheid en weekendjes Berlijn en Gent!  
Esther, wat bewonder ik je om je enorme kennis, perfectionisme, wilskracht en betrokkenheid. 
Bedankt voor de hele gezellige en leerzame samenwerking - maar meer nog voor de wijze 
lessen over de liefde en het leven met een glaasje wijn in de hand.  
Dieuwertje, dankjewel voor de gezelligheid en de samenwerking! Ik ben erg onder de indruk 
van hoe je het onderzoek combineert met het klinische werk en hoe je in korte tijd zo 
ontzettend veel voor elkaar hebt gekregen. Ik hoop tot snel! 
 
Glory days well they'll pass you by,  
Glory days in the wink of a young girl's eye 
Glory days, glory days 
Bruce Springsteen, Born in the USA - 1984 
 
Ik denk dat Bruce in deze zinnen de essentie van de jaren aan de Boelelaan perfect heeft 
gevangen - ze zijn voorbij gevlogen. Collega’s werden vrienden, vrijdagmiddagborrels 
escaleerden niet zelden en congressen ontaardden in de mooiste verhalen. Er zijn vele 
onderzoekers gekomen en gegaan; maar enkele wil ik toch persoonlijk benoemen.  
 
Als eerste mijn kamergenootjes op 6D, Paul, Pia en Justine.  
Justine, hipster avant la lettre, harde werker en vooral heel fijn mens, ik heb genoten van je 
gezelligheid, nuchterheid, humor en relativeringsvermogen. Bedankt voor de hele mooie tijd! 
Paul, ‘grote broer’, en vooral grootste man met het kleinste hartje -  wat hebben we een 
supermooie tijd gehad. Onze goede gesprekken over het leven en het werk als iedereen al 




het leven een feest te maken zijn fantastisch. Hoogtepunten waren de buckets bij Edel, je 
connecties in de Bubbels, je vis-op-het-droge zijn in het trollendoolhof en in de Suicide Circus 
in Berlijn, je tree met tequila-shotjes na een minstens 16-uur durende reis naar San Diego en 
als klap op de vuurpijl enkele dagen later onze wellicht niet geheel nuchtere zoektocht naar 
feestartikelen in de plaatselijke supermarkt om 5 uur ’s nachts. Wat is het mooi dat de dromen 
waar we zo vaak over gefilosofeerd hebben nu voor een groot deel aan het uitkomen zijn! 
Door jou heb ik BHD altijd in mijn DD staan.  
 
Mijn eerste kamergenootjes op 3F; Onno, Hans en later Anna.  
Beste Hans aka ‘the Voice’, wat fijn dat jij kwam! Jouw stemgeluid was het enige wat mijn 
toonhoogte kon neutraliseren, ook dank namens de buren daarvoor! En hoewel Onno om 
duistere redenen het predikaat ‘goed met computers’ kreeg, ben jij de enige die daarvoor 
echt in aanmerking komt.  
 
Onno/Onnie - one of the very good guys, de enige man met een eigen dansmove, 
katerkoning en ouwe hipster, weinig mannen hebben het zoveel uren in één kleine ruimte 
met mij volgehouden. Respect daarvoor. Je zou kunnen denken dat mijn stemgeluid in 
combinatie met jouw soms matige articulatie zou kunnen leiden tot een moeizame 
communicatie, maar ik denk dat we toch kunnen concluderen dat dit meer dan goed 
gekomen is. Vanaf het eerste moment was het vertrouwd en ik heb jouw adviezen, rust, humor 
en gezelligheid altijd enorm gewaardeerd. Elk willekeurig congres, weekendje weg of borrel 
heeft wel geleid tot een mooi verhaal, of dit nu een plotselinge bestorming van een VIP-
podium was of het eindigen in een willekeurige Valenciaanse huiskamer. Dank voor alle good 
times, binnen maar eigenlijk ook vooral buiten muren van het VUmc. Ik kan niet wachten op 
een nieuwe borrel!  
 
Anna, hoewel jouw frisse wind en daadkracht in het begin misschien wat overweldigend waren 
hebben we na een korte adaptatieperiode ontzettend veel gelachen en een heel gezellige 
tijd gehad – zowel binnen als buiten werk. Jouw enthousiasme en doorzettingsvermogen is 
enorm, waardoor je ook in recordtijd je boekje af hebt gekregen! Dank dat je altijd een 
luisterend oor wilde zijn voor alle onderzoeksperikelen, dat heeft ontzettend geholpen!  
 
Dan ‘The Dark Side’ – de tweede ronde op 3F. Onno en Hans waren vertrokken, en Anna was 
verhuisd. Gelukkig kwamen daar twee nieuwe roomies; Adinda en Gwen. Het was in mijn 
laatste onderzoeksjaar; ook wel bekend als het jaar waarin het meest moet gebeuren – onder 
de grootste tijdsdruk. Het had dus erg ongezellig kunnen worden. Gelukkig was dit alles 
behalve het geval. Adinda; op het gebied van voedselintake en fysieke beweging zijn we 
nogal tegenpolen. Gelukkig op veel andere vlakken niet! Heel mooi dat ook jij nu je boekje 
klaar hebt! Gwennie, jouw kwaliteiten om een plant in leven te houden en de theevoorraad 
te beheren zijn ongekend. En samen klagen is zoveel beter dan alleen! Thanks voor de mooie 
tijd guys! 
 
Lieve AL, homie aan de andere kant van de gipsplaat. We hebben het af en toe zwaar te 
verduren gehad met alle fitgirls om ons heen. Zelfs jij, met je shinende tenniscarrière, werd 




waaronder op het terras of in de Mahler zitten met een witte wijn. Dankjewel voor al het 
aanhoren, kletsen en vooral alle gezelligheid!   
 
Lieve Eveline, jij begon zo ongeveer met je PhD toen ik al weg was, en wat is het dan toch 
extra bijzonder dat we dat laatste tijd zo naar elkaar toe gegroeid zijn! Eindelijk iemand die 
ook alle eredivisie-wedstrijden volgt (al is het dan vanaf ‘de verkeerde kant’), ook kan genieten 
van obscure sporten bij Studio Sport, een wereldvoorraad memes heeft én met name ook 
een grote voorliefde heeft voor de après-ski playlist! Lalalalalalala baby give it up, give it up… 
Ik hou van je energie, de fles in je bureau-la voor het eerste vrijmibo shotje, wijsheden en 
vooral je vriendschap (#samesies)! Dank!  
 
Ik wil ook graag de andere (oud-)klinische onderzoekers en collega’s van 3 en 4F heel erg 
bedanken voor de samenwerking en goede tijd; Suzan, Luuk, Jurjan, Azar, Chermaine, Jelco, 
Jeroen, Jessie, Josien, Liza, Mariëlle, Natalia, Romane, Samara en Wouter. En natuurlijk mag 
de pre-klinische kant hier niet bij ontbreken: Deni (Queen of Caipirinha’s), Michiel, Emmy, 
Robert, Sun, Pan, Rowan, Sylvia, Silvia, José en Babu. Thanks!  
 
En dan denk ik aan Brabant…. 
Na al die tijd boven de rivieren was de tijd gekomen om terug te keren naar het land waar 
de G geen pijn aan je oren doet en het bourgondische leven hoogtij viert. 
 
Als eerste wil ik prof. dr. Smeenk, dr. van Balkom, dr. Wielders, drs. Aldenkamp, dr. van den 
Borne, dr. J. Creemers, drs. Schakenraad, drs. Rietdijk en alle long-assistenten van het 
Catharina Ziekenhuis bedanken. Vanaf het eerste moment heeft het werken in Eindhoven als 
een warm bad gevoeld en dat komt vooral door de zeer laagdrempelige sfeer, het 
teamgevoel en de persoonlijke betrokkenheid. Daarnaast is er altijd interesse geweest voor 
‘mijn boekje’. Dank daarvoor! Ook wil ik jullie heel erg bedanken voor de steun na mijn val 
op onze ski-reis (na welgeteld 4 uur op Oostenrijkse bodem). De dierenavond zullen we nog 
steeds een keer moeten inhalen! Jullie bezoek in het ziekenhuis, de autorit naar het vliegveld, 
de vlucht naar huis (speciale dank voor dr. van Balkom) en de enorme betrokkenheid daarna 
heeft veel voor mij betekend!  
 
De maatschap Interne Geneeskunde en alle arts-assistenten; bedankt voor de fantastische 
tijd tot nu toe! De geweldige ski-reis (deze keer zonder botbreuken), vrijmibo’s en het enorme 
groepsgevoel (wat alleen maar werd versterkt gedurende de COVID-periode) maakten dat ik 
afgelopen jaar elke dag met veel plezier naar werk ben gegaan. Wat een fijne groep mensen! 
Dank voor de steun en betrokkenheid, ook toen mijn fysieke gestel het tijdelijk liet afweten! 
 
Oh, I get by with a little help from my friends 
Mm, I get high with a little help from my friends 
Mm, gonna try with a little help from my friends 
- Beatles, Sgt. Pepper’s Lonely Hearts Club Band, 1967 
 
Ook al kan ik niet iedereen bij naam noemen, ik wil ook zeker een paar ‘matties’ buiten de 





Team Zachte G 
Lieve Karlijn, Vivian en Lisette – we go way back. Ik vind het zo leuk en bijzonder om elkaar 
volwassen te hebben zien worden en iedereen zijn eigen pad te zien vinden in het leven. En 
ook al worden veel dingen anders, de belangrijkste dingen veranderen gelukkig nooit! 
Dankjewel voor jullie luisterend oor en de vele mooie momenten! Liefde!  
 
Lieve Carina, het is nu bewezen dat vriendschap op het eerste gezicht bestaat –een 
gemeenschappelijke geschiedenis helpt hier alleen maar bij. Gelukkig hebben we nog veel 
meer gemeenschappelijk. Dankjewel voor de puppy-liefde, tennisavondjes, de heerlijke 
avondjes aan de borrel of met BZV, en vooral voor je vriendschap. Lieve Michelle/Mies, tennis- 
en wijnmattie. Onze ABBA-avond was zonder twijfel een van de mooiste avonden van 2020. 
Ik hoop snel te genieten van je balkonlampje! Lieve Lisanne/Lies, de Jut van m’n Jul. Het is 
een feest om met jou te werken, te borrelen en je altijd fosfaat te zien suppleren. Op naar 
meer! Ook nog even speciale dank aan Michelle, Sophie en Marion – de beste collega’s en 
vrijmi-maatjes die je wensen kan! 
 
Lieve VVO, lieve Marjolein aka Lama, Caïa en Sylvester – grootste levensgenieters en 
Bourgondiërs van Eindhoven en omstreken. Na twee weken vooropleiding zaten we om voor 
mij nog steeds onduidelijke redenen samen in een app-groepje en was besloten dat we 
vrienden waren. Daar ben ik nog steeds dagelijks gelukkig om! Sharing is caring is naar een 
nieuw niveau getild, er is meer dan eens gehuild (of getuft, Lama) van het lachen, maar jullie 
waren er ook zomaar ineens voor me toen het leven wat moeilijker was én bij de laatste 
loodjes van dit boekje. Dat waardeer ik echt enorm!  
  
Lieve Milou, dat een bijzondere gemeenschappelijke patiënt, een paar vrij inefficiënte maar 
erg gezellige ochtendvisites en een beetje ‘Savage Love’ tot deze vriendschap zou leiden.. 
dat hadden we denk ik allebei niet verwacht. Vanaf moment één zit het goed en wat is het 
leuk om zo veel gemeen te hebben, het leven af en toe van een heel andere kant te bekijken 
en van dezelfde dingen te genieten (behalve AYNIL dan). Dankjewel voor de hele fijne 
gesprekken (gemiddelde duur: 8 uur), je inzichten en je kritische blik bij de Nederlandse 
Samenvatting. Ik kijk uit naar onze toekomstige avonturen! (en misschien echt een keer een 
serie kijken?) 
 
Team boven de Rivieren 
Lieve Joanne, we hebben elkaar ontmoet op de allereerste dag van de studie en vanaf toen 
had het lot ons aan elkaar verbonden. Meerdere gezamenlijke  studiegroepjes, een 
bijzondere verpleegstage en 2x per toeval op dezelfde etage in Uilenstede wonen later, was 
het maar goed dat we toch al besloten hadden vriendinnen te worden. Wat is het bijzonder 
dat we daarna ook nog eens beiden student-assistent werden van de PH-onderzoeksgroep 
en dat we daarna allebei aan een promotie-avontuur begonnen. Het was heel fijn en 
vertrouwd om dit allemaal te kunnen delen. Samen hebben we inmiddels veel mooie en 
onvergetelijke momenten meegemaakt en ik ben ervan overtuigd dat er nog vele zullen 





Lieve Yvette en Maartje aka de 1.60 clan. Dank voor de gezelligheid en de steun tijdens de 
theetjes en lunches in Utrecht en omgeving. Wat is het fijn om vriendinnen te hebben die 
precies door dezelfde promotie-struggles gaan!  
 
Lieve Madde, coschap-vriendin van het eerste uur maar nog veel belangrijker; mijn 
allerfavorietste vrijmibo-maatje. Hoe de week ook was, als het vrijdag vier uur-bieruur was en 
we met een Félix in de hand zaten, was alles meteen vergeten. Ik kan nog altijd nagenieten 
van alle verhalen met bijbehorende foto’s, maar ik kijk ook enorm uit naar het creëren van 
nieuwe. Thanks voor de good times en het er zijn tijdens de bad times! En heel veel succes 
met jouw PhD, superleuk dat je ook onderweg bent!  
 
Lieve Esther, heel veel succesvolle en minder succesvolle culturele uitspattingen later weet ik 
nog steeds niet wat ons grootste talent is. Ik weet ook niet of dat nu juist een goed of een 
slecht teken is. Dank voor alle afleidende wijntjes, etentjes en fijne avonden. 
 
Chris, waar een memorabel nachtje in de Opium in Barcelona wel niet toe kan leiden! We 
hebben ons PhD-traject voor een groot deel samen doorlopen, en ik kan zeker zeggen dat je 
daarin mijn steun en toeverlaat bent geweest. ‘Life begins at the end of your comfort zone’; 
maar in deze spreuk is zeker geen rekening gehouden met mijn lab-avontuur met de 
kleuringen voor de BMPR2 studie. Het woord ‘life’ zou je in dit geval voor vele woorden 
kunnen vervangen, maar ik denk dat ‘crying’ het meest toepasselijk zou zijn. Door jouw 
positiviteit, vindingrijkheid en vooral vermogen om alles gezellig te maken is het toch nog 
goed gekomen en ik ben heel trots op het resultaat! En of het nu gaat om congressen, 
roadtrips (Florida!), oneindige vrijdagmiddagborrels, feestjes, avondjes Paradiso of Tivoli of 
om grootse plannen maken; met jou is alles leuker! Op naar nog vele homemade pizza’s, 
tripjes en concerten!  
 
‘Dancing queens, young and sweet, only seventeen (+++)’  
Lieve cocktail-, champagne,- drankvriendinnen, lieve Pia, Gerrina & Lonneke. Onze 
vriendschap is misschien wel het mooiste en meest waardevolle gevolg van mijn 
onderzoekstijd. Zoals Willeke Alberti, Paul de Leeuw en Lonneke weleens zingen; ‘Samen zijn, 
is samen lachen, samen huilen, leven door dicht bij elkaar te zijn’, en ik denk dat onze 
vriendschap zo perfect wordt samengevat. Met jullie is het leven een feest, of we nu een 
cocktailavond hebben, on tour zijn, minstens 5 uur in het ABBA-museum doorbrengen of 
wanneer we voor de zoveelste keer chagrijnig worden aangekeken in een random restaurant 
of café vanwege onze decibellen (fijn om een groepje vriendinnen te hebben waarin mijn lach 
zeker niet de meest luidruchtige is). Maar nog meer waardeer ik dat jullie er áltijd voor me 
zijn, bij elke breakdown of tegenslag, onafhankelijk van tijd of afstand. Zonder jullie was alles 
anders, en daar kan ik jullie niet genoeg voor bedanken!    
 
Lieve Lonny, Thank God dat je nog één plekje over had op je sociaal-leven-vriendenlijst! Ik 
werd zomaar ineens in jullie cocktailgroepje opgenomen voor ons champagne-tripje, en vanaf 
de eerste minuut waren we vriendinnen; alsof het nooit anders was geweest. Dankjewel voor 
de enorme hulp gedurende de moeilijke momenten (ik hoef hier mijn huisje maar rond te 




times. Jij bent de grootste doorzetter die ik ken en kijk heel erg uit naar alles wat de toekomst 
ons gaat brengen! 
 
Lieve Sherry, hoewel jij initieel telkens als ik op 6D kwam werken ineens ging thuiswerken, is 
het gelukkig toch nog goed gekomen! En hoe! Want wat is er beter dan samen het leven 
vieren met een vrouw die de meest indrukwekkende drankkast van heel de Vinex en wijde 
omgeving heeft, en ook nog eens een eigen cocktail heeft? (de ‘Pornstar Gerrini’ 
welteverstaan) Onze dagen en avondjes (samen met Geert) zijn altijd een feest. En als jij achter 
mijn keuzes staat, voelt het altijd beter. Ik ben blij dat dat vertrouwen wederzijds is, en dat ik 
op onze vakantie vorig jaar zo ongeveer twee uur in Der Wagen mocht rijden (J). Je weet 
ook niet half hoe ik het waardeer dat je altijd zo enorm voor me klaar staat. En als jij erbij bent 
heb ik altijd het idee dat alles goed komt, dus ik ben ontzettend blij dat je naast me wil staan 
op deze dag! The winner takes it all!  
 
Lieve Pi, in 2011 begon dit avontuur als jouw student-assistent. Na daarna jouw 
wetenschappelijke stage-student te zijn geweest, werden we collega’s en uiteindelijk 
vriendinnen (al was ik daar wat eerder van overtuigd dan jij, ik wijt dat maar aan onze 
respectievelijk Groningse en Brabantse inborst..). Wat is het een geluk om iemand te vinden 
die zo hetzelfde in het leven staat en die zo van dezelfde (kleine) dingen kan genieten! En 
over genieten gesproken.. het eindeloos dansen in Buenos Aires, de full Rio experience, de 
nachttrein in Moskou, roadtrippen in Andalusië en California of onze ‘retraites’– het zijn stuk 
voor stuk memories for a lifetime! Maar waar we ook zijn, het concept is hetzelfde; een wijntje 
- de lekkerste hapjes van de kaart - drie keer met onze ogen knipperen en dan is ineens het 
restaurant/café leeg, gaan de lichten aan en is er weer een avond voorbij gevlogen. Zonder 
jouw kritische vragen, matig enthousiaste reacties op menig van mijn eigen ideeën (‘tsja, je 
moet het zelf weten’) en enorme steun gedurende de ‘lows’ zou dit boekje niet zijn wat het 
nu is geworden. Ik geniet enorm van je eerlijkheid, (tijdelijk) zeer belangrijke principes en 
overtuigingen, onze reisjes en belevenissen, onze creatieve hobby’s, onze gesprekken, maar 
boven alles van jouw vriendschap – want ik ken niemand met een groter hart dan jij. Op naar 
alle nieuwe highs, lows en in betweens!  
 
De bakermat 
Lieve Sandra en Mat, jullie zijn me ontzettend dierbaar. Dankjewel voor alle kaartjes, appjes 
en natuurlijk de fijne herinneringen.  
Lieve familie, bedankt voor alle betrokkenheid, gezelligheid en afleiding. Ik kijk er nu al naar 
uit dat de Landdagen en neven- en nichtjesweekenden weer kunnen plaatsvinden! 
Lieve Jan, jij overleed in mijn onderzoekstijd. Dat er zes jaar later bij de ‘Eeuwig Licht’-actie 
in het Philips Stadion nog meerdere lichtjes voor jou brandden zegt denk ik genoeg; je wordt 
niet vergeten. Lieve Roel, dat er eerder een boek over mij was dan door mij komt door jou; 
en dat blijft voor altijd!    









Dit is een (t)huis waar liefde woont  
- Guus Meeuwis, Morgen 2015 
 
Lieve papa en mama / het fundament, zonder jullie was ik nergens. Ondanks jullie drukke 
levens en carrières hebben jullie ons altijd op de eerste plaats gezet en ons een hele warme 
en veilige thuishaven gegeven. Jullie hebben mij altijd alle vrijheid en kansen gegeven om 
me te kunnen ontwikkelen tot wie ik nu ben, al was en is het soms een uitdaging om een vrij 
eigenwijze dochter te hebben. Gelukkig maken de daarbij horende discussies al mijn keuzes 
meer beargumenteerd en krijgen ze daardoor meer waarde. Ik hou van jullie!  
Lieve mama, wat is het bijzonder om zowel als longarts in spé als nu met deze promotie in 
jouw voetsporen te mogen treden. Ik hoop dat ik nog in vele opzichten, op professioneel en 
nog belangrijker  op persoonlijk gebied, jouw voorbeeld mag volgen. Dankjewel voor je  
buitengewone liefde, enorme betrokkenheid, het altijd al tien stappen vooruit denken en les 
dat je als je iets maar écht wilt, je dat kan bereiken.  Lieve papa, ik lijk steeds meer op jou. 
Wat is het bijzonder om iemand te hebben die zo hetzelfde in elkaar zit en waarmee je 
dezelfde hobby’s en passies kan delen. Dankjewel dat je er al bijna 30 jaar echt áltijd voor me 
bent.  
Lieve Phil, grote kleine broer, maar vooral grootste held; jij bent alles wat ik niet ben en daar 
bewonder ik je enorm om. Al sinds jongs af aan zijn we twee handen op één buik en dat is 
altijd zo gebleven. Ik ben heel dankbaar dat je zo dicht bij me staat en vind het superbijzonder 
hoe jij altijd voor anderen en ook voor mij klaar staat – in het geval van alle promotie-
perikelen, maar ook in alle andere aspecten van het leven. Dat betekent ontzettend veel voor 
mij! Ik ben zo trots op jou! 
 
Dan last but not least mijn oma’s, aan wie dit boekje is opgedragen. Het is een groot 
voorrecht dat jullie al zo lang deel uitmaken van mijn leven en dat ik jullie zo goed heb mogen 
leren kennen. Jullie zijn het ultieme voorbeeld van (veer)kracht, betrokkenheid, 
doorzettingsvermogen, eigenwijsheid, humor en warmte. In jullie tijd was het niet 
vanzelfsprekend dat je als vrouw mocht ‘doorstuderen’, maar jullie hebben me vaak verteld 
dat jullie dit zo ontzettend graag hadden gedaan. Dat ik hier op deze dag mag staan is dan 
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